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A GENOMIC PORTRAIT OF HEPATITIS C VIRUS AND MICRORNA-122
Joseph M. Luna, Ph.D.
The Rockefeller University 2015
Hepatitis C virus (HCV) uniquely requires the liver specific microRNA-122 (miR122) for replication, yet global effects on endogenous microRNA (miRNA) targets
during infection are unexplored. In this body of work, we employed highthroughput sequencing and crosslinking immunoprecipitation (HITS-CLIP)
experiments of human Argonaute (AGO) during HCV infection. We demonstrate
robust AGO binding on the 5' untranslated region of HCV RNA at known and
predicted miR-122 sites, thereby establishing conclusive biochemical evidence of
endogenous miR-122 action on HCV RNA that firmly agrees with previous
genetic evidence. We further characterize novel AGO binding on HCV RNA to
determine

its

dependence

on

miR-122,

miRNAs

generally,

replication

competence and time. These results establish an unbiased interaction landscape
between HCV RNA and cellular miRNAs, mostly miR-122.
On the human transcriptome, we observed reduced AGO binding and
functional mRNA de-repression of miR-122 targets during virus infection. This
miR-122 "sponge" effect was relieved and redirected to miR-15 targets by
swapping the miRNA tropism of the virus. Single-cell expression data from
reporters containing miR-122 sites showed significant de-repression during HCV
infection depending on expression level and site number. Based on these results,
we describe a quantitative mathematical model of HCV induced miR-122

sequestration and propose that such miR-122 inhibition by HCV RNA may result
in global de-repression of host miR-122 targets. This in turn may provide an
environment fertile for the long-term oncogenic potential of HCV.
This last point presented a fitting entree into miR-122 biology, given its
known tumor suppressive activity in the liver. To conclude this work, we
performed AGO-CLIP in miR-122 knockout mouse livers as well as in human
liver samples, to determine the in vivo targetome for this miRNA across two
species. Surprisingly, we discovered widespread and non-canonical miR-122
binding throughout the transcriptome. Furthermore, a substantial fraction of this
binding was not conserved between mouse and human transcriptomes, despite
the fact that miR-122 is highly conserved. These results, in concert with AGOCLIP in HCV infected cells, point to a model where HCV may have evolved the
use of miR-122 for its high abundance and its well buffered capacity to be
inhibited with minimal detrimental effects to the host, and perhaps benefits for the
virus.
In sum, this thesis reveals how miR-122 is redistributed in the cell
following HCV infection. As a molecular mechanism, chronic inhibition of miR-122
by HCV RNA is proposed to impact, and may very well help induce, the complex
constellation of liver diseases that characterize this infection in humans.

To my grandparents

Che non men che saper dubbiar m'aggrada
"For doubting pleases me as much as knowing"
-Dante, Inferno XI
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Chapter 1: Introduction
In 1989, Qui-Lim Choo, Michael Houghton and colleagues at the Chiron
corporation identified a positive sense, ~10kb RNA of exogenous origin that was
closely associated with non-A, non-B hepatitis (NANBH) and renamed HepatitisC Virus (HCV) (Choo et al., 1989). With a molecular handle for identifying HCV,
work quickly progressed in establishing a causal role in NANBH, identifying antiHCV antibodies in NANBH patients, and linking HCV with end-stage liver disease
and hepatocellular carcinoma (HCC) in humans (Alter et al., 1989; Kiyosawa et
al., 1990; Kuo et al., 1989). Despite comprising its own genus among the
flaviviridae family of viruses, HCV was later found to exhibit significant sequence
heterogeneity and was grouped into at least seven major genotypes with
numerous subtypes (Bukh et al., 1993; Smith et al., 2014). The domestication of
HCV to enable detailed laboratory investigation in tissue culture was a long and
laborious process that ultimately succeeded with the development of subgenomic replicons, the isolation of highly permissive cell lines, and the isolation
of adaptive HCV variants that lead to the establishment of viral clones capable of
producing infectious virus particles in cell culture (Blight et al., 2002; Lindenbach
et al., 2005; Lohmann et al., 1999; Wakita et al., 2005). In the quarter century
since its discovery, strategies to cure HCV have progressed dramatically from
interferon therapy, with ~50% cure rates, to direct acting anti-viral agents (DAAs)
with cure rates in excess of 95% across a variety of viral genotypes (Sadler and
Lee, 2015). These stunning developments, only apparent in the past few years
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and currently ongoing, were coincident and dependent upon breakthroughs in
basic studies of HCV in virus labs the world over, to whom full credit as a field is
due. For anyone who has borne witness to the discovery and cure of HCV within
the span of one scientific lifetime, it is tempting to declare an end to this viral
scourge in the age of highly effective curative therapy. And yet, much remains to
be done. It is, in this student's eyes, only the beginning.
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An overview of hepatitis C virus
As of 2014, HCV remains a major global public health burden with an
estimated 185 million people ~(2.8% of the world's population) currently infected
(Mohd Hanafiah et al., 2013). In the United States, between 3.4 and 4.4 million
people are estimated to be infected with HCV (Chak et al., 2011). While most
infections are asymptomatic, symptoms during an acute HCV infection include
hepatitis and jaundice (Hoofnagle, 1997; Villano et al., 1999). Between 10-40% of
HCV infections spontaneously resolve while the majority of cases result in a
chronic infection (Figure 1.1) (Thomas et al., 2000; Thomas, 2013). Persistent
HCV infections can result in an array of outcomes, including cirrhosis and HCC,
which manifest over decades in 2-30% of patients (Bruno et al., 1997).
Complications from cirrhosis and related end-stage liver diseases (ESLDs)
combined with HCV-associated HCC have made HCV the primary cause of liver
transplants in the U.S. (Davis et al., 2010). Moreover, HCV-induced cirrhosis
constitutes a top risk factor for HCC (Herbst and Reddy, 2013).
While HCV infections are globally prevalent, they are unevenly distributed
across regions and age groups. HCV is the largest proximal cause of liver
transplantations in industrialized nations where infection prevalence remains
highest among marginalized populations such as the incarcerated, injection drug
users, and the homeless (Chak et al., 2011). Global prevalence is highest in
developing nations, particularly in the Middle-East and Asia (Mohd Hanafiah et
al., 2013).
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Figure 1.1. HCV infection natural history. An acute infection may result in
hepatitis and jaundice, which in 10-40% of cases resolves within 3-6 months.
Unresolved infections persist for decades in 60-90% of cases and can result in
extra-hepatic complications. A wide range of cases (2-30%) progress to end
stage liver disease including cirrhosis and HCC. ALT: Alanine transaminase.
Figure from (Thomas, 2013).

Egypt is estimated to have the highest HCV prevalence among nations, where up
to 50% of persons born before 1960 are affected. The history of HCV infection in
Egypt exemplifies global HCV transmission in the era before mass blood
surveillance: mass public health injection campaigns to eradicate schistosomiasis
from the 1950s to 1970s resulted in millions of Egyptians unknowingly becoming
infected with HCV. These mid-20 century surges in infection, in Egypt and
th

elsewhere, were subsequently linked to unsafe injection and unsterile treatment
practices that largely no longer occur (Thomas, 2013). Combined with routine
blood screening in place since the early 1990s, incidences of HCV infection from
contaminated blood products are exceedingly remote (Chak et al., 2011).
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Despite tremendous advances in stemming new HCV infections from
blood products, the epidemiology of HCV in the 20 century presents a continued
th

challenge given that the infection is largely asymptomatic and presents with liver
disease decades after the initial infection (Thomas et al., 2000). It is estimated
that in the U.S., persons born between 1946 and 1965, the so-called "baby
boom" generation, will likely bear the brunt of HCV related complications. Peak
projections estimate over a quarter million HCV liver-related deaths between
2020 to 2029 (Davis et al., 2010). Concurrently, estimates on the need for liver
transplantations are expected to sharply rise in the coming decade (Biggins et
al., 2012). These sobering statistics combined with their projected economic and
quality-of-life impacts, even in the age of curative DAAs, make continued
scientific efforts at understanding the role of HCV in promoting liver disease all
the more relevant (Thomas, 2013).
The uneven global distribution of HCV is reflected in the distribution of the
various genotypes of the virus (Figure 1.2) (Messina et al., 2015). At both the
nucleotide and amino acid level, genotypes differ around 30%, subtypes around
20%, and isolates within a subtype between 2-10% (Simmonds et al., 2005). Of
the six major known genotypes, Genotype 1 predominates in the Americas and
western Europe, accounting for 70% and between 50-70% of cases in each
region, respectively. Genotype 2 is prevalent in the Americas, sub-Saharan
Africa, and Japan, where genotype 1 is also present.
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Figure 1.2. Relative prevalence of each HCV genotype by Global Burden of
Disease (GBD) region. Size of pie charts is proportional to the number of
seroprevalent cases as estimated by (Mohd Hanafiah et al., 2013). Figure from
(Messina et al., 2015).

Genotype 3 is mostly found in Europe, southern and western Asia, while
genotypes 4 and 5 are prevalent in central and South Africa. Genotype 6 mostly
affects East and Southeast Asia. A recent and novel genotype 7, with only a few
cases, appears to be present in central Africa (Murphy et al., 2014). While all
genotypes appear to have similar pathogenic features, some differ in their
association with certain complications and their abilities to be studied in the lab.
For example, genotype 3 has been associated with an increased risk of liver
steatosis and HCC compared to other genotypes (Adinolfi et al., 2001; Nkontchou
et al., 2011; Rubbia-Brandt et al., 2000). Historically, Genotype 1 has been both
the most prevalent and difficult to treat (Hoofnagle and Seeff, 2006). Genotype 2
viruses have been the most proximate source of cell culture adapted HCVs: a
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Japanese genotype 2 isolate (JFH-1) was the progenitor of fully infectious HCV
cell culture systems (Lindenbach et al., 2005; Wakita et al., 2005).
With the advent of DAAs providing highly curative, interferon-free,
treatment regimens that exhibit pan-genotypic effectiveness with minimal side
effects, it is conceivable that viral genotyping will cease to be relevant for HCV
therapy (Messina et al., 2015). And yet, with a plurality of outcomes for HCV
infections, from asymptomatic to sever liver disease, environmental factors such
as genotypic differences, combined with host-genetics in the dynamically
regulated and aging liver only highlight how much there is to learn about HCV
disease causation. For our purposes, this introduction will start small and at the
source by turning our attention to the virus.

The HCV life cycle
HCV is an enveloped, spherical virus particle between 50-80nm in
diameter (Catanese et al., 2013b). The virion is studded with E1 and E2
glycoprotein heterodimers embedded in the lipid bilayer, which encloses a
nucleocapsid consisting of the core protein and a positive sense RNA genome
approximately 9.6kb in length. The RNA genome consists of highly structured 5'
and 3' untranslated regions (UTRs) that flank a single viral open reading frame
(ORF) which encodes a single polyprotein of around 3000 amino acids that is
processed into ten distinct components comprised of structural proteins (Core,
E1, and E2), p7 channel, and the non-structural proteins (NS2, NS3, NS4A,
NS4B, NS5A, and NS5B) (Figure 1.3) (Lindenbach and Rice, 2005).
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Figure 1.3. HCV genome organization and polyprotein processing. The HCV RNA
genome (top) contains highly structures 5′ and 3′ UTRs (red) which flank a single
long ORF (blue). IRES-mediated translation of the ORF leads to a polyprotein
(bottom) that is co- and post-translationally processed into ten viral proteins. Core
protein maturation involves a cellular signal peptide peptidase cleavage of a Cterminal signal peptide (white triangle) and cleavage from E1 by the cellular
signal peptidase, which also cleaves E1, E2 and p7 from the polyprotein (gray
triangles). In an autocleavage mechanism requiring a dimer to make up the
composite active site, the NS2-NS3 protease cleaves itself (red triangle). The
NS3 protease located in the first one-third of NS3, assisted by its membrane
bound cofactor, NS4A, cleaves the remaining proteins NS3, NS4A, NS4B, NS5A
and NS5B (green triangles). Glycosylation of the envelope proteins (black dots)
and the functions of the individual HCV proteins are indicated. Figure adapted
from (Scheel and Rice, 2013).

HCV entry
Among the most well studied aspects of HCV biology, viral entry presents
a multitude of unique features and outstanding questions (Lindenbach and Rice,
2013). HCV particles typically exist as lipoviroparticles (LVPs) in infected hosts,
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so described due to the association of the virion with low-density and very-lowdensity lipoproteins (LDL and VLDL) (Andre et al., 2002; Merz et al.,
2011)(Figure 1.4). In addition to association with ApoE and ApoB, LVPs engineer
a "Trojan horse" for HCV by coercing lipoprotein secretion and adsorption
mechanisms for productive entry into cells, and may help shield the virus from
neutralization (Bartenschlager et al., 2011). To present a summarized model of
HCV entry (comprehenisvely reviewed by (Lindenbach and Rice, 2013)), LVPs
are thought to first make contact with host cells via low affinity engagement of the
LDL receptor (LDLR) and glycosaminoglycans (GAGs), before E1-E2 interactions
engage co-receptors Scavenger Receptor class B member 1 (SR-B1) and
Cluster of Differentiation 81 (CD81) with higher affinity promoted in part by
epidermal growth factor receptor (EGFR) and ephrin receptor type A2 (EphA2).
The CD81 bound HCV particles are then thought to traffic laterally to tightjunctions where Claudin-1 (CLDN1) and Occluding (OCLN) play critical roles in
late stages of entry thorough interactions with the NPC1L1 cholesterol absorption
receptor.
At this point, LVP uptake occurs via clathrin mediated endocytosis, likely
into endosomes wherein low pH alongside CD81 priming is sufficient to trigger
fusion of the viral envelope with the host membrane (Sharma et al., 2011).
Although E2 is predicted to be a class II fusion protein, recent structures on
highly related pestivirus E2 has led to speculation that E1 may be fusogenic (Li et
al., 2013e; Omari et al., 2013).
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Figure 1.4. The HCV life cycle. Interaction of extracellular HCV LVPs with cellular
surface receptors initiates the entry process, which can also occur from direct
cell-to-cell transmission. After pH-dependent fusion and uncoating, the incoming
HCV genome is translated and the resulting polyprotein is processed (bottom
inset and Figure 1.3). HCV NS proteins set up ER-derived membrane spherules
(membranous web, bottom right inset) to initiate the process of RNA replication.
The spatiotemporal contribution of miR-122 binding to the HCV genome is not yet
fully understood, and miR-122 presence is indicated with '?'. In the assembly and
release process (top right inset), core protein is transferred from cytoplasmic
Lipid Droplets (cLD) to form nucleocapsids are loaded with viral RNA, with the
help of NS5A, NS2, NS3-NS4A and perhaps p7. It is not clear whether the RNA
is transiently located on the cLD. Virion morphogenesis is coupled to the VLDL
secretion pathway through luminal lipid droplets (LuLD), and particles are
produced as LVPs. EphA2, ephrin receptor type A2; GAG, glycosaminoglycans;
PL, phospholipids; TG, triglycerides; MTP, microsomal transfer protein. Figure
adapted from (Scheel and Rice, 2013).

10

Further work on the E2 ectodomain has recently resolved a novel IgG like fold
that does not appear to undergo structural rearrangements in low pH (Khan et al.,
2014). The late stages of entry, especially fusion and viral uncoating remain
poorly understood.

HCV translation, protein processing and RNA replication
As mentioned above, the HCV genome is highly structured with critical
RNA elements in the 5' and 3' UTRs (Lohmann, 2013). Following uncoating and
release of viral genome into the cytoplasm, the pioneer round of translation of
HCV RNA is initiated by an Internal Ribosome Entry Site (IRES) located in the
5'UTR (Figure 1.3 and 1.4) (Fraser and Doudna, 2007). Translation begins on the
IRES through direct and RNA structure-guided recognition of the 40S ribosomal
and eukaryotic initiation factor 3 (eIF3), thus bypassing the need for the capstructure and related binding factors (Tsukiyama-Kohara et al., 1992; Wang et
al., 1993). The AUG start codon is directly placed into the peptidyl (P) site of the
40S subunit (Reynolds et al., 1995; Rijnbrand et al., 1996). The resulting HCV
polyprotein is co- and post-translationally cleaved by the viral NS2-NS3 and NS3NS4A proteases and by cellular proteases (signalase and signal peptide
peptidase), respectively into ten HCV proteins (Figure 1.3) (Lindenbach and Rice,
2005). The NS4B and NS5A proteins are believed to induce ER rearrangements
that result in membrane spherules which in aggregate are termed the
"membranous web" (Figure 1.4) (Egger et al., 2002; Romero-Brey et al., 2012).
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RNA replication occurs in this membranous web, which is thought to offer
protection from dsRNA sensing and damaging reactive oxidants. As the RNAdependent RNA polymerase, NS5B forms the core of the HCV replicase
complex, which in concert with the NS3 helicase, NS4A, and multi-functional
NS5A, synthesizes anti-sense RNA genomes from sense templates (Lohmann,
2013). Anti-sense genomes serve as the template for continual and successive
production of sense genomes, which can then undergo translation, assembly and
export, or RNA replication. The assembly, stability and decay of the replicase is
thought to be a highly dynamic process, and so determining the precise
spatiotemporal roles for replicase components has been difficult, and much
remains to be explored (Lohmann, 2013).

HCV assembly and release
Virus assembly and release is tightly coupled with host cell lipid
biosynthesis (Lindenbach and Rice, 2013). Upon protease cleavage and
liberation from the HCV polyprotein, the mature core protein critically relocates to
cytoplasmic lipid droplets (cLDs) (Barba et al., 1997; Miyanari et al., 2007).
Nucleocapsid formation involves the interaction of core with NS5A, though the
precise mechanism for delivery of the RNA genome to sites of assembly is poorly
understood (Lindenbach and Rice, 2013). Close juxtaposition of sites of RNA
replication and virion assembly are thought to facilitate nucleocapsid formation
alongside NS2 coordination of assembly through interactions with E1 and E2, p7,
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NS3, and NS5A (Jones et al., 2007; Phan et al., 2009). E1 and E2, once
processed, proceed through the ER where they assume a type 1 membrane
topology. Further post-translational processing of E1 and E2 takes place to
include the addition of N-linked sugar moieties and their trimming with
glycosidases (Lavie et al., 2007). Nucleocapsids forming at cLDs link up with
mature E1 and E2 by budding into luminal lipid droplets (luLDs) where the virion
completes maturation and is secreted via the VLDL pathway (Gastaminza et al.,
2008). As virus particles transit through this secretory pathway, they are thought
to be protected from low pH exposure by the p7 ion channel (Wozniak et al.,
2010). Once secreted from the cell as LVPs, the process then begins anew
(Bartenschlager et al., 2011).

HCV interactions with the innate immune response
HCV presents a thought-provoking case in that the standard of care prior
to DAAs was interferon treatment, a central molecule in the innate immune
response. And yet the mechanisms by which IFN therapy failed to work were
mostly unknown and continue to be a major focus of current research (Horner
and Gale, 2013). One theme centers on unique features of the HCV RNA
genome. Unlike normal cellular mRNAs, the HCV genome lacks a 5' capstructure. And like all RNA viruses, HCV replication goes through an intermediate
phase where double stranded RNA (dsRNA) is produced. As such uncapped
RNAs or dsRNA products are rarely found in normal cellular cytoplasm, these
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molecules constitute pathogen associated molecular patterns (PAMP) for which
the cell has evolved sensing and effector mechanisms to mount an anti-viral
response (Beutler et al., 2007). Early reports linking innate immunity to HCV
infection focused on protein kinase R and RNAseL, two classical interferon
stimulated genes (ISGs), as effector molecules counteracted by HCV proteins or
RNA structures (Han and Barton, 2002; Taylor et al., 1999). Still, how HCV
evaded innate immune sensing was a mystery. Clarity emerged in 2003, when
Foy, Gale and colleagues established a role for NS3/4A protease activity as
critical for preventing IRF3 activation and the downstream IFN response (Foy et
al., 2003). A flurry of subsequent reports established that NS3/4A antagonizes a
molecule dubbed the mitochondiral antiviral signaling protein (MAVS, aka IPS-1,
VISA, and Cardif), a key player downstream of retinoid acid-inducible gene-I
(RIG-I) (Meylan et al., 2005). In this manner, NS3/4A cleavage of MAVS blunts
RIG-I activation of the interferon response. MAVS cleavage has been observed
in patients where importantly, the presence of MAVS cleavage fragments
correlated with lower levels of IFN activation (Bellecave et al., 2010).
The story of MAVS is presented here as one of a growing list, which
includes TRIF (also cleaved by NS3/4A), a renewed interest in the sensing and
effector activities of PKR, and the enigmatic clinical and predictive associations of
HCV with IFNL4 (Horner and Gale, 2013; Prokunina-Olsson et al., 2013). The
fact that HCV proteins have evolved functions that antagonize the host innate
immune response is not surprising, particularly given what is known for other
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viruses, notably HIV-1, for which each accessory protein seems all but tailormade to counter a host restriction factor (Malim and Bieniasz, 2012). Work
utilizing ISG screens has provided a compelling platform to systematically
address these issues in HCV and in other viruses (Diamond and Schoggins,
2013; Dittmann et al., 2015; Schoggins et al., 2011; Wilson et al., 2012). What
bears keeping in mind for HCV is that the complete picture of its regulation and
subversion of innate immunity is unclear and that future surprises lie in store.

HCV interactions with protein host factors
As detailed above, HCV depends extensively on the host cell to infect,
replicate and spread, is subject to host innate immune control, and has evolved
mechanism to evade innate immune detection. While too numerous to list here, a
vast number of host factors influencing each aspect of the viral life cycle have
been identified using RNAi-screening and mass spectroscopy methods (Shulla
and Randall, 2012). HCV interactions with the host can be broadly classified as
either pro- or anti-viral, on the basis of functional studies aimed monitoring the
effect of factor perturbation on measureable virus outputs: RNA, protein and
infectious virus. Many pro-viral factors have been the subject of detailed
mechanistic investigation, as potential therapeutic targets complementary to DAA
centered approaches. A few examples are highlighted here:
Cyclophilin A (CypA), a peptidyl-proyl cis-trans isomerase required for
HCV replication through its interaction with NS5A, is a prime example, as it was
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discovered after observing that the immunosuppressive drug cyclosporin A
(CsA), which targets CypA, inhibited HCV replication in cell culture (Watashi,
2003). While the precise role for CypA in HCV replication is still not clear, CsA
derivatives are highly effective at antagonizing the critical NS5A-CypA interaction
across all genotypes, and importantly, pose a high genetic barrier to drug
resistance in vivo (Flisiak et al., 2012)
Diacylglycerol acyltransferase-1 (DGAT1) is an ER resident, triglyceride
synthesizing enzyme, that was found to be critical for HCV particle formation
(Herker et al., 2010). DGAT1 appears to regulate core trafficking via NS5A to lipid
droplets, such that DGAT1 knockdown or pharmacologic inhibition prevents virus
assembly (Camus et al., 2013; Herker et al., 2010).
Found in several siRNA screens, phosphatidylinositol-4 kinase III-α
(PI4KIIIα) is an ER associated lipid kinase that hijacked by NS5A and seems to
be essential for the integrity of the membranous web (Berger et al., 2009; Reiss
et al., 2011). Later work identified that HCV inhibitors thought to target NS5A
were actually directed to PI4KIIIα. While promising, transient ablation of PI4KIIIα
lead to sever liver pathology in mice, so clearly more work is needed to
determine if strategies aimed at inhibiting this enzyme are viable (Vaillancourt et
al., 2012).
The mechanisms of how these host proteins facilitate HCV replication
have been and are being worked squarely with therapeutic potential in mind. The
overall motivation is that by developing host targeting agents (HTAs), problems
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with viral resistance associated with prototypical DAAs can largely be
circumvented, and in select cases perhaps eliminated (Scheel and Rice, 2013).

Host protein interactions with HCV RNA
As the master blueprint for HCV, the viral RNA genome must interact with
many host RNA binding proteins (RNABPs) to facilitate its tripartite role as
template for replication, translation, and RNA packaging into virions. It also
presents a central node whose targeted disruption theoretically presents an
insurmountable barrier for virus resistance. A number of proteins bind the 3'UTR
of HCV RNA to include heterogeneous nuclear ribonucleoprotein C (HNRNPC),
ELA V-like RNA-binding protein 1 (ELAVL1, or HuR), glyceraldehyde-3phosphate dehydrogenase (GAPDH) as well as polypyrimidine tract binding
protein (PTBP1/2) (Ito and Lai, 1999; Luo, 1999; Petrik et al., 1999; Spångberg et
al., 2000). As the latter would suggest, the poly-U/C tract of HCV RNA as well as
the highly conserved 3' X-tail serve as binding sites for the above proteins though
by and large, the functional importance of these protein-RNA interactions is far
from clear. Most were found to interact with in vitro transcribed HCV RNA in cell
lysates, so it's possible that many of these founding results are artifacts. Proteins
binding the 5'UTR include poly(rC)-binding protein 2 (PCBP2), the La antigen,
polypyrimidine

tract

binding

protein

(PTBP1/2),

heterogeneous

nuclear

ribonucleoprotein L (HNRNPL), insulin-like growth factor 2 binding protein 1
(IGF2BP1), and U6 snRNA-associated Sm-like protein (LSM1-7) (Ray and Das,
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2011; Rosenfeld and Racaniello, 2005; Scheller et al., 2009; Weinlich et al.,
2009). These proteins may act as IRES-transactivating factors (ITAFs) as their
specific depletion impairs HCV translation in cell culture and in general they are
thought to be cofactors for a variety of IRESes (King et al., 2010). Some ITAFs
bind the 3'UTR in addition, as shown for PCBP2, which may promote translation
via circularization of the viral genome (Wang et al., 2011). Circularization of viral
genomes is a common theme for regulating translation versus RNA replication in
flaviviruses, however its role on HCV biology is unclear outside of in vitro
systems. With the advent of CLIP methods to be discussed below, the functional
genomic characterization of these and other protein-RNA interactions on a viral
genome is increasingly within reach and represents a frontier ripe for
advancement. For now, I focus your attention on one class of very well studied
RNABPs, the Argonautes (AGOs), and their unique association with HCV RNA.
But before that, we must explore a unique feature of this protein as being
programmed by small snippets of RNA, called microRNAs, that allow AGOs to
play critical roles in a multitude of biologic processes.

MicroRNAs, small RNAs and silencing
MicroRNAs (miRNAs) are a class of small (~22nt) noncoding RNAs
(ncRNAs) that regulate gene expression by sequence-specific targeting of
mRNAs causing mRNA degradation or translational repression (Bartel, 2009).
Initially identified as non-coding RNAs, lin-4 and let-7, which control the timing of
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larval development in the worm C. elegans, miRNAs were soon found to
represent an abundant class of small endogenous RNAs with a variety of
regulatory roles throughout diverse metazoans (Lagos-Quintana et al., 2001; Lee
and Ambros, 2001; Lee et al., 1993; Reinhart et al., 2000). In addition, miRNAs
have also been found in plants, green algae, and viruses (Griffiths-Jones et al.,
2008).
In general, miRNAs are but one class of a number of small endogenous
RNAs that include small interfering RNAs (siRNAs) and Piwi-interacting RNAs
(piRNAs) (Ambros et al., 2003; Aravin et al., 2007). These small RNA types
broadly contribute to the phenomena of RNA silencing, whereby small RNAs act
as guides for PIWI domain containing RNA nucleases, predominantly the
Argonautes (AGOs), to repress gene expression. However, miRNAs differ
considerably from other small RNAs in their mode of biogenesis (Figure 1.5)
(Bartel, 2004). miRNAs are transcribed by RNA polymerases II and III into
primary miRNA (pri-miRNA), which undergoes processing into pre-miRNA
hairpins through the action of the Microprocessor complex composed of the
RNAse III enzyme Drosha and Di-George syndrome critical region 8 (DGCR8)
proteins (Gangaraju and Lin, 2009). For a minority of miRNAs, Drosha
independent pre-miRNA production can occur from miRNA genes present in
introns, called "mirtrons", for which the spliceosome functions analogous to
Drosha (Okamura et al., 2007; Ruby et al., 2007).
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Figure 1.5. Canonical miRNA and siRNA biogenesis in metazoans. (A)
MicroRNA (miRNA) genes are transcribed by RNA polymerases II and III into primiRNAs. These are processed into pre-miRNAs in the nucleus by the
Microprocessor complex, which contains the RNase III enzyme Drosha and the
double-stranded RNA-binding protein DGCR8. Some miRNAs, called mirtrons,
have also been shown to be generated from introns that bypass Drosha
requirement. Pre-miRNAs are then transported into the cytoplasm by the
karyopherin exportin-5 and RanGTP, where they are further processed by the
RNAse III enzyme Dicer. This results in double-stranded 20–25nt intermediates
with 2nt overhangs on the 3′ end. One of the RNA strands is then loaded by
Dicer into an RNA-induced silencing complex (RISC), which contains an
Argonaute family member, that then targets the 3′ untranslated region of the
target mRNAs by an imperfect match between the miRNA and the mRNA, to
induce mRNA degradation or repress translation. (B) The small interfering RNA
(siRNA) pathway initiates with either bidirectional transcription or transcription of
an inverted repeat that results in a double-stranded precursor. This precursor is
also processed in the cytoplasm by Dicer and is loaded into a small interfering
RISC (siRISC) complex intended for target mRNA degradation. Alternatively,
dsRNA from an exogenous source (viral, transfected, careless graduate students,
etc) can be processed directly from the cytoplasm. Figure modified from
(Gangaraju and Lin, 2009).
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Pre-miRNAs are exported from the nucleus through the action of exportin5 and RanGTP (Bohnsack et al., 2004). Once in the cytoplasm, pre-miRNAs
undergo processing by the RNAse III enzyme Dicer, generating a double
stranded 20-25nt intermediate that gets loaded onto AGO to form a RNA-induced
silencing complex (RISC) (Hutvágner and Zamore, 2002). The miRNA bound
RISC represses through base pairing of the miRNA with the 3'UTR of the mRNA
target, and subsequently promotes mRNA decay or translational repression, via
partially understood mechanisms (Filipowicz et al., 2008).
The small interfering RNA (siRNA) pathway initiates with either
bidirectional transcription or transcription of an inverted repeat that results in a
double-stranded precursor. This precursor is also processed in the cytoplasm by
Dicer and is loaded into a small interfering RISC (siRISC) complex intended for
target mRNA degradation (Carthew and Sontheimer, 2009). Alternatively, dsRNA
from an exogenous source can be processed directly from the cytoplasm and
loaded onto RISC (MacKay et al., 2014). While this pathway is present in
mammalian cells, it is not thought to compose an appreciable anti-viral response
(see below).
In theory, the capacity for siRISC or miRISC to silence target mRNAs
without nuclear control or input offers a highly flexible and rapid platform for an
immune response to foreign nucleic acids (Carthew and Sontheimer, 2009).
Indeed, RNA interference (RNAi) as described above forms that backbone of the
innate immune response in both plants and invertebrates (Baulcombe, 2004).
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Along similar lines, CRISPR systems in bacteria and archaea provide somewhat
analogous protection mechanisms from invading bacteriophage DNA or RNA,
with the added benefits of being both adaptive and heritable (Bondy-Denomy and
Davidson, 2014). Given the above, vertebrates appear to be outliers with
elaborate protein based immune responses, centered largely on interferon
signaling, that induce the production of hundreds of effector proteins called
interferon stimulated genes (ISGs) (Schoggins and Rice, 2011). The relationship
between a robust protein based and an ancient, though ancillary RNA-based
immune response in vertebrates will be discussed in a following section. It
suffices here to mention that recent findings have only reinvigorated the
discussion on the anti-viral functions of RNAi in mammalian cells (Burgess, 2013;
Li et al., 2013c; Maillard et al., 2013; Sagan and Sarnow, 2013; Tanguy and
Miska, 2013).
MicroRNA target recognition, function and expression
At the simplest level, miRNA function is governed within the AGO protein.
On AGO, a miRNA encounters its mRNA target via Watson-Crick base pairing to
a "seed" region on the mRNA (positions 2-7 from the miRNA 5' end) (Figure
1.6A) (Bartel, 2009). Each miRNA is predicted to regulate hundred of targets,
primarily by engaging 3'UTRs (Lewis et al., 2005). With hundreds of known and
predicted miRNA genes in the human genome, and comparable numbers in mice
and other mammals, the array of possible regulatory events is astounding.
However, three key principles are worth emphasizing.
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Figure 1.6. miRNA seed characteristics and repression features. (A) Schematic
of miRNA (miR-122) engagement of mRNA targets displaying all major classes of
miRNA seed pairing: 8mer, 7mer-m8, 7mer-A1, 6mer, offset 6mer, and 3'
supplementary or compensatory pairing, which can occur with all of the above
seeds, but is illustrated here with 7mer-m8. The predicted frequency of each
seed class for conserved mRNA targets for a prototypical and conserved miRNA
is shown at right from calculations by (Friedman et al., 2009). (B) Target mRNA
repression is schematized along the y-axis where repressive potential of seed
site types, site number and positioning, and 3' supplementary pairing is displayed
graphically. Panel B modified from (Bartel, 2009)

23

First, binding energetics and the location of mRNA binding sites are
important in terms of delineating functional repression. The strength of target
mRNA repression is directly proportional to seed energetic stability, as
summarized in Figure 1.6B. Practically, this means that 8mers are on average
more repressive than 7mers, which are more repressive than 6mer seeds, and
so on. 7mer-m8 seeds are typically more repressive than 7mer-A1 seeds, as the
first miRNA position does not engage in base pairing with mRNA; instead the
mRNA binding pocket in AGO structurally prefers an adenosine to allow seed
binding to occur (Elkayam et al., 2012; Schirle et al., 2014). Supplementary 3'
pairing of a miRNA to its target beyond nucleotides 10-12 can boost repression
largely by increasing base pairing stability, though these are considered rare
(Bartel, 2009). By and large, miRNA binding to 3'UTRs is more repressive than
binding to coding exons, presumably due to competition of the translocating
ribosome, though this has not been directly tested. As might be expected,
multiple miRNA seeds per mRNA are more repressive than single seeds, where
notably, cooperative repression is observed if miRNA sites are within 40nt of one
another (Grimson et al., 2007; Saetrom et al., 2007).
Second, functional conservation tends to matter for both the miRNA and
its mRNA binding seed targets. Many miRNA families−i.e. a collection of miRNAs
that share the same seed−are broadly conserved throughout metazoans while
others are found in only a few lineages (Altuvia et al., 2005). miRNAs related by
family typically regulate the same sets of genes in various organisms, such as
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miR-142-3p in myeloid cells or miR-1 in muscle, though this is not always the
case (Lee et al., 2007). In broad terms, the conservation of a miRNA binding site
on its target mRNA can be viewed as evidence for its functional selection. This is
particularly true for miRNAs with critical roles in developmental transitions or
stem cell maintenance (Gangaraju and Lin, 2009).
Lastly, one point that tends to be overlooked is that functional
miRNA:mRNA interactions can only take place if both species are co-expressed.
Like mRNAs, miRNA expression ranges dramatically from ubiquitous to highly
tissue specific. In their current iterations, most miRNA prediction methods
overwhelmingly fail to account for co-expression of a miRNA and its target,
providing instead a static list of every possible interaction. In principle,
miRNA:mRNA co-expression is highly related to the conservation status of a
miRNA binding site, since a selected-for site will be most "functional" upon
encountering its expressed cognate miRNA. Conversely, one can also think of
the depletion of sites from messages co-expressed with miRNAs. For a
prototypical transcriptome, 3'UTR targets contained on average about half as
many conserved and non-conserved binding sites for expressed miRNAs as
expected by chance. In other words, large swaths of the transcriptome appear to
be selectively avoiding regulation by a co-expressed miRNA (Farh et al., 2005).
Furthermore, the evolutionary pressure to avoid miRNA sites is specifically
detected in "housekeeping genes" which might explain their shorter 3′UTRs in
animals compared to the longer 3′UTRs of orthologous transcripts in plants and
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fungi, which lack the same miRNAs (Stark et al., 2005). Considered a major
driver of 3'UTR evolution, the phenomena of selective avoidance has given rise
to the term miRNA "antitargets" to describe mRNAs lacking co-expressed miRNA
sites (Bartel and Chen, 2004; Farh et al., 2005). This negatively impacts miRNA
prediction in that many bona-fide, but tissue-specific or species-specific binding
sites are missed as false negatives.
The situation described above makes it unsurprising that the bioinformatic
emphasis on conservation of miRNA seeds has limits. While conservation of a
miRNA or its target binding site has historically been a key predictive and
computationally searchable hallmark for phenotype screening, more recently it
has become clear that both non-conserved and non-canonical targeting are
frequent occurrences with functional importance (Frankel et al., 2014; Loeb et al.,
2012). The emphasis on miRNA and target conservation is historically justifiable
given the blind frequency of miRNA seeds on target transcripts (on average one
7mer every 10kb, multiplied by ~1000 miRNAs). Reliance on conservation and
strict seed definitions dramatically reduced the searchable space on a
transcriptome and with it, the number of false positives. In this vein, the advent of
CLIP based NGS methods, to be discussed later in this chapter, is a further
refinement to target prediction, and arguably supercedes the reliance on
conservation, seed definition and co-expression by providing direct biochemical
evidence of a miRNA engaging its target in a native setting (Chi et al., 2009;
Grosswendt et al., 2014; Hafner et al., 2010)(Moore, et al. 2015. Submitted).
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To sum, miRNAs likely influence the expression or evolution of nearly all
mammalian mRNAs, via direct interactions or inversely through selective
avoidance, as well as through a myriad targeting rules (Bartel, 2009). In so doing,
we can readily appreciate the ability by which new regulatory events in 3'UTRs
can rapidly emerge within organisms. As 3'UTRs drift to include or exclude
miRNA seeds, or as miRNAs become expressed in certain conditions to regulate
previously unperturbed gene networks, the stage is set for functional modulation
in species and tissue specific realms towards the evolution of new regulatory
features.
Mechanisms of miRNA mediated control
But what of more proximal functions for miRNAs within individual cells? As
strictly post-transcriptional modifiers of gene expression, miRNAs are unique in
that they exert regulatory effects at the level of transcriptional noise (<2 fold
repression in most cases) as defined by inter-individual variation in gene
expression (Cheung et al., 2003). This modest regulation provides an added
dimension to finely tune mRNAs to generate a rich palette of gene expression
(Figure 1.7A-B). This concept is similar to a dimmer switch or rheostat, which
forms an apt analogy to explore the various classes of miRNA targets under
changing environments (Figure 1.7C) (Bartel and Chen, 2004). In the rheostat
model, regulation can proceed in one of three ways: switch-like, tuning, and
neutral. Switch-like regulation is the most familiar in that it is binary; the
expression of a miRNA "turns off" the expression of its target protein by inhibiting
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Figure 1.7. Mechanisms of miRNA control. (A) Transcriptional regulation can
provide a variety of distinct expression levels, illustrated graphically as various
shades of blue. (B) Additive miRNA action adds an additional and posttranscriptional layer of control to produce a richer and more complex expression
palette. (C) Three categories of miRNA targets are presented. Upper dashed line
indicates the upper limit of desired protein expression, lower line demonstrates
the threshold under which the protein is no longer active; in the top panels, these
lines overlap indicating that these thresholds are one and the same and act in a
binary on-off fashion. On the left, miRNA expression induction can engage like a
switch and turn off the expression of a protein (top); can tune protein expression
to within an ideal range (middle) or may have a neutral effect (bottom). On the
right, target induction can be highly dampened by a constitutively expressed
miRNA (top), can be titrated to an optimal expression (middle), or have a neutral
effect (bottom). Panels A and B adapted from David Bartel's iBiology "Intro to
miRNAs" Youtube series. Panel C is modified from (Bartel and Chen, 2004).
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its mRNA. Similarly, a constitutively expressed miRNA can silence abherrent
mRNA expression as a means to dampen transcriptional noise. In the tuning
mode, miRNA expression can lower protein amounts to some desired level, or
can dampen an overshooting transciptional event. Lastly, miRNA action can exert
neutral effects where a protein is repressed but still within an optimal range for
activity. Importantly, examples of each of these versions of miRNA targeting have
been described (Bartel and Chen, 2004).
The optimal expression ranges for proteins whose mRNAs undergo
miRNA regulation--the dashed lines in the figure--are crucial to the model of
miRNA activity presented in Figure 1.7C. Numerous factors can influence the
location of these lines, and by extension, the capacity for protein expression to be
buffered from miRNAs. Here we focus on two related factors: the expression
difference between a miRNA and its target, and the cumulative effect of all
expressed targets of a miRNA (target abundance).
Single cell work from the van Oudenaarden and Sharp labs revealed that
miRNA repression is not uniform across cells and is driven by the expression
level and number of miRNA binding sites in target mRNAs (Mukherji et al., 2011).
Consequently, miRNAs can generate gene expression thresholds. At one
extreme, a target can be dramatically silenced if its mRNA is low relative to the
expression of its regulating miRNA, i.e. it resembles switch-like behavior. At the
other extreme, high target mRNA expression vastly overpowers the inhibitory
effect of a low expressed miRNA (neutral). The middle ground, where miRNA
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abundance and target expression converge, serves a tuning function by
balancing mRNA abundance with repressive miRNA pressure. Adding multiple
miRNA binding sites per transcipt shifts the threshold in mathematically
predictable ways (Mukherji et al., 2011). In these manners, target expression and
the number of miRNA sites appear to govern expression thresholds for individual
miRNA regulated transcripts.
While the above considers the expression difference between one miRNA
and one target, it is important to highlight the aggregate effects of all the targets
of a particular miRNA, and their role in influencing the gene expression
thresholds for one another. Also termed "target abundance" (TA), this parameter
has been incorporated into miRNA target prediction methods to aid in discovering
functional sites (Garcia et al., 2011). Nevertheless, TA implementation typically
relies exclusively on counting the number of conserved miRNA targeting events
in 3'UTRs; thus, real target abundance (the total number of miRNA sites
expressed in a transcriptome) is likely under-estimated. Recent demonstrations
that long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) bind
miRNAs and impart no repressive function on a coding transcript would agree
with TA under-estimation. Moreover, these data point to an entirely new layer of
miRNA regulation by competing endeogenous RNAs (ceRNAs) (Hansen et al.,
2013; Liu et al., 2014b; Memczak et al., 2013; Salmena et al., 2011; Wang et al.,
2013b).
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ceRNAs (including miRNA sponges) will be discussed in Chapters 5. For
now, it suffices to say that miRNAs have continued to reveal their mysteries in
the age of high-throughput sequencing, proving that they are far from settled and
predicable regulators. And as we'll see, their role in virus biology is only
beginning to be revealed.

miR-122
The liver specific miR-122 is the central miRNA player for our purposes. A
confluence of events that lead to its discovery are worth mentioning. As a distinct
miRNA entity, miR-122 was initially cloned in 2002 from a survey of small RNAs
from mice and notably displayed expression only in the liver, where it was also
the most abundant (Lagos-Quintana et al., 2002). At that time, the only known
database sequence match for the miR-122 came from woodchuck liver, as a
result of work done over a decade earlier. In the mid-1980's, Buendia and
colleagues at the Pasteur Institute were studying genetic rearrangements that
resulted in HCC from chronic woodchuck hepatitis virus (WHV) infections.
Closely related to carcinogenic hepatitis B virus (HBV), WHV was and remains
an excellent tractable model for studying hepadnavirus induced liver tumors
(Tennant and Gerin, 2001). The Pasteur group found that the majority of tumors
were the result of a rearrangement and enhanced expression of N- or c-myc, due
to viral insertional mutagenesis (Moroy et al., 1986). In one unique case, they
characterized a chromosomal translocation in which the 5' end of a previously
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unknown gene recombined with the second exon of c-myc, resulting in a 50-fold
increase in c-myc expression (Etiemble et al., 1989; Moroy et al., 1989). Termed
the hcr locus, the unknown gene was found to encode a highly abundant
polyadenylated RNA around 4.7kb in length (Moroy et al., 1989). Curiously, the
RNA was essentially non-coding as the longest ORF was only 37aa in length.
The link between the mature miR-122 sequence and its parent hcr gene was
finally made in 2003-2004, while Chang, Taylor and colleagues were studying the
effects of Dicer on hepatitis delta virus (HDV) infections and confirmed that miR122 was highly abundant in rodent livers and in human hepatoma (Huh-7) cells
(Chang et al., 2003). Shortly thereafter, they confirmed hcr gene as the source
for miR-122, and provided the first functional evidence of its ability to downregulate an mRNA target, cationic acid transporter protein (CAT-1, aka SLC7A1),
with a clear seed dependence (Chang et al., 2004). Much has been learned since
then about miR-122 in terms of its role in many, if not most, aspects of liver
biology. While its association with HCV is most germane to the present work (see
next section), a comprehensive account of all other miR-122 functions is
presented here.
Possible roles in liver development
miR-122 expression begins as early as e12.5 in mice where its expression
is promoted by hepatocyte nuclear factor 6 (HNF6), a hepatocyte-specific
transcription factor (Laudadio et al., 2012; Xu et al., 2010). miR-122, in turn,
forms a positive feedback loop by enhancing the expression of HNF6 and other
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liver-enriched transcription factors (LETFs) (Laudadio et al., 2012). HNF6 along
with other LETFs participate in a network of transcriptional regulation essential
for terminal hepatocyte differentiation (Kyrmizi et al., 2006). More directly, miR122 also downregulates CUTL1, a transcription factor that represses genes
required for hepatocyte differentiation (Xu et al., 2010). It should be noted
however, that these tissue culture based results are largely based on miR-122
overexpression, and may be artifactual (Wang et al., 2010). Moreover, the miR122 knockout mouse, both total and liver specific, is viable and displays no major
defects in anatomical or functional liver development (Hsu et al., 2012; Tsai et al.,
2012).
Lipid metabolism
Studies

in

mice

following

miR-122

antagonism

with

anti-sense

oligonucleotides (ASOs) or locked nucleic acids (LNAs) revealed altered lipid
profiles characterized by reduced plasma cholesterol levels, increased hepatic
fatty-acid oxidation, and a decrease in hepatic cholesterol and fatty-acid
synthesis rates (Elmén et al., 2008; Esau et al., 2006; Krützfeldt et al., 2005).
Interestingly, while a number of direct miR-122 targets were identified in these
studies using microarrays, a substantial fraction of up and down-regulated genes
did not contain miR-122 sites, indicating substantial and indirect roles for miR122 activity. Indeed several genes with crucial to lipid metabolism (ACC1, ACLY,
SCD1, SREBP2 and HMGCR) were down-regulated (Esau et al., 2006; Krützfeldt
et al., 2005). Consistent with these findings, miR-122 antagonism decreased
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serum cholesterol levels in chimpanzees (Lanford et al., 2010). Recent work with
the miR-122 knock-out mouse has linked AGPAT1 and CIDEC as direct targets
of miR-122 (Hsu et al., 2012). CIDEC, also called FSP27, regulates triglyceride
storage and fatty acid oxidation within lipid droplets (Keller et al., 2008; Vila-Brau
et al., 2013). In the liver, CIDEC is induced during the initial stages of fasting, but
decreases during late fasting (Vila-Brau et al., 2013); this oscillation is notable in
light of circadian miR-122 activity (discussed below). AGPAT1 is mostly involved
in regulating the energy state in adipose and muscle tissues by stimulating the
conversion of fatty acids into triglycerides (Ruan and Pownall, 2001; Takeuchi
and Reue, 2009). It is thought that miR-122 repression of CIDEC and AGPAT1
inhibits the storage of triglycerides in liver tissue, and may account for the
increased triglyceride secretion observed in miR-122 KO mice (Hsu et al., 2012).
These two relatively well-studies examples are likely the tip of the iceberg for the
role of miR-122 in hepatic lipid metabolism, as we shall soon see in our own work
using CLIP in miR-122 knockout mice.
Iron metabolism
miR-122 depletion was also observed to cause iron deficiency in mice
where it was found that miR-122 directly targets the hemochromatosis (Hfe) and
hemojuvelin (Hjv) mRNAs for suppression (Castoldi et al., 2011). These proteins
activate hepcidin, a hormone that controls systemic iron levels, which in turn
binds to and induces the degradation of ferroportin, an iron efflux channel
expressed in hepatocytes (Castoldi and Muckenthaler, 2012; Nemeth et al.,
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2004). Consequently, by suppressing the activators of hepcidin, miR-122
prevents the degradation of ferroportin, which permits proper iron uptake in the
liver (Castoldi and Muckenthaler, 2012).
Circadian rhythm inputs to metabolic control
In addition to being controlled by HNF transcription factors, expression of
the miR-122 locus oscillates in a circadian manner and is under the control of two
retinoid-related orphan receptor elements (ROREs) upon which the oscillating
REV-ERBα transcriptional repressor acts to start and stop expression (Gatfield et
al., 2009; Ueda et al., 2002). In the mouse liver, mature miR-122 levels remain
relatively constant, but pre- and pri-miR-122 levels fluctuate such that levels of
these intermediates are lowest at Zeitgeber Time (ZT) 8-12 and highest at ZT24.
These periods correspond to the peak and minimal expression of REV-ERBα
respectively; in REV-ERBα knock-out mice, near constant levels of pre- and primiR-122 were observed (Gatfield et al., 2009). Many miR-122 targets also
demonstrate circadian oscillations in expression that are consistent with miR-122
expression, where a few targets, such a PPARb/d and Nocturnin play key roles in
the liver circadian clock (Gatfield et al., 2009; Kojima et al., 2010). These results
are particularly puzzling, given that mature levels of miR-122 do not fluctuate.
Much remains to explore on this front.
As a biomarker for liver damage
The world of serum miRNA profiling as non-invasive biomarkers for a
variety of disease is vast, sometimes oversold, and often contradictory. While
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comprehensive and rigorous studies to determine the utility of miR-122 as a
biomarker for a variety of complex liver diseases has not yet been performed,
one trend is seemingly apparent: in the many small scale studies, miR-122 levels
are elevated in serum upon liver damage or disease. Correlating with disease
scoring and severity, miR-122 levels were elevated in human and murine models
of liver damage from alcohol and HBV (Zhang et al., 2010). Elevated serum miR122 has been identified as a potential biomarker for liver damage from many
sources, including acute hepatotoxicity, chronic HBC and HCV infections, HCCassociated liver damage, non-alcholic fatty liver disease, acetaminophen
poisoning, and liver transplant rejection (Cermelli et al., 2011; Ding et al., 2012;
Farid et al., 2012; Hu et al., 2013; Starkey Lewis et al., 2011). It should be noted
however, that elevated alanine transaminase (ALT) in serum, a classic marker for
liver injury, was observed in these studies alongside increased serum miR-122.
Thus, it's likely that miR-122 in the blood reflects hepatic cytotoxicity more than
anything else. Still, there is some evidence for miR-122 as a marker for specific
liver injuries, which opens the door for delineating functional differences in miR122 secretion. A study using a mouse model of liver damage demonstrated that
circulating miR-122 could be used to differentiate between causes of liver
damage: drug-induced injury led to miR-122 partitioning to the protein fraction of
mouse serum, while alcohol and inflammation-induced liver injury led to miR-122
circulation in exosomes (Bala et al., 2012).
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Tumor suppressor activities and loss in HCC
miR-122 has been implicated as a tumour suppressor in several different
conditions and model systems, and is notably and typically lost in HCC (Bai et
al., 2009; Coulouarn et al., 2009; Hsu et al., 2012; Kutay et al., 2006; Tsai et al.,
2009). In the HCC cell lines HepG2 and Hep3B, which express little miR-122,
restoration of miR-122 promotes apoptosis and is thought to inhibit proliferation
by suppressing Wnt/β-catenin signaling (Xu et al., 2012). Furthermore, loss of
miR-122 expression in HCC cell lines correlates with increased cell migration and
invasion, while restoration of miR-122 reversed these effects (Coulouarn et al.,
2009). Although a comprehensive evaluation of the role miR-122 targets in tumor
suppression has not yet been performed (but is the focus of Chapter 5),
numerous studies have begun to link miR-122 tumor suppressor activity to
specific targets. miR-122 appears to stabilize the p53 tumor suppressor by
regulating Cyclin G1, and consequently sensitizes cells to doxorubicin
chemotherapy (Fornari et al., 2009). The muscle specific isoenzyme of pyruvate
kinase, PKM2, is a miR-122 target that is upregulated in HCC, is inversely
correlated with miR-122 expression, and is thought to contribute to altered
energy metabolism in HCC cells (Jung et al., 2011). miR-122 knockout mice are
prone to tumor development with age: after progressive liver pathology to include
fibrosis and steatosis, many mice spontaneously develop HCC after a year in
age, and phenocopy the higher male-to-female disease incidence observed in
humans (Hsu et al., 2012; Tsai et al., 2012). These studies demonstrated altered
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lipid metabolism consistent with findings with LNA or ASO treated mice and
furthermore characterized increased liver inflammation and infiltration of IL-6 and
TNF producing cells as well as linked a disregulation of a miR-122 target KLF6,
to fibrosis (Hsu et al., 2012; Tsai et al., 2012). Importantly, both studies showed
that miR-122 loss was reversible: a myc model of liver tumorigenesis could be
rescued by over expressing miR-122, and miR-122 loss could be corrected by
overexpressing microsomal triglyceride transport protein (MTTP), which largely
restored lipid metabolism (Hsu et al., 2012; Tsai et al., 2012). It should be noted
that these rescue experiments, especially in the myc system, were devoid of the
chronic inflammation that usually accompanies and often precedes HCC
development, thus it can be argued that miR-122 tumor suppressor activity is
partially inflammation independent. Still, other studies suggest otherwise. A
subset HCC patients bear a polymorphism (rs3783553) in a putative miR-122
binding site in the 3' UTR of IL-1α. As IL-1α is implicated in carcinogenesis and
tumour growth, as well as in controlling tumor immunity, miR-122 regulation of IL1α may provide a link to liver inflammation upon miR-122 loss (Gao et al., 2009).
A similar argument has been made for the myeloid cell chemoattractant CCL2,
also a miR-122 target, which when derepressed alters the immune cell profile of
the liver (Hsu et al., 2012). The multi-valent role of miR-122 in liver cancer
reflects its role in maintaining liver homeostasis, yet clearly there is much more to
learn.
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Roles in other cancers
Although miR-122 is not expressed in high levels in other tissues, it has
been implicated in cancers of other tissue types. Compared to normal tissues,
miR-122 was found to be downregulated in gastrointestinal primary tumours and
cell lines (Wang et al., 2009). This study further linked miR-122 to APC-mediated
growth inhibition, as miR-122 sequestration had promoted growth; a similar result
to those mentioned above in HCC cell lines (Wang et al., 2009). In a rat model of
colorectal cancer, lowered miR-122 in healthy tissues was predictive of
carcinogenesis elsewhere in the colon, and could be monitored ex vivo from fecal
colonocytes present in the stool (Kunte et al., 2012). In breast cancer, miR-122
was identified in serum deep sequencing of stage II-III patients, with increased
levels of miR-122, and presumably liver damage, correlating with and later
predicting non-responsiveness to neoadjuvant chemotherapy and metastatic
outcomes (Wu et al., 2012). More recent work has begun to establish a causal
role for circulating miR-122 to reprogram glucose metabolism of the premetastatic niche in breast cancer (Fong et al., 2015). Lastly, in anaplastic thyroid
cancer, miR-122 levels increase in thyroid cancer cell lines that respond to
treatment with a PAX8/PPARγ fusion protein, and subsequently are play a tumor
suppressive role, both in vitro and in xenografts (Reddi et al., 2013). This would
suggest that tumor suppressor activity for miR-122 might extend to other tissues,
however, some caution is warranted in interpreting these findings given that miR122 levels in non-hepatic cells is very low.
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Roles in HBV infection: a case for viral restriction?
In HBV infected patients, Wang et al. found a striking negative correlation
between hepatic miR-122 levels and HBV viral load. Loss of miR-122 led to
increased viral replication in HepG2 and Huh-7 cells, suggesting an anti-viral role
for miR-122 in HBV (Wang et al., 2012b). Further work demonstrated that miR122 suppresses Cyclin G1 (also mentioned above), which forms a complex with
p53, itself a negative regulator of HBV transcription. Thus, virus driven
suppression of miR-122 leads to increased Cyclin G1, sequestering anti-viral
p53, and permitting HBV transcription (Wang et al., 2012b). In addition, miR-122
has been shown to directly bind to conserved HBV sequences, and is thought to
directly suppress viral replication. In apparent response to this, miR-122
expression in inhibited by the HBx viral protein by binding PPARγ, a
transcriptional activator of miR-122 (Chen et al., 2011; Song et al., 2013). It has
also been proposed that HBV transcripts harboring conserved miR-122 binding
sites behave as miR-122 sponges, though some caution is warranted as these
results are based solely on overexpression of HBV RNAs (Li et al., 2013a). As in
HCV, miR-122 has been proposed as a serum marker for HBV associated liver
damage and hepatocellular carcinoma, as a means of detecting active or occult
HBV infections, and of predicting HBV disease progression in patients (Chen et
al., 2012; Ding et al., 2012; Qi et al., 2011; Waidmann et al., 2012; Zhang et al.,
2010). While the lack of robust HBV infection systems currently presents a barrier
to identifying the precise role of miR-122 in natural HBV infections, the general
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and compelling evidence that miR-122 expression does appear to inhibit HBV
replication reveals that there is much more to learn.

HCV and miR-122: coming together as a fascinating outlier
And then there's HCV. In 2005, Jopling, Lemon, Sarnow and colleagues,
mostly at Stanford, wondered why HCV replicons could grow in Huh-7 cells but
not in HepG2 cells, despite the fact that both were HCC derived hepatoma cell
lines. Starting with the observation by Chang et al. that miR-122 was found to be
expressed in Huh-7 but not in HepG2 cells, the Stanford group posited that miR122 could be regulating HCV expression (Chang et al., 2004; Jopling et al.,
2006). After confirming miR-122 expression in liver and Huh-7, but not in HepG2
or HeLa cells, they found that suppression of miR-122 using ASOs inhibited HCV
sub-genomic replicons (SGRs) in Huh-7 cells (Jopling et al., 2005). They then
searched the the HCV genome for miR-122 seeds and began a mutagenesis
study, and found remarkably that a miR-122 site in the 5' UTR, when mutated at
various seed positions (p3, p3,4, and p6), resulted in dead SGRs (Jopling et al.,
2005). The mutation could be rescued by transfected miR-122 variants bearing
complementary mutations (Jopling et al., 2005). This genetic evidence formed
the basis of subsequent studies of miR-122 and HCV, which from the outset
represented a unique outlier on two fronts. Whereas miRNAs typically interact
with the 3'UTRs of mRNAs to suppress gene expression, HCV engagement of a
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miRNA at its 5'UTR was critical for viral RNA accumulation. Subsequent work to
describe the unique mechanism at play is described here.
miR-122 binding sites on the HCV genome
In addition to the original miR-122 site (termed S1), a second miR-122 site
(S2) located 10nt downstream of S1 in the 5'UTR is also critical for viral RNA
accumulation, and both sites engage with auxiliary pairing at nucleotides 2-3nt for
S1 and 30-31nt for S2 (Jopling et al., 2008; Machlin et al., 2011). Importantly, S1
and S2 sites are highly conserved across all known HCV genotypes (Jopling et
al., 2006). Additionally, viruses closely related to HCV, such as GVB-V, and the
recently identified non-primate hepacivirus (NPHV), retain two and one
conserved miR-122 sites in their respective 5'UTRs (Burbelo et al., 2012; Kapoor
et al., 2011; Sagan et al., 2013). The very recent isolation of additional rodent
and perhaps bat hepaciviruses will likely add to this list, and may offer long
sought after murine models of HCV infections (Drexler et al., 2013; Firth et al.,
2014; Kapoor et al., 2013).
For HCV, S1 and S2 sites were found to be simultaneously required for
viral RNA accumulation, where interestingly, swapping the S1 seed for a miR-21
binding site was non-viable (Jopling et al., 2008). More recent work has delved
deeper into the base contacts proposed at S1/S2. Two studies have applied
selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) analysis to
measure RNA nucleotide flexibility in the HCV 5'UTR with or without miR-122 in
vitro. In both studies, SHAPE and gel shift assays revealed additional base
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contacts at the S2 site, resulting in higher energetic stability (Mortimer and
Doudna, 2013; Pang et al., 2012). While the functional consequences of
differential S1 versus S2 binding have yet to be worked out, one recent study
looking for HCV variants that would be resistant to miR-122 sequestration found
that a G to A mutation at position 28, between S1 and S2, was partially resistant
to miR-122 inhibition (Israelow et al., 2014).
In addition to increased contacts at the S2 site, Pang et al. observed miR122 dependent changes in SHAPE reactivity in the IRES domain 4, suggesting a
3 albeit very non-canonical miR-122 site in the IRES (Pang et al., 2012). The
rd

relevance of this site for a fully infectious virus is unknown. Other miR-122 sites
on the virus genome can be found in the NS5B coding sequence and
interestingly, one very highly conserved site in the 3'UTR; however, none of
these sites appear to be functionally important, at least in cell culture system
settings, as mutagenesis of these sites showed no major effects on viral
replication (Jopling et al., 2008; Nasheri et al., 2011).
Interactions of other miRNAs with the HCV genome
With the discovery of a positive role for miR-122 in HCV replication, much
attention turned to the role, if any, of additional miRNAs on impacting HCV by
directly engaging the viral RNA genome. In 2007, Pedersen, Chisari and
colleagues reported that upon IFNbeta treatment in cell culture, miR-122
expression was repressed and that surprisingly, a number of IFN stimulated
miRNAs could antagonize HCV RNA directly and repress viral gene expression
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(Pedersen et al., 2007). Furthermore, over-expression of the five IFN induced
"anti-viral" miRNAs reduced HCV RNA replication in a manner that was seed
dependent, as chimeric viruses of isolates containing natural mutations in
putative seeds were no longer repressed (Pedersen et al., 2007). Not
surprisingly, there was much excitement surrounding these findings, as they
seemed to merge the protein based ISG response with one that included miRNA
function in an ancient and anti-viral RNAi-like mode (Beard and Helbig, 2008).
Enthusiasm was soon tempered as no correlation between miR-122 levels and
HCV viral load was found in patients undergoing IFN therapy. Furthermore, the
absolute expression of the "anti-viral" set of miRNAs was dramatically low in both
mouse liver and in Huh-7 cells, even with IFN treatment (SarasinFilipowicz et al.,
2009). Despite these findings, numerous groups have continued to find additional
miRNAs that antagonize the HCV genome (reviewed in (Singaravelu et al.,
2014)). It must be stressed however, that as these results are overwhelmingly
based on the overexpression of small RNAs and reporter constructs, artifactual
findings can be considered likely.
miR-122 function on HCV: stabilizing RNA and promoting translation
As the HCV genome lacks a 5' cap structure, one early hypothesis was
that the Ago:miR-122 complex may serve as a type of cap to protect the 5' end
from exonuclease recognition. This appears to be the case. A study using
replication defective genomes found that miR-122 transfection slowed the decay
of HCV RNA, while miR-122 inhibition enhanced decay (Shimakami et al., 2012).
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Furthermore, this activity was dependent on the presence of AGO2 (Shimakami
et al., 2012; Wilson et al., 2011). AGO2:miR-122 complexes appear to protect
HCV RNA from 5' exoribonucleases XRN1 and XRN2 , as knockdown of these
factors largely rescues viral replication after miR-122 antagonism(Li et al., 2013d;
Sedano and Sarnow, 2014).
In addition to protecting the 5' end of viral RNA, two studies have shown
that miR-122 promotes translation, albeit somewhat transiently. Using HCV RNA
in a non-premissive rabbit reticulocyte lysate system, Henke et al. observed a
50% increase in HCV translation in the presence of miR-122 but not miR-124
(Henke et al., 2008). Similar results were observed using replication defective
reporter genomes in Huh-7 cells and measuring shortly after RNA electroporation
(Jangra et al., 2010).
miR-122 function on HCV: a replication and translation switch?
Very recent work from Masaki, Lemon and colleagues has posited a role
for miR-122 as a regulator for positive strand replication versus translation. Using
5-ethnyl uridine incorporation into nascent RNA, miR-122 transcfection was
found to transiently increase HCV RNA synthesis and was dependent on protein
synthesis (Masaki et al., 2015). Consistent with this, a small reduction in
polysome associated HCV RNA was observed upon miR-122 transfection
(Masaki et al., 2015). As the S2 miR-122 site overlaps with a PCBP2 binding site,
thought to aid in the circularization of the HCV genome, a competition model has
been

proposed

where

miR-122
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occupancy

prevents

PCBP2

induced

circularization, and subsequent translation in favor of RNA replication. How this
effect on increased RNA replication squares with increased HCV translation
observed with miR-122 in other HCV contexts remains to be determined.
Making cells permissive: miR-122 expression engineering
The initial impulse to explain the HCV permissiveness of Huh-7 but not
HepG2 cells highlights the importance of miR-122 as important for cell tropism
(Jopling et al., 2005). With this in mind, miR-122 expression has been
engineered to make cells permissive to HCV in HepG2 cells and in mouse cells
with limited success (Israelow et al., 2014; Lin et al., 2010; Narbus et al., 2011). It
is generally thought that miR-122, alongside entry factors, is a major determinant
for the hepatotropism of HCV. In support of this, ectopic expression of miR-122
can render numerous non-hepatic cell lines permissible for HCV infection,
including 293T cells, Hec1B (uterus), MC-IXC (nerve), and RERF-LC-AI (lung)
cells (Da Costa et al., 2012; Fukuhara et al., 2012). Whether the low levels of
miR-122 in non-hepatic tissues might support an extra-hepatic reservoir of HCV
is unknown at present.
HCV exceptions to miR-122
Despite the fact that miR-122 seeds sites are conserved in all HCV
genotypes, mutants have been isolated that are largely resistant to miR-122
antagonism (Li et al., 2011). The most resistant variant in this study, called the
U3 virus, replicated in the presence of miR-122 antagomir. This recombinant
virus was found to have replaced stem loop I of the IRES with cellular U3
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snoRNA, ablating the S1 site while maintaining S2 (Li et al., 2011). As mentioned
above, the isolation of horse, rodent and bat hepaciviruses with between one and
two miR-122 sites in various configurations raises the question as to their
putative miR-122 dependence. Additional work has pinpointed miR-122
independence for the hepatotropic GB virus B (GBV-B), a close relative to HCV
(Sagan et al., 2013).
Antagonizing miR-122 as an anti-viral therapy: a high resistance barrier
That HCV uses a small RNA as a critical host factor raised the immediate
possibility that miR-122 antagonism could be a viable anti-HCV therapy (Jopling
et al., 2005). Work has progressed systematically on this front, with the
demonstration that miR-122 locked nucleic acid (LNA) inhibitors were well
tolerated in in mouse livers and in HCV infected chimpanzees (Elmén et al.,
2008; Lanford et al., 2010). The resulting human compound, called miravirsen,
represents a first-in-class therapy aimed at targeting a cellular miRNA (Scheel
and Rice, 2013). Phase II studies in humans treated with miravirsen resulted in
rapid drops in viral load for the duration of therapy and long-term follow-up has
not resulted in any major adverse effects (Janssen et al., 2013; van der Ree et
al., 2014). Importantly, no virus breakthrough or escape mutants were observed
for the duration of treatment, highlighting the utility of targeting a small RNA host
factor and furthermore suggestive of a high barrier to resistance (Janssen et al.,
2013). While miravirsen resistant HCV variants have been uncovered in vitro,
none have yet to be reported in patients.
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Viruses and miRNAs: a novel axis of host pathogen interaction
The story of HCV and miR-122 is illustrative but certainly not unique. Early
speculation that other viruses, particularly large and complex dsDNA viruses,
might manipulate the miRNA pathway was confirmed early on with the discovery
that Epstein Barr Virus (EBV) encodes miRNAs (Pfeffer et al., 2004). Subsequent
work revealed that the majority of herpesviridae family members encode multiple
miRNA genes (Cullen, 2013). Generally, natural viruses that encode miRNAs
have a DNA component to their replication cycle, have full access to host primiRNA biogenesis machinery by replicating in the nucelus, and typically undergo
long-term persistent infections (Kincaid and Sullivan, 2012). Viruses with DNA
genomes (the Herpesvirus, Polyomavirus, Ascovirus, Baculovirus, Iridovirus, and
Adenovirus families) and at least one member of the retrovirus family, bovine
leukemia virus (BLV) have been shown to encode functional miRNAs (Kincaid
and Sullivan, 2012). Most work has focused on the herpesviruses due to the
sheer number (usually dozens) of miRNAs that each virus encodes as well as the
relative ease by which miRNA expression can be measured.
In general, the functions of DNA virus encoded miRNAs are thought to
relate to DNA virus lifestyles which, in the case of herpesviruses, have both latent
and lytic phases. From the perspective of a latent herpesvirus infection, a miRNA
presents a wonderfully subversive means to auto-regulate viral gene expression
or to manipulate host gene expression, all in a non-immunogenic manner
(Umbach and Cullen, 2009). This hypothesis has animated the herpesvirus field
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to uncover such examples and in the process has helped shed light on long
mysterious phenotypes. For instance, during latency, Herpes simplex virus 1
(HSV-1) expresses one non-coding transrcipt called the latency associated
transcript (LAT) and little else (Stevens et al., 1987). The precise role of the LAT
was mysterious until it was found to encode numerous miRNAs that targeted the
HSV reactivating transciption factors ICP0 and ICP4 (Umbach et al. 2008).Thus
LAT expression represses leaky expression of ICP0 and ICP4 which would
otherwise compromise latency if minimally expressed. Supporting this,
suppression of LAT results in spontanous reactivation in ganglia (Du et al., 2011).
In addition to auto-regulation, herpesviruses have co-opted existing
miRNA network for selfish ends. A notable example is Kaposi's sarcoma
associated herpesvirus (KSHV), which encodes a miRNA called miR-K12-11 that
acts as a miRNA analog to cellular miR-155 (Gottwein et al., 2007). In this
manner, KSHV can subvert the miR-155 targetome in its native B-cell setting by
expressing its own version, which in this case, appears to suppress innate
immune, pro-apoptotic and transcription factors (Gottwein et al., 2007).
Moreover, as miR-155 over-expression is thought to drive B-cell lymphomas,
these data also provide compelling molecular evidence for the mechanism of
KSHV induced B-cell transformation (Eis et al., 2005). Similar anti-apoptotic
themes were also found among Epstein Barr virus (EBV) encoded miRNAs, in
analyses for which I was able to take part (Riley et al., 2012a). As many EBV
miRNAs have no host analog, these data were demonstrative of the unique
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capabilitiy of a virus evolving a miRNA to target new sets of genes (Riley et al.,
2012a). Moreover, recent evidence suggests that EBV induced lymphoma critical
requires viral miRNAs to suppress apoptosis (Vereide et al., 2013).
The story is quite different for RNA viruses and is currently evolving. It was
not widely accepted that naturally occuring ssRNA or dsRNA genome viruses
encode functional miRNAs (Cullen, 2010). To a degree, the arguments
supporting this claim make sense: a miRNA hairpin or dsRNA precursor
produced by an RNA genome should by definition undergo Drosha or Dicer
cleavage of either the genome, anti-genome or subgenomic RNAs and is likely to
result in reduced fitness. Additionally, dsRNA or extant hairpins are obvious
targets for PAMP detection. One early study failed to show any miRNAs from six
well characterized RNA viruses (Parameswaran et al., 2010). Emerging
exceptions can be found among retroviruses, which package an RNA genome
into virions but uniquely go through a DNA stage in their lifecycle via reverse
transcription and and integration into the host genome. While early studies
purportedly found small RNAs encoded in the HIV-1 genome in addition to a
suppressor of RNA silencing, they could not be confirmed (Bennasser et al.,
2005; Lin and Cullen, 2007; Triboulet et al., 2007). A more recent renewed focus
on retroviral miRNAs has centered on bovine leukemia virus (BLV), which clearly
encodes a miRNA that interestingly acts as a cellular miR-29 mimic (Kincaid et
al., 2012). Both simian and bovine foamy viruses (SFV and BFV) were shown to
encode functional miRNAs (Kincaid et al., 2014; Whisnant et al., 2014). Notably,
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SFV possesses a unique mechanism for controlling Drosha processing by
regulating RNA pol II versus pol III transcription of the viral miRNA; in this
manner, the virus is thought to avoid the fitness penalty associated with Drosha
cleavage (Kincaid et al., 2014). Moreover, one SFV miRNA appears to act as a
mimic to miR-155, which is very reminiscent of the KSHV story presented above.
The emerging picture painted for retroviruses has not gone unnoticed by
RNA virologists in re-evaluating the potential for other RNA viruses to encode
miRNAs. While still too early to draw firm conclusions, miRNAs have been
putatively discovered in flaviviruses such as West Nile virus (WNV) and Dengue
virus (DENV) (Hussain and Asgari, 2014; Moon et al., 2012; Pijlman et al., 2008;
Schnettler et al., 2012).
Perhaps the most interesting recent take on miRNAs as an "anti-viral"
effector concerns the North American eastern equine encephalitis virus (EEEV),
a highly virulent mosquito-borne alphavirus that results in a 30-70% mortality rate
in humans. Unlike its South American counterpart, Venezuelan equine
encephalitis virus (VEEV), EEEV is restricted from myeloid cells which in turn do
not produce interferon. It was found that this EEEV restriction in immune cells
was due to the presence of miR-142-3p sites, a myeloid specific miRNA, in the
EEEV RNA genome (Trobaugh et al., 2013). By this mechanism, EEEV has
evolved to be suppressed in myeloid cells specifically so as to evade the innate
immune response. Moreover, the selective maintenance of miR-142-3p sites on
the viral genome also seemed to confer a benefit for mosquito borne
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transmission, so there appears to be a selective advantage for the miR-142-3p
sequence in both host and vector backgrounds (Trobaugh et al., 2013). In sum,
these findings turn the anti-viral miRNA hypothesis on its head, by placing the
virus in control of its own tropism where miRNAs can be considered essential
host factors required to negatively select virus replication from specific contexts.

Uncovering host-viral interactions at the RNA level
As the above discussion highlights, the role of small RNAs in viral
infections is far from complete and is under current, active investigation.
Nevertheless, we can consider a comprehensive framework that attempts to
address the possible roles by which a miRNA (or siRNA) can aid or inhibit a
virus, taking into account the host or viral source of the RNA (Figure 1.8)
(inspired by the discussion in (Cullen, 2009)). In this framework, we consider
AGO as the protein stage for an unfolding drama between host and viral RNAs.
In normal cells, miRNA:mRNA interactions take place as usual, but upon virus
infection, switching and tuning of a host response (anti-viral or otherwise) can
occur. Viral coercion can take place in three direct forms: by encoding viral
miRNAs, by permitting miRNA targeting of viral transcripts, and by the complete
viral re-programming of AGO. As highlighted above, examples of each of these
forms of regulation have been documented, especially in DNA viruses.
Importantly, it must be noted that each of these forms of regulation do not have to
occur in isolation and can influence one another. For instance, a viral miRNA
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Figure 1.8. A comprehensive scheme of AGO associated miRNA:mRNA
interactions between host and virus. In this model, four main interactions are
considered: host responses to virus infection (top left), viral miRNA targeting of
host mRNAs (top right), host miRNA targeting of viral mRNAs (bottom left), and
viral auto-regulation (botom right). Note that effects of one type of targeting may
have effects on others. For instance, in miRNA sponging, an abundant viral
transcript sequesters a cellular miRNA and would thus affect the normal host
targeting of that miRNA. The obverse of this scenario are viral mimics of celluler
miRNAs. For each scenario, relevant viruses that offer experimental support are
highlighted (see text for details).

sponge would resemble a host miRNA:viral mRNA regulation on AGO, but its
effects would be functionally exerted on inhibiting normal cellular miRNA function
and de-repressing specific targets. This is consistent with a few examples from
herpesviruses, which encode non-coding RNAs that serve as decoys for miRNA
activity: Herpesvirus saimiri produces RNAs that were found to sequester miR27, while human cytomegalovirus (HCMV) produces a stretch of intergenic RNA
that functionally inhibits the miR-17 family (Cazalla et al., 2010; Lee et al., 2013).
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Virus miRNAs that mimic a cellular miRNA are the obverse of this scenario
(Kincaid et al., 2014). However, it must be stressed that these examples are all
mostly anecdotal, relying on specific genetic characterization and reporter
validation that misses the global picture of the RNA traffic on AGO in the infected
cell. To circumvent this, we must turn our attention to genomics methods aimed
at achieving a high resolution and unbiased map of global miRNA:mRNA
interactions across the cell.

HiTS-CLIP, a method for global interrogation of protein-RNA interactions
High-throughput sequencing crosslinking and immunoprecipitation (HiTSCLIP aka CLIP-seq) is a method that combines the stringent purification of RNAs
bound to an immunoprecipitated RNABP and massively parallel sequencing of
these RNAs by cDNA cloning and library construction (see Chapter 2). It is useful
to consider HiTS-CLIP as a subset of total RNA-seq, where instead of purifying
mRNA on the basis of a polyA tail (or negative selection of ribosomal RNAs),
RNA is "filtered" through a protein. In this manner, the specific targets of an
RNABP may be identified from the level of transcriptomes to nucleotides (Darnell,
2010).
The motivation behind CLIP based methods owes much to work aimed at
understanding DNA-protein interactions in living cells. Early attempts to isolate
DNA-protein complexes, often weakly bound in vivo, harbored the major concern
of ensuring that physiologic complexes were preserved and not artifactually
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created upon cell disruption (Dedon et al., 1991). Improved biochemical
purification methods in the mid 1980's that incorporated a chemical crosslinking
step greatly enhanced signal to noise (Gilmour and Lis, 1984; Kuo and Allis,
1999; Solomon and Varshavsky, 1985). In this manner, the DNA biochemists
were able to ascertain physiologic DNA-protein complexes in a variety of
systems, and thus underwrote the growth of the chromatin field.
The relative fragility of RNA relative to DNA is probably the most proximal
cause for the lag between pioneering work with chromatin IP (or ChIP) and its
protein-RNA equivalent in CLIP. Re-association artifacts in early RNA IP ("RIP")
work were later confirmed to have confounded early work, presumably due to the
"stickiness" of ssRNA relative to dsRNA (Brown et al., 2001; Darnell et al., 2001;
2005). Compellingly, RNA-protein artifacts were shown to be a major driver for
RIP experiments with ELAV and AGO (Mili and Steitz, 2004; Riley et al., 2012b).
Again, crosslinking came to the rescue, but unlike the chromatin field,
which primarily uses formaldehyde as a general and reversible crosslinking
agent, UV crosslinking became the method of choice for CLIP precisely for its
specificity and irreversibility (Darnell, 2010). Although the mechanism is
incompletely understood, UV-mediated crosslinking is thought to involve UV light
absoprtion by nucleic acid bases (Brimacombe et al., 1988). This in turn raises
their grounded energy state to enable the formation of a covalent bond with
molecules very closely opposed, within the order of ångstroms (Fecko et al.,
2007). Importantly, UV light (at 254nm) only induces protein-RNA and RNA-RNA
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crosslinks, no protein-protein crosslinks are observed as they are with chemical
reagents. Moreover, while the true figure is unknown, it does appear that the
protein-RNA crosslinking reaction occurs on a minority of contact sites (estimated
between 1-5%) (Darnell, 2010). The crosslink itself also does not appear to
substantively interfere with the reverse transcription of RNAs with crosslinked
amino acid moieties; instead RT tends to skip such bases, resulting in deletions
that can be used to map RNABP binding sites to single nucleotide resolution
(Zhang and Darnell, 2011). Most importantly, the covalent bond afforded by UV
crosslinking enables the rigorous purification of protein-RNA complexes under
stringent wash conditions.
The benefits provided by crosslinking RNA to protein enabled pioneering
work by Ule, Jenson, Darnell and colleagues to map the RNA network regulated
by NOVA in the mouse brain (Ule et al., 2003). What is prescient about this work
is how clearly the idea was ahead of the sequencing technology: NOVA bound
RNAs were cloned as a library (presumably with millions of individual binding
events) but underwent TOPO cloning and Sanger sequencing. The result was a
then heroic, but now measly ~340 CLIP "tags" from that mapped to NOVA
regulated exons (Ule et al., 2003). Within three years, the "HiTS" was added with
the adaptation of CLIP libraries for sequencing on early Illumina machines, in this
way the NOVA regulated network expanded three orders of magnitude by tag
number (>200K tags) (Licatalosi et al., 2008). Since then, numerous RNABPs
have been studied at the systems level with CLIP to reveal transcriptome wide
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roles in RNA regulation: HuC, Rbfox, RBM47, FMRP, MBNL2, FUS, PTBP2 to
name but a few (Darnell et al., 2011; Ince-Dunn et al., 2012; Licatalosi et al.,
2012; Nakaya et al., 2013; Vanharanta et al., 2014; Wang et al., 2012a; WeynVanhentenryck et al., 2014).
Common among all of these studies is the study of "binary" protein-RNA
interactions, that is, a protein bound to a single RNA target. Applying this method
to a "ternary" interaction, namely AGO bound to miRNAs and mRNA targets, was
achieved shortly before I joined the Darnell lab. Unequivocally, everything to be
presented in this thesis is based on work done by Sung Wook Chi, Julie Zang,
Aldo Mele & Robert Darnell, who in 2009 published results obtained from
applying HiTS-CLIP to AGO (AGO-CLIP) and revealing a miRNA:mRNA
interaction map in the mouse brain (Chi et al., 2009). It was immediately apparent
to me, given the anecdotal and largely un-resolved role of small RNAs in virus
infections that this could be a technique to steer towards questions in virology.
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Aims of this thesis
The preceding sections build a case for studying virus infections with AGO HiTSCLIP and using HCV as a model system, given its well-known association with
miR-122 as a positive control. The overall goal of this thesis has been to
generate a physical and testable miRNA:mRNA interaction map for an HCV
infection genome wide. Moreover, the study of HCV raises an intriguing
possibility, given that HCV causes liver cancer and critically requires miR-122 for
its replication. Combined with the observation that miR-122 knockout mice
spontaneously develop liver cancer, a tantalizing hypothesis emerges: HCV
might effectively lower miR-122 levels in hepatocytes, which in turn may
constitute an oncogenic stress in chronically infected cells. In all honesty,
presenting this as an a priori hypothesis is a bit misleading, since it constitutes
both the main conclusion and the main question raised by the work to be
presented. Thus, only with a bit of hindsight can the following aims be proposed:

• Adapt and carry out AGO HiTS-CLIP analysis of HCV infected cells
• Characterize and validate AGO binding events on the HCV RNA genome.
• Characterize and validate AGO binding events on the host transcriptome.
• Interrogate the miR-122 target network in mouse and human livers.
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Chapter 2: Materials and methods
Far from being a dense recitation, this section provides a holistic view of
the materials and methods used in this thesis. This will include the reasoning
behind the selections of reagents and protocols, the justifications for
modifications, and key optimization experiments not discussed in the main text.
The scope of this section will range from wet to dry, that is, from experiments at
the bench or tissue culture hood, to finished bioinformatic analyses and
visualization. It is my goal to provide the reader with a deep view of the thinking
behind how experiments were planned and performed, how assumptions were
managed, and in the case of seemingly arbitrary decision-points (particularly
informatics ones), what course of action was decided upon. Most importantly, this
section is written with practitioners in mind, in the hope that any graduate student
or postdoc who is engaged in similar work may find something useful.
Selection, construction, and culture of cell lines
Huh-7.5 cells were clonally derived from Huh-7 cells that had been
transduced with HCV subgenomic replicons (SGRs) and subsequently cured of
HCV using IFN-alpha (Blight et al., 2002). These cells were found to exhibit
enhanced HCV replication and virus production largely without inducing adaptive
mutations, and resultantly have been a staple of HCV research in the Rice lab.
Later work suggested that this enhancement in permissiveness was due to
defective RIG-I signaling which abrogated an otherwise antiviral IFN response
(Sumpter et al., 2005). With the observation that HCV NS3/4A specifically
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antagonizes a key down stream component of RIG-I signaling, mitochondrial
antiviral signaling protein (MAVS, a.k.a. IPS-1, VISA, and Cardif) (Meylan et al.,
2005), we reasoned that the Huh-7.5 context would illuminate small RNA:viral
RNA interactions in a setting where the innate immune response has failed, in
other words, when the virus had effectively disabled the protein-based IFN
response. Ultimately, however, these cells were chosen for the practical concern
of enabling high infection frequency, unlike parental Huh-7 cells. Such a large
and homogenously infected population of cells was critical for interpretable
genomics results due to the high sensitivity, though still population based,
measurements provided by CLIP and RNAseq.
Huh-7.5 cells and related variants were maintained in Dulbecco's Modified
Eagle Medium (DMEM) (Invitrogen, Life Technologies) supplemented with 5%
heat inactivated fetal bovine serum (FBS, Hyclone, Thermo Scientific), and
0.1 mM nonessential amino acids (NEAA, Invitrogen, Life Technologies). Cells
were maintained at 37ºC in 5% CO2. For single cells plated for clonal expansion,
cell conditioned media with 10% FBS was used to enhance cell viability. To make
conditioned media, cell were incubated with media containing 10% FBS and
serially harvested every 24 hours. This conditioned media was filtered through
0.22µm Amicon filters (Millipore).
Huh-7.5 TetON cell construction
These cells were a kind gift from Nick Takacs, who made them as follows:
Huh-7.5 cells were transduced with retroviral particles made in 293T cells
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following co-transfection with pRetroX-Tet3G (Clontech), MLV GagPol and VSVg
plasmids. Transduced cells were selected using 500 μg/mL G418, plated in 96well format at 0.5-0.8 cells/well, and single cell clones were expanded. The
clones were tested for permissiveness to HCV infection, growth rate, doxycycline
dose-response of induction and timecourse of induction after transduction with a
mCherry fluorescent protein reporter expressed from retroviral vector pRetroX
TRE3G (Clontech). The clone deemed to have the optimal overall performance in
these assays was re-named Huh-7.5 TetON and used in subsequent assays.
Huh-7.5 TetON cells were maintained in DMEM with 10% FBS, 0.1mM NEAA,
and 500µg/ml G418 (Gibco).
CRISPR mediated deletion of miR-122 in Huh-7.5 cells
Guide

sequences

122.sgRNA1

and

122.sgRNA2

(to

remove

approximately 38 nucleotides including the miR-122 seed and partial stem-loop
(Figure 2.1A) were cloned into pX330-U6-chimeric_BB-CBh-hSpCas9 (pX330,
Addgene plasmid #42230) following published protocols (Ran et al., 2013). After
sequence confirmation, 1.25µg of each pX330-122.sgRNA1 and pX330122.sgRNA2 (2.5µg total) was used to electroporate 1x106 low passage Huh-7.5
cells with an Amaxa Nucleofector 2b machine (Lonza) using program T-28 and
Nucleofector Kit V reagents, following the manufacturers instructions. The
supplied GFP plasmid was used as an electroporation control. Two days after
electroporation, cells were seeded in 96 well plates at 0.5 cells / well for single
cell clonal expansion. To genotype single cell clones and to approximate editing
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Figure 2.1. A CRISPR based targeting strategy to delete miR-122 from Huh-7.5
cells. (A) Guide RNAs were designed to delete a 38bp region encompassing the
5' end of the miR-122 stemloop, including the entire miR-122 seed, and an
adjacent DdeI restriction site. Approximate cut sites indicated with red triangles.
PAM: protospacer adjacent motif. (B-C) Location of DdeI restriction sites and
fragment sizes relative to the miR-122 PCR amplicon for WT (B) and the ΔmiR122 (C) mutant, used for genotyping. Targeted deletion of one DdeI site is
expected to yield two fragments (190 and ~300bp respectively), while unedited
clones should produce three fragments (190, 100 and 231bp). (D) Genotyping of
GFP or CRISPR transfected and expanded clonal cell lines after DdeI digestion
of PCR amplicons. Suspected ΔmiR-122 clones where one DdeI site has been
deleted are indicated with black arrows.
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efficiency in bulk cells, DNA was extracted using QuickExtract (Epicentre) and
the miR-122 locus PCR amplified for 30 cycles. The resulting PCR products were
purified, digested with DdeI (NEB), and underwent gel electrophoresis. As the
deleted segment destroyed a DdeI restriction site, CRISPR deletions were
identifiable on the basis of an altered restriction digest pattern (Figure 2.1B-D).
Homozygous deletions, along with unedited and GFP only clones were expanded
and used for subsequent studies. Guide sequences are in the Appendix.
CRISPR mediated deletion of Drosha in Huh-7.5 cells
For

Drosha

deletion,

guide

sequences

Drosha.sgRNA1

and

Drosha.sgRNA2 were designed to excise exon 9 and force an out of frame
splicing between exons 8 and 10 as reported previously (Chong et al.,
2008)(Figure 2.2). Guide RNAs were cloned into pX458-pSpCas9(BB)-2A-GFP
(pX458, Addgene plasmid #48138). After sequence confirmation, transfection
and single cell dilution cloning proceeded as above. To genotype single cell
clones and to approximate editing efficiency in bulk cells, DNA was extracted
using QuickExtract (Epicentre) and the Drosha exon 9 locus PCR amplified for 35
cycles. The resulting PCR products underwent gel electrophoresis, where deleted
cells yielded shorter amplicons. One homozygous deletion clone (ΔDrosha) was
isolated, along with unedited clones. Western and northern analysis of ΔDrosha
cells are described in the next chapter. Guide sequences are listed in the
Appendix.
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Figure 2.2. A CRISPR based targeting strategy to delete Drosha from Huh-7.5
cells. (A) Guide RNAs were designed to delete a 166bp region encompassing
exon 9 of the Drosha gene. Approximate cut sites indicated with red triangles.
PAM: protospacer adjacent motif. (B) Genotyping of CRISPR transfected and
expanded clonal cell lines after PCR amplification surrounding exon 9. One clone
(#55) exhibited a deletion consistent with exon 9 homozygous removal. Plus sign
indicates PCR from bulk transfected cells prior to single cell dilution cloning.
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CRISPR mediated deletion of Dicer in Huh-7.5 cells
Initial Dicer deletion was attempted by following a similar scheme as
Drosha, to delete a coding exon with an out-of-frame splice to force a frameshift
and premature stop. Exons 1 and 2 was successfully deleted independently in
this manner, yet full Dicer activity was observed in exon 1 deleted cells, and
residual activity in exon 2 deleted cells, likely due to a downstream start codon
that resulted in a tolerable N-terminal deletion (Ma et al., 2008)(see Chapter 3).
To make a complete knockout, I focused on deleting exon 19 in both WT and in
exon 2 deleted cells, to induce a frameshift whereby any downstream translation
would make a fragment lacking the helicase domain, the domain of unknown
function (DUF), and the Piwi Argonaut and Zwille (PAZ) domain, all known to be
critical for dsRNA and miRNA processing by Dicer (Ma et al., 2012). Guide RNAs
were cloned into pX458-pSpCas9(BB)-2A-GFP (pX458, Addgene plasmid
#48138). After sequence confirmation, transfection and single cell dilution cloning
proceeded as above. Genotyping was performed from QuickExtract (Epicentre)
isolated DNA and the Dicer exon 19 locus was PCR amplified for 35 cycles. The
resulting PCR products underwent gel electrophoresis, where deleted cells
yielded shorter amplicons (Figure 2.3). Two homozygous deletion clones were
isolated in WT cells (ΔDicerEx19) and one in exon 2 deleted cells
(ΔDricerEx2.19), along with unedited clones. Western and northern analysis of
ΔDicer cells are described in the next chapter. Guide sequences are listed in the
Appendix.
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Figure 2.3. A CRISPR based targeting strategy to delete Dicer from Huh-7.5
cells. (A) Guide RNAs were designed to delete a 194bp region encompassing
exon 19 of the Dicer gene. Approximate cut sites indicated with red triangles.
PAM: protospacer adjacent motif. (B) Genotyping of CRISPR transfected and
expanded clonal cell lines after PCR amplification surrounding exon 19. Four
clones (12, 17, 19, 20) exhibited a deletion consistent with exon 19 homozygous
removal. Plus sign indicates PCR from bulk transfected cells prior to single cell
dilution cloning.

Generation of recombinant HCV plasmids
The selection of which HCV to use in these studies has largely centered
on genotype 2 viruses, due to their ability to generate relatively high titer stocks
(by historical HCV standards), as well as the ability to generate the large and
homogeneously infected population of cells needed for CLIP. Moreover, as the
5'UTR miR-122 sites are completely conserved across all genotypes, results
related to miR-122 studies with this virus are likely to be generalizable to other
genotypes, though importantly, this has not been directly studied.
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pJ6/JFH1-Clone2,
nsGluc2A)

are

pJ6/JFH-Clone2-5AB-Ypet,

fully-infectious

HCV

non-reporter

and
and

pJc1FLAG(p7reporter

viruses

respectively, that have been previously described (Catanese et al., 2013a;
Horwitz et al., 2013; Marukian et al., 2008). Clone2 HCV is notable for efficient
cell-to-cell spreading and is resistant to SR-BI antibody mediated inhibition, in
this manner a high proportion of infected cells is thought to be achieved
(Catanese et al., 2013a). To construct miR-15 dependent viruses in both
backgrounds, we used overlap extension PCR. Briefly, pJ6/JFH1 Clone 2
plasmid DNA was digested with EcoRI and KpnI to yield a 1298nt fragment
encompassing the start of T7 transcription, both miR-122 sites, and reading into
the E1 coding sequence. A 1.2kb region (Fragment A), upstream of miR-122
sites, was PCR amplified from the parental 1298nt fragment with Accuprime Pfx
Supermix (Invitrogen). Approximately 5ng of Fragment A was mixed with 5ng of a
primer containing the EcoRI site, T7 start, 5' HCV sequence with miR-15 S1 and
S2 sites and 20nt overlap with Fragment A, and the overlap product was
amplified with 5μM of EcoRI and KpnI primers at either end. This PCR product
was digested with EcoRI and KpnI, religated into the backbone, and sequence
verified along the 1.3kb insert. The same strategy was used for miR-15 viruses in
the Jc1FLAG2(p7-nsGluc2A) context but with EcoRI and BsiWI, resulting in a
1373nt fragment), 1st PCR primers (Pos43_F and Pos1358_R), and overlap PCR
primers (Pos12343_F and Pos1358_R). Similarly, fusion PCR was used to
generate pJ6/JFH1-Clone2-U3, –U3S2p3 and –U3S2p3,4 mutants using primers

67

m122toU3_F and F S2p34, R S2p34, F S2p3 and R S2p3. All cloning oligos are
listed in the Appendix.
RNA transcription
In vitro transcripts were generated as previously described (Lindenbach et
al., 2005). Briefly, plasmid DNA was linearized by XbaI and purified by using a
Minelute column (Qiagen). RNA was transcribed from 1 μg of purified template
by using the T7 RiboMAX Express RNA polymerase kit (Promega). Reaction
mixtures were incubated at 37 °C for 30min to 1hr, followed by a 15-min digestion
with 5U of RQ1 DNaseI (Promega). RNA was purified by using the RNeasy kit
with DNAseI (Qiagen), and was quantified by absorbance at 260 nm and diluted
to 0.5 μg/μl. Prior to storage at −80 °C, RNA integrity was determined by agarose
gel electrophoresis and visualization by ethidium bromide staining.
RNA electroporation
Huh-7.5 cells were electroporated with HCV RNA as previously described
(Lindenbach et al., 2005). Briefly, Huh-7.5 cells were treated with trypsin, washed
twice

with

ice-cold

phosphate-buffered

saline

(PBS)

(Invitrogen)

and

resuspended at 1.75×107 cells/ml in PBS. Then, 5 μg of each RNA was
combined with 0.4 ml of cell suspension and immediately pulsed using a BTX
ElectroSquare Porator ECM 830 (820 V, 99 μs, five pulses). Electroporated cells
were incubated at room temperature for 10 min prior to resuspension in 15 ml or
30 ml complete medium for non-reporter and reporter constructs, respectively.
Resuspended cells were plated into 24-well, 6-well, and P150 tissue culture

68

dishes for reporter, RNA, and CLIP analysis respectively, at indicated timepoints.
For U3 virus electroporations, cells were monitored until greater than 80% of cell
were infected, then harvested (around 13-17 days post electroporation).
Supernatants from electroporations meant for virus production were serially
harvested and replaced starting at 48 hours, every 24 hours, for up to 5 days.
Supernatants were filtered using 0.22µm filters to remove cell debris prior to
concentration either under centrifugation in Amicon Ultracell 100kDa filters
(Millipore), or concentration under N2 pressure using a Stirred Cell ultrafiltration
device and membranes (Millipore, Model 8400).
Two color miR-122 target fluorescent reporter construction
Construction of miR-122 fluorescent reporters largely mirrored previous
work with miR-20 (Mukherji et al., 2011). In brief, a nuclear localization sequence
(NLS: ATGGGCCCTAAAAAGAAGCGTAAAGTC) was appended to the Nterminus TagBFP and TagRFP (Evrogen) open reading frames via overlap PCR.
The resulting nlsTagBFP was cloned into the pTre3G-BI vector (Clontech,
#631337) between EcoRI and NdeI restriction sites. nlsTagRFP was PCR
amplified to add 3'UTRs with N=1 bulged, mutant, or perfectly complementary
miR-122 sites before insertion between BamHI and EcoRV sites in the
nlsTagBFP containing plasmid. The artificial 3'UTRs for N=4 and N=6 constructs
were chemically synthesized as GeneBlocks (IDT) before undergoing Gibson
Assembly (NEB) with the BamHI/EcoRV digested pTre3G-nlsTagBFP plasmid,
nlsTagRFP, and the artificial 3'UTR. Gibson assembly was also used to
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seamlessly append full-length 3'UTRs of cellular targets to nlsTagRFP, after
amplifying miR-122 target 3'UTRs from human genomic DNA. While Gibson
assembly was initially chosen due to problems with overlapping restriction
enzyme sites that could not be resolved with traditional cloning methods, the
ease, flexibility and power to "scarlessly" modify a DNA sequence using Gibson
assembly quickly made it the method of choice. All cloning oligos are listed in the
Appendix.
HCV infection and LNA treatment assays
Infectious units were quantified by limiting dilution titration on naïve Huh7.5 cells and counted using the median tissue culture infective dose [TCID50]
method (Lindenbach et al., 2005) or the focus-forming units (FFU) method
(Gottwein et al., 2009). For infection experiments with WT or m15 Clone2
viruses, cells were seeded in 6 well or P150 plates, infected at an MOI of 1-2 the
following day, inoculum removed at 6 hours post-infection (hip) and harvested for
RNA-Seq or CLIP at 72 or 96hpi. Samples harvested for CLIP from cells
electroporated with WT Clone2 RNA were harvested at 48 hours postelectroporation (hpe).
For miRNA and LNA experiments, cells were seeded the day before, and
transfected with miRNA (Thermo Scientific) or LNA or miravirsen/SPC3649 (5'CcAttGTcaCaCtCC-3'; LNA in capitals, DNA in lower case, Exiqon) at indicated
concentrations using RNAi/Max (Invitrogen) for 48 hours. For cultures that were
subsequently infected, this was done 24 hours later with WT, U3 or m15 viruses
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at an MOI of 1-2. Cells were harvested at indicated time points for RNA and flow
cytometry,

while

supernatants

were

harvested

for

titer

measurements.

Replication of Gaussia luciferase expressing HCV genomes was monitored by
measurement of secreted Gluc in supernatants using the Renilla Luciferase
Assay System (Promega) on a Berthold LB960 luminometer (Bad Wildbad,
Germany) or an Omega Fluorostar reader (BMG Labtech). Media was replaced
at each time point measured. No significant cytotoxicity was observed from the
applied concentrations of LNA and miravirsen/SPC3649, as determined using
CellTiter-Glo (Promega).
For two color fluorescent reporter measurements, Huh-7.5 TetON cells
were plated at 1.5x105 cells/well in 6 well plates. Infection with WT-Clone2-5ABYpet virus was carried out 12 hours after plating at an MOI of 3. The inoculum
was removed and replaced with fresh media after 6 hours. LNA and miR-122
mimics were transfected at the indicated concentrations 24 hours after infection
as outlined above. Media was replaced 48 hours after infection to include 1µg/ml
doxycycline (Sigma) and reporter constructs were then transfected at 1.6µg/well
using Lipofectamine2000 (Invitrogen) reagent. To harvest, cells were trypsinized,
fixed in FACS fixation buffer (0.5% PFA, 1% FBS, in 1xPBS) on ice for 10
minutes, and stored at 4°C in FACS buffer (1% FBS in 1xPBS). A small number
of cells were harvested without fixation for RNA analysis.
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RNA isolation and qPCR
Total RNA was prepared via Trizol extraction (Life Technologies,
Carlsbad, CA), precipitation with ethanol, and yields determined by absorption
spectroscopy using a NanoDrop (NanoDrop Products, Wilmington, DE). HCV
genomes were quantified using the EraGen MultiCode-RTx method (EraGen
Biosciences, Madison, WI) as described previously (Mulligan et al., 2009), and
was run on the LightCycler 480 Real-Time PCR System (Roche Applied
Sciences, Indianapolis, IN). MicroRNA qPCR was performed using the miScript
RT II system (Qiagen) following the manufacturers instructions for absolute
quantification. The resulting cDNA was used with the FastStart SYBR Green
qPCR system (Roche Applied Sciences, Indianapolis, IN) following the
manufacturers instructions and was run on a iCycler/IQ5 (BioRad). Synthetic
miR-122, miR-21, miR-15a and miR-196 mimics (Dharmacon) were used to
make a standard curves for each miRNA. The miscript RT II kit was also adapted
to quantify HCV genomes (for Fig. 1G and Fig. S7) by using a sense HCV
specific

primer

at

the

3'end

of

the

genome

(JFH1-3UTR:

CTGGTCTCTCTGCAGATCATGT). Previously determined amounts of in vitro
transcribed HCV RNA were used to generate a standard curve. Per cell RNA
amounts were determined by Trizol extracting RNA from 106, 105, and 104 Huh7.5 cells at 60-80% confluence, in duplicate, summing the total amount of RNA
recovered, and dividing by the number of cells to reach a measurement of
17.28±4.83pg RNA/cell. RNA measurements per nanogram were transformed to
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per cell measurements with this number. For liver biopsy per cell estimates, we
relied upon human hepatocellularity measurements of 139±25 million cells/gram
of liver from (Sohlenius-Sternbeck, 2006). Four liver specimens of various
weights (2-40mg of tissue) underwent RNA extraction with Trizol. The summed
total of extracted RNA per sample was divided by specimen weight to arrive at an
RNA/mg of tissue estimate, and transformed by 139000 cells/mg of tissue to
reach a measurement of 1.27±0.39pg RNA/cell. Per nanogram qPCR results
were transformed accordingly.
Small RNA Northern analysis
Ten micrograms of Trizol extracted total RNA from Huh-7.5 cells was
separated on a 15% acrylamide/7M urea gel. After transfer onto Hybond-N1
membrane (Amersham Pharmacia Biotech), small RNAs were detected with 32Pend-labeled DNA probes complementary to human miR-122-5p, miR-16-5p, miR21-5p, and U6 snRNA.
Western blotting
Cells were lysed at the indicated times using 1X PXL (1X

PBS,

tissue

culture grade; no Mg2+, no Ca2+, 0.1% SDS, 0.5% deoxycholate, 0.5% NP-40,
sterile filtered), triturated and placed on ice for 15minutes. 15 μg of protein lysate
was separated on 4–12% Bis/Tris NuPage polyacrylamide gels (Invitrogen).
Proteins were transferred to nitrocellulose membranes and proteins of interest
were detected using antibodies against NS5A (9E10; 1:5000) (Lindenbach et al.,
2005), AGO2 (ab32381, 1.3µg/mL, 1:1000) (Abcam), DICER (ab14601, 1:1000)
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(Abcam), DROSHA (ab12286, 1:1000) (Abcam) or β-actin (AC15, 1:10000)
(Sigma); secondary antibodies were AffiniPure Donkey-anti-Mouse IgG (H+L)
(115-035-003, 1:10000) (Jackson Immuno Research), Goat-anti-Rabbit-HRP
(31462, 1:10000) (Pierce), Goat-anti-rabbit IRDye 800CW (926-32211, 1:15000)
(Licor Biosciences), or Goat-anti-rabbit IRDye 680RD (926-68070, 1:15000),
(Licor Biosciences). Western blots were visualized using SuperSignal West Pico
(Thermo Scientific) or the Odyssey CLx imaging system (Licor Biosciences).
Fluorescence microscopy
Images were captured on an Axioplan 2 imaging fluorescence microscope
(Zeiss, Thornwood, NY) using Metavue Software (Molecular Devices, Sunnyvale,
CA). Images were processed using ImageJ software (NIH, Bethesda, MD).
Luciferase reporter assays
Luciferase reporter vectors were cloned by inserting short oligonucleotides
or PCR amplified target 3'UTRs into psiCHECK-2 (Promega) using XhoI and
NotI. For luciferase reporter assays, 5x104 Huh-7.5 cells per well in 48-well plates
were transfected over night with 2.56nM final concentration LNA122 (Exiqon) or
miR-122 mimic (Thermo Fisher) using RNAi/MAX (Invitrogen). Alternatively, cells
were infected with HCV (J6/JFH1-clone2), MOI=3 over night. 24 hrs later, cells
were

transfected

with

1ng/well

psiCHECK-2

reporter

plasmid

using

Lipofectamine2000 (Invitrogen) and incubated over night before lysis in Passive
Lysis Buffer and evaluation of luciferase levels using the Dual Luciferase
Reporter Assay (Promega) on a Omega Fluorostar reader (BMG Labtech).
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Flow cytometric analysis
For NS5A flow cytometry, cells were harvested using AccuMax
(eBioscience)

and

fixed

using

Fixation/Permeabilization

buffer

(BD

Biosciencesfor 10 min at 4 °C. Fixed cells were washed with BD Perm/Wash
buffer (BD Biosciences), incubated 30 min at RT with AlexaFluor-647-conjugated
9E10 antibody (1:4000 in BD Perm/Wash buffer), washed twice with BD
Perm/Wash buffer and once with FACS buffer (PBS/3%FBS) prior to analysis
using a BD FACS Calibur and BD FACSDiva software. Analysis was performed
using FlowJo software.
Two-color fluorescent miRNA reporter flow cytometry
For fluorescent protein reporter measurements, cells were run on a
MACSQuant VYB flow cytometer (Miltenyi Biotec) after fixation to detect
TagBFP, TagRFP, and Ypet signals. The raw FACS data were analyzed with
FlowJo to gate single, intact cells according to their forward (FSC-A) and side
(SSC-A) scatter profiles. HCV positive cells were gated on the basis of Ypet
signal above uninfected background. Untransfected cells were used to
characterize the cellular autoflourescence in BFP and RFP channels, from which
we subtracted the mean plus two standard deviations of the autofluorescent
signal for each channel in transfected cells. Cells with BFP and RFP
fluorescence levels less than 0 after background subtraction were excluded from
further analyses. Data were log-transformed and binned according to BFP levels,
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and the mean RFP signal was calculated for each BFP bin. See Chapter 4 for
details.
High-throughput sequencing methods
The work presented in this thesis makes extensive use of high-throughput
sequencing methods, many customized and invented in the Darnell lab. As such
methods are constantly evolving, this section will outline the basic principles of
experimental design using these techniques, describe the flow, aims and
assumptions of these methods, as well as provide the finer details of their
execution.
Experimental designs
The proper design of experiments involving highly sensitive genomics
methods is critical for minimizing technical or biologically spurious sources of
variation that at best mask the variation between the intended biological variables
tested, or at worse mislead to false conclusions. Long known to be an issue in
many microarray studies, batch effects represent a major and sometimes
unacknowledged source of technical variation in next-generation sequencing
(NGS) studies (Leek et al., 2010). To minimize the sometimes impossible task of
correcting for a batch effect after-the-fact, CLIP and RNAseq experiments were
designed to account for and mitigate batch effects in the following ways:
1.

For all cell work, each well or dish from which a library was made is

defined as a biologic replicate. One perturbed versus its un-perturbed sample
(thus two biologic replicates) constituted one biologic replicate comparison.
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2.

For all animal and human work, all samples coming from the same donor

are defined as a biologic replicate.
3.

All cellular perturbations (virus infections, LNA treatments, etc) were

paired with un-perturbed controls under identical conditions. Comparisons across
controls from different experiments were not used beyond as a measure for cross
batch variation.
4.

Harvest of paired samples was carried out at the same time, in the same

order (perturbed then control), and frozen in -80C. Subsequent CLIP and RNA
library prep were initiated on paired samples on the same day.
5.

For timecourse measurements, paired samples were frozen at the time of

harvest. All subsequent CLIP or RNaseq library prep was initiated for all
biological replicates for all time points on the same day.
6.

Sample processing was done in separate tubes; where protein gels were

concerned, all samples were separated by one empty lane. Where DNA gels
were concerned, all samples were split by condition and run on separate gels. In
other words, all perturbed biologic replicates were run on one gel, and all unperturbed samples on a separate gel. Samples were separated by one empty
lane.
7.

Pooling of samples was performed to include both perturbed and un-

perturbed controls in the same lane of the same sequencing run. Splitting
samples across lanes was avoided, unless a measure of technical variation was
sought.
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Sample generation
As stated above, Huh-7.5 cells were used for all HTS work. Cells were
infected with virus or electroporated with viral RNA, the media replaced at 6 hpi
or 24hpe, respectively, and harvested at time points indicated in the figures. In all
cases, wells with identical numbers of cells were mock infected or mock
electroplated with media or PBS.
For miR-122 knockout mouse studies, the livers form five floxed control
mice and four liver specific miR-122 knockout mice, were provided by Kalpana
Ghoshal at the Ohio State University. Dissected livers were wrapped in foil and
flash frozen in liquid nitrogen before being shipped to RU on dry ice.
For human normal versus liver tumor, five samples from patients with HCC
(all HCV negative) were flash frozen in liquid nitrogen after autopsy, in
accordance with IRB approved protocols at the Ohio State University.
Specifically, per patient approximately one gram of tumor and histologically
normal adjacent tissue were frozen simultaneously before being shipped to RU
on dry ice.
Sample harvest
Cells growing in p150 plates were washed with cold PBS and irradiated
over ice once for 400mJ/cm2 and once again for 200mJ/cm2 using a
Spectrolinker XL-1500 (Spectronics Corporation). Cells were then trypsinzed (Life
Technologies), pelleted, and stored at -80°C until use. One p150 plate would
typically yield between 3 and 10 million cells per pellet.
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Mouse and human liver tissue was pulverized in a mortar and pestle with
liquid nitrogen. A small portion (20-50mg) of the resulting powder was saved for
RNA analysis. The remaining powder was crosslinked on a bed of dry ice with
three irradations at 400mJ/cm2 using s Stratlinker XL-1500 (Stratagene). All
samples were then stored in -80°C until lysis.
Argonaute CLIP
Argonaute CLIP was performed generally following previous work (Chi et al.,
2009) and is most comprehensively described in (Moore et al., 2014) with
modifications listed here. The basic outline for AGO-CLIP consists two parts:
from cells to autorad, that is, from cellular lysates to the isolation of AGO
associated RNA fragments, and the DNA library preparation steps from small
samples of isolated CLIPped RNA. For a schematic view of the standard AGOCLIP protocol with variations, see Figure 2.4 and Figure 2.5.
Bead preparation
Protein A Dynabeads (Invitrogen) were washed 3x and resuspended in
antibody binding buffer (AB: PBS, 0.02% Tween-20). Per p150 dish or liver
sample, 100μl of beads was used. Beads were rotated with 12.5μl of bridging
antibody (rabbit anti-mouse IgG, Jackson Immunoresearch) per 100μl of beads
for 30 minutes at room temperature. Beads were then washed 3x with AB before
adding 1μl of the pan-AGO antibody (2A8, ascetic provided by Dr. Zissimos
Mourelatos and described in (Nelson et al., 2007)) per 100μl beads. For IgG only
antibody controls, AGO antibody was omitted. Beads were rotated at for 30 min
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Figure 2.4. Ago-CLIP schematic from cells to Ago associated mRNA isolation.
Cells or tissues are crosslinked, undergo lysis and partial RNAse digestion before
undergoing IP using anti-Ago (2A8) antibody coated magnetic beads. Following
extensive wash steps, protein bound RNAs are enzymatically manipulated to
enable down stream sequencing either by ligating a radiolabeled 3' RNA linker
(left side) or direct radiolabeling with PNK (right). Radioactivity is indicated with a
star. Following SDS-PAGE and proteinase K treatment, isolated Ago bound RNA
is cloned. For RNA with 3' linkers, cloning proceeds with 5' linker ligation or BrdUCLIP. For RNA without linkers, poly-A or -G tailing CLIP is implemented.
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Figure 2.5. Two cloning strategies for Ago-CLIP isolated RNA fragments. (A) In
standard CLIP, RNA reads undergo sequential ligation of 5' and 3' RNA adapters,
followed by RT-PCR. Note that the RNA input contains the 3' adapter, as this is
done on bead prior to SDS-PAGE where the radiolabeled 3' RNA linker is used
for auto-radiography. The 5' adapter contains a barcode (NNNNG) such that each
RNA tag is uniquely labeled, thus cataloging a single Ago binding event. An index
specific for each library is added with a 2 PCR step to enable multiplexing.
Reads are sequenced starting with the index. (B) In Poly-G (or A) CLIP,
completely independent of RNA ligation, reads are first tailed with a homopolymer
polymerase and undergo RT using an oligo that recognizes the poly-G stretch,
and using BrdUTP in place of UTP. This RT oligo contains Illumina sequencing
adapters separated with an APE1 site. The cDNA undergoes BrdU IP, on bead
circularization, APE1 digestion, then is PCR amplified to create the library. As in
standard CLIP, each RNA read is tagged with a unique barcode.
nd

at room temperature or overnight at 4°C. Just prior to IP, beads were washed in
1X PXL lysis buffer (1X PBS tissue culture grade without magnesium or calcium,
0.1% SDS, 0.5% Sodium-deoxycholate, 0.5% NP-40) with protease inhibitors
(Roche, mini EDTA-free).
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Cell lysate preparation and IP
Frozen lysates of crosslinked cells or powdered liver tissue were prepared
by adding 1ml of 1X PXL (with protease inhibitors) and triturating to disrupt cells.
Lysates treated with 10μl DNAse (RQ1, Promega) for 5 minutes, thermomixing at
37°C at 1100rpm. Samples were then treated with RnaseA or RNaseI, first
diluted to the indicated concentration by volume (e.g. 1:100, or 1:10,000) in lysis
buffer and then added at 10μl per ml of lysate. Critical for interpreting CLIP
autorads, the amount of RNAse to be added was empirically determined in pilot
experiments using an RNase titration. Range concentrations that yielded a smear
10-50kDa above the collapsed band were typically chosen, in some cases no
RNase was required. Figure 2.6 shows an example of an RNase titration yielding
a working concentration amenable for the partial RNAse digest needed for CLIP.
Lysates underwent thermomixing again for 5 minutes at 37°C at 1100rpm before
being treated with 10μl RNAsin RNase inhibitor (Promega) and spun at 4°C on
max speed of a table-top micro centrifuge for 30 minutes. Supernatants, along
with any lipid layer, were harvested and mixed with PXL equilibrated antibody
bound beads for IP. A small amount of pre-IP lysate was kept to monitor Ip
efficiency. Samples were rotated with beads at 4°C for 2-4 hours. Following IP, a
small amount of post-IP lysate was kept. Beads were washed sequentially twice
each with 1X PXL, 5x PXL (same as 1X but using 5X PBS), and 1X PNK buffer
(50mM Tris-HCl, pH 7.5, 10mM MgCl2, 0.5% NP-40).
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Figure 2.6. An RNAseA titration experiment for Ago-CLIP. Two mouse livers were
processed for Ago-CLIP using 3' radiolabeled L32 linker under decreasing
RNAseA concentrations (lanes 2-4), without RNAseA (lane 5), or without
RNAseA plus RNAse inhibitors (lane 6). Minus crosslink control from similar
amount of tissue is shown (lane 1). Ago:miRNA complex at 110kDa is highlighted
with an arrow. Note that as RNAse concentration decreased the sharp 110 kDa
band became more diffuse, indicating an RNAse dependence "collapse" of the
radioactive signal to the modal size of Ago plus miRNA. On the basis of this
experiment for mouse liver, lane 4, corresponding to 1:10K dilution of RNAse A
was chosen for downstream processing, and became the RNAseA condition of
choice for liver tissue studies in mouse and human.

Removal of 3' phosphate, 3' linker ligation, and re-phosphorylation of 5' ends of
AGO bound RNA
To prevent RNA circularization of RNA tags, IPs were treated with alkaline
phosphatase. Beads were resuspended in 80μl containing 1x dephosphorylation
buffer, 3U of CIAP (Roche), RNasin inhibitor (Promega), and thermomixed for 20
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minutes at 37°C, shaking at 1100rpm for 15s ever 2 minutes. Samples were then
washed as above sequentially in 1X PNK, 1X PNK plus 20mM EGTA, and twice
with 1X PNK.
Radiolabeled linkers for 3' linker ligation per sample were set up by
preparing a T4 phosphonucleotide kinase (PNK, NED) reaction according to the
manufacturers instructions using 2.5μl

32

P-γ-ATP and an RNA linker, either

20pmol L32 or L34 RNA linker (Dharmacon or IDT) and incubating for 30 minutes
at 37°C. To drive the reaction to completion, 0.5μl of 1mM ATP was added and
incubated for an additional 5 minutes. Linkers were purified from free nucleotides
using G-25 columns following the manufacturers instructions (GE Healthcare).
Ligation reactions on bead were prepared using Rnl1 RNA ligase (Fermentas)
and 12pmol radiolabeled linker following the manufacturers instructions. Samples
were incubated for one hour at 16°C, shaking at 1100rpm for 15s every 4
minutes. After this hour, 60pmol cold linker was added and the reaction allowed
to go overnight. The next morning, beads were washed twice each with 1XPXL,
5X PXL, and 1XPNK. A final PNK reaction was performed on bead to restore the
5' phosphate. To each sample an 80μl mix containing 1mM ATP, 1X T4 PNK
buffer, 4μl T4 PNK and RNasin inhibitor. Samples were incubated for 20 minutes
at 37°C, shaking at 1100rpm for 15s ever 2 minutes.
SDS-PAGE resolution of AGO:RNA complexes
Beads were washed twice each with 1XPXL, 5X PXL, and 1XPNK. Protein
was eluted off the beads by incubating with in 30μl of 1X LDS loading buffer
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(Invitrogen) with reducing agent for 10 minutes at 70°C, shaking at 1100rpm.
Supernatants were run on Novex NuPAGE 8% Bis-Tris cels (Invitrogen) in SDSMOPS buffer (50mM MOPS, 50mM Tris Base, 0.1% SDS, 1mM EDTA, pH7.7)
for 2.5 hours at 175V at 4°C. Radiolabeled protein RNA complexes were
transferred to BA85 nitrocellulose (Whitman) using a Novel wet transfer
apparatus for 1 hours at 30V. After transfer, the membrane was rinsed with
RNAse-free PBS, and exposed to Biomax MR film (Kodak) at -70°C typically from
3 hours to up to 5 days.
Recovery of AGO-RNA complexes
Nitrocellulose membranes were aligned with the exposed film and regions
of the membrane from low RNase IP lanes were excised. Typically, binary AGOmiRNA complexes migrated at 110kDa, while AGO-mRNA and ternary AGOmiRNA-mRNA complexes migrated between 130-150kDa. These two regions
(110kDa and 130-150kDa) were excised and processed separately, though I
noted no qualitative differences between the ability to clone miRNAs or mRNA
targets from either region. Put another way, mRNAs could often be cloned from
the 110kDa band, and miRNAs from the 130-150kDa bands. Parallel processing
of these regions was often used as technical replicates. In general, the regions
excised did not extend beyond 150kDa, due to the large length of the RNA
recovered. Short mRNA fragments between 30 and 60nts were preferred to
facilitate read clustering and peak finding; I note this only because most NGS
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RNA protocols call for longer (100-300nt) reads, to more effectively leverage
paired end sequencing and more accurate splice site identification.
Proteinase K digestion, RNA recovery, and 5' linker ligation
RNA was liberated from membrane fragments using 200μl of a proteinase
K solution (Roche) diluted in PK buffer (100mM Tris-HCl, pH 7.5, 50mM NaCl,
10mM EDTA) to 4mg/ml and incubated for 20 minutes at 37°C, shaking at
1000rpm. RNA was further denatured by adding 200μl of PK buffer with 7M urea
and incubating for 20 minutes at 37°C, shaking at 1000rpm. RNA fragments
underwent acid phenol:chloroform extraction and were precipitated overnight at 20°C in 1ml of 1:1 ethanol:isopropanol and 50μl of 3M NaOAc, pH 5.2.
RNA was pelleted by spinning at max speed (>13,000rpm) in a table top
centrifuge at 4°C, and washed twice with 75% ethanol. Following speedvac
drying of the RNA, the pellet was dissolved in 6μl RNase-free water. The 5' linker
was ligated using Rnl1 (Fermantas) and 20 pmol of the 5' linker following the
manufacturers instructions and in a total volume of 10μl. Samples were
incubated at 16°C for 5 hours with intermittent shaking. Ligated RNA was DNase
digested by adding 30μl RNase-free water, 5μl 10X RQ1 buffer, 2.5μl RQ1
DNase and 2.5μl RNasin inhibitor; and incubating at 37°C for 20 minutes.
Samples then underwent phenol chloroform extraction as above.
Reverse transcription and 1 PCR
st

RNA was pelleted by spinning at max speed (>13,000rpm) in a table top
centrifuge at 4°C, and washed twice with 75% ethanol, and dried. Following
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speedvac drying of the RNA, the pellet was dissolved in 10μl RNase-free water.
8μl RNA was mixed with 10pmol DP3 primer, 3μl 3mM dNTPs, and incubated for
5 minutes at 65°C in a thermocycler; the remaining RNA from all samples was
pooled and 8μl of this was used for the -RT control. Samples were ramped down
to 50°C, after which RT was added: 1μl 0.1M DTT, 4μl 5x Superscript buffer, 1μl
RNasin and 1μl Superscript III (Invitrogen ) or 1μl water for -RT controls.
Samples were incubated in a thermocycler at 50°C for 45 minutes, 55°C for 15
minutes, 90°C for 5 minutes then chilled to 4°C. PCR was performed immediately
after using 27μl Accuprime Pfx (Invitrogen), 0.15μl DP5 primer (at 100 pmol/μl),
0.15μl DP3 primer (at 100 pmol/μl) , and 4μl of the RT reaction, for a total of 4
reactions per sample. PCR conditions were 95°C for 2 minutes, 20-35 cycles of
95°C for 20s denature, 58°C for 30s anneal, and 68°C for 30s extension.
Typically, miRNA plus linker fixed products arose around 20-24 cycles, mRNA
plus linkers from 22-30 cycles. Reactions were taken out the the thermocycler
following extension starting at 22 cycles, every two or three cycles. RT negative
samples were taken out 4-5 cycles after the last +RT sample.
The entire PCR reaction was loaded with an equal volume of 2x loading
buffer (95% formamide, 5% 100mM EDTA pH 8.0, and a dash of bromophenol
blue and xylene cyanol) and run on 10% denaturing PAGE gels in 1X TBE for 1
hour at 300V. Amplify molecular rulers (Biorad) were used as markers. To
visualize DNA, gels were stained in 1X SYBR Gold (Molecular Probes) in 1X TBE
for 10 minutes. PCR products corresponding to miRNAs flanked by adapters
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(~55-60bp) or adapter flanked mRNAs (80-150bp) were cut from the gel. DNA
was extracted by soaking gel slices in DNA diffusion buffer (0.5M ammonium
acetate, 10mM Mg-acetate, 1mM EDTA, 0.1% SDS) and incubating at 50°C for
30 minutes, shaking at 1200rpm. Gel slurry was filtered through Whitman glass
filters in Nanosep columns (VWR). DNA was recovered from the filtrate using
Qiaquick gel purification (Qiagen) and resuspended in 30μl.
Multiplexed AGO-CLIP
To enable cost-effective multiplexing of standard CLIP libraries as well as
compatibility with sequencing on MiSeq machines, we adapted the 2 PCR step
nd

of the standard CLIP protocol to add sequencing adapters and 5' indices. This
strategy uses the DP5 and DP3 sequences of the 1 PCR product as priming
st

sites to add 5' indices and 3' adapters for a short (4-10 cycles) 2 PCR step
nd

(Figure 2.5A). PCR was performed using 27μl, Accuprime Pfx (Invitrogen), 0.5μl
MSFP5 5' primer (at 20 pmol/μl, each sample with different indexed primer), 0.5μl
MSFP3 3' primer (at 20 pmol/μl) , and 3μl of the 1 PCR product, in triplicate.
st

PCR conditions were 95°C for 2 minutes, 4, 7 or 10 cycles of 95°C for 20s
denature, 58°C for 30s anneal, and 68°C for 30s extension. The 2 multiplexed
nd

PCR product was separated on a 2% Metaphor agarose gel (Lonza) and the
lowest cycle number visible purified Qiaquick gel purification (Qiagen) and
resuspended in 30μl. Following DNA concentration and integrity analysis using
TapeStation (Agilent), each individual sample was diluted down to 10nM, pooled
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in equal parts with all other samples containing unique indices, and submitted for
high throughput sequencing. All cloning oligos are listed in the Appendix.
Poly-G CLIP
Poly-G CLIP is a direct adaptation of the single linker ligation BrdU CLIP
protocol (Weyn-Vanhentenryck et al., 2014) and was inspired by ribosomal
profiling methods (Ingolia et al., 2009). In contrast to standard CLIP, which relies
on two sequential RNA linker ligation steps, and BrdU CLIP, which relies on one
RNA ligation step, the poly-G CLIP protocol relies on tailing CLIP'ed RNA,
performing RT with a primer capable of circularization and subsequent cleavage
to generate a cDNA library amenable for high-throughput sequencing (Figure
2.5B).
Regarding the choice of nucleotide for tailing, we chose G for a few
practical but mostly empirical reasons. As poly-A tails can range in size from
>100nt to >1kb, working out conditions for uniform poly-A tail lengths became
impractical. Aldo Mele in the Darnell lab took an unbiased approach and tested
two polyA polymerases, from E. coli or S. cerevesiae, and monitored their ability
to generate homopolymeric tracts that could be used for priming. ATP yielded
long tails for both enzymes as expected, but only yeast polyA polymerase
created short, 12-15nt G tails on any input RNA (Figure 2.7). Moreover, the yeast
enzyme most efficiently added tails to completion such that little input RNA was
left untailed. On this basis of these experiments, I adapted Aldo's findings to aid
in miRNA cloning efforts using polyG tailing.
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Figure 2.7. Ribonucleotide incorporation comparison between poly-A polymerase
enzymes from E. coli (E-PAP) and S. cerevisiae (Y-PAP). Exactly 20 pmol RL5D
RNA linker was radiolabeled with 32P-γ-ATP in a PNK reaction and underwent
poly A polymerase reactions with 5U E-PAP (left, NEB) or 300U Y-PAP (right,
USB) in manufacturer recommended buffer conditions supplemented with 1mM of
the indicated rNTP. Reactions proceeded for 20 minutes at 37°C, before stopping
via heat denaturation at 65°C for 10 minutes. Samples were run on 20%
denaturing Urea-PAGE gels and exposed to film. E-PAP readily incorporated
ATP as expected forming products with median polyA lengths of 150-200nt, and
was unable to incorporate an other rNTPs. Y-PAP synthesized polyA tails greater
than 1kb in length and was largely incapable of incorporating UTP or CTP, but
interestingly incorporated short well defined tails of polyG, between 12-15nt in
length. Experiment performed by and data courtesy of Aldo Mele.

The standard CLIP protocol was followed to directly PNK label AGO
bound RNA with 32P-γ-ATP (Moore et al., 2014); the 3' RNA linker ligation steps
were skipped. Following autorad exposure, 100-110kDa regions were excised
from the membrane for RNA isolation as described above. The resulting RNA
was tailed with yeast poly-A polymerase (USB Affymetrix 74225Y) using GTP
with the final concentrations: 1X Y-PAP buffer, 1mM GTP, 7.5U RNAsin
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(Promega N261), and 300U Y-PAP. The reaction was incubated at 37°C for 20
minutes, then 65°C for 10 minutes. After tailing, reverse transcription was carried
out using 5μl polyG tailed RNA, 1μl 0.752M Tris, 1μl 8.2mM dATP, 1μl 8.2mM
dCTP, 1μl 8.2mM dGTP (all Invitrogen), 1μl 8.2mM Br-dUTP (Sigma), 1μl 25μM
RT Primer and 1μl H2O. This mix was incubated for 3min at 75°C then ramped
down to and held at 48°C. To this reaction, 1μl 82mM DTT, 1μl 10U/μl RNasin
and 1μl SuperscriptIII (or H2O for –RT) pre-warmed to 48°C was added to the
original mix, then incubated for 45 minutes at 48°C, 15 minutes at 55°C, and 5
minutes at 85°C then held at 4°C. Following RT, 1μl of 2U/μl RNaseH
(Invitrogen) was added to destroy RNA and incubated at 37°C for 20 minutes,
after which 10μl RNase-free H2O was added and the cDNA purified by spinning
through a G-25 column.
cDNA purification and BrdU IP
The cDNA was then purified using Protein G dynabeads (Invitrogen)
coupled with an anti-BrdU antibody (Santa Cruz). Briefly, 50μl of ProteinG
dynabeads per sample were washed in AB buffer and resuspended in 25μl of AB
buffer along with 25μl 50X Denhardt's Solution (Sigma) and rotated at room
temperature for 1hr. Beads were then washed three times with 1X IP buffer (0.3X
SSPE (Ambion), 1mM EDTA, 0.05% Tween-20), resuspended in 25μl IP buffer
plus 25μl of anti-BrdU antibody (5g, Santa Cruz, sc-32323) and rotated at room
temperature a minimum of 45 minutes for antibody binding, then washed and
equilibrated in 1X IP buffer. The equivalent of 25μl starting volume of beads were
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used per BrdU IP. The volume of cDNA was brought up to 40μl with H2O and
10μl 50X Denhardt's solution before adding 50μl of 2X IP buffer (2X IP
buffer:0.6X SSPE (Ambion), 2mM EDTA, 0.1% Tween-20). The mix was
incubated for 5 minutes 70°C, 2 minutes 25°C, spun down and added to the
equivalent of 25μl starting volume of the prepared anti-BrdU beads. Tubes were
rotated at room temperature for 30mins and washed once with 1X IP buffer plus
5X Denhardt's, twice in low salt buffer (15 mM Tris- HCl, pH 7.5, 5 mM EDTA),
and twice with 1X IP buffer. cDNA was eluted from the beads via BrdU
competitive elution by adding 50μl 100μM BrdU (Sigma) in 1X IP buffer, rotating
for 30min and collecting the eluate. Eluted cDNA was purified by spinning
through a G-25 column, the volume adjusted to 97.5μl with H2O, after which
37.5μl 4X IP buffer and 15μl Denhardt's solution was addedadded. The anti-BrdU
IP was repeated as above with the remaining 25μl of prepared beads, and
washed. The final two washed consistent of 1X CircLigase Wash Buffer (33mM
Tris-acetate, 66mM KCl, pH7.8).
On-bead cDNA Circularization and ApeI Linearization
On bead, cDNA was circularized by incubation for 1 hour, 60°C, 1300rpm
thermomixer mixing for 15 seconds, every 30 seconds, with 2μl CircLigase 10X
Reaction Buffer (Epicentre), 4μl 5M betane, 1μl 50mM MnCl2, 0.5μl CircLigase
ssDNA Ligase II (50U, Epicentre) and 12.5μl H2O. Beads were washed by
rotating for 5min, two times each with 1X IP buffer and ApeI buffer (50mM
potassium acetate, 20mM Tris-acetate, 10mM magnesium acetate, pH7.9).
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cDNA was then linearized on bead by adding 2μl 10X NEB Reaction Buffer 4,
1.25μl ApeI (10U/μl NEB) and 16.75μl H2O, and incubating for 1 hour, 37°C
1300rpm thermomixer mixing for 15 seconds, every 30 seconds. Beads were
washed twice with low salt buffer, and twice with Phusion wash buffer (50mM
Tris, pH8.0).
PCR amplification
To elute cDNA off of beads, 10μl 5X Phusion HF Buffer (NEB), 1μl 10mM
dNTPs and 37.5μl H2O were added, the mix transferred to a thin walled PCR
tube and incubated at 98°C for 45 seconds. Superntatants from beads after
agent capture were transferred to a fresh PCR tube. To this was added 0.5μl
20μM P5 primer, 0.5μl 20μM P3 primer, 0.5μl Phusion DNA polymerase and
0.5μl 50X SYBR Green I (Invitrogen).
PCR amplification was carried out on iQ5 or CFX real-time PCR machines
(Biorad) in order to monitor amplification, with the samples being removed when
the RFU signal reached ~800-1000. PCR cycle conditions were as follows: 1X
98°C 30s, 15-20 cycles as necessary 98°C 10s, 60°C 15s, 72°C 20s. PCR
products were run on 2% metaphor agarose gels (Lonza), purified using Qiaquick
gel purification (Qiagen) and resuspended in 30μl. Unlike standard CLIP, each
RT primer contained it's own index for multiplexing, and thus only one PCR
reaction was ultimately performed to append Illumina sequencing linkers.
Following DNA concentration and integrity analysis using TapeStation (Agilent),
each individual sample was diluted down to 10nM, pooled in equal parts with all
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other samples containing unique indices, and submitted for high throughput
sequencing. All cloning oligos are listed in the Appendix.
mRNA-seq library construction
mRNA-seq libraries were prepared from Trizol extracted RNA following Illumina
TruSeq protocols for poly-A selection, fragmentation, and adapter ligation.
Alternatively, total RNA underwent RiboZero purification (Epicentre) to negatively
select ribosomal RNA sequences. Multiplexed libraries were sequenced as 100nt
single-end or paired-end runs on HiSeq-2000 sequencers.
Illumina sequencing
CLIP library next-gen sequencing was carried out on HiSeq2000 (RU
genomics Core) or Hiseq2500 (NYGC) machines, set up for 100nt single-end
(SE) sequencing and typically run between 2-5pM per lane, using v2 or v3
chemistry. Unless noted, the Illumina Read 1 primer was used. For RNAseq,
samples were processed under 100nt paired-end sequencing, using standard
Read1 and Read2 primers.
Bioinformatic analysis
Argonaute-CLIP
Analysis of AGO-CLIP data was carried out similar to previous work (Chi
et al., 2009; Moore et al., 2014; Riley et al., 2012a). Data processing was carried
out using the Galaxy suite of bioinformatics tools (Goecks et al., 2010) and the
UCSC genome and table browsers (Kent et al., 2002), in addition to in-house
tools developed by Chaolin Zhang. A schematic of data processing for CLIP is
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presented in Figure 2.8. Using FASTX tools in Galaxy, FASTQ sequence files
were first filtered for quality such that 80% of the read contained a mean PHRED
score of 20. Reads were then collapsed on sequence to remove sequencing and
PCR duplicates. The fold coverage, that is the raw reads divided by the collapsed
reads, as a rough estimate of sequencing saturation, was typically as low as 5
but up to 100 fold depending on the presence of multiplexed samples and was
used as a rough proxy for sample complexity.
In theory, a CLIP-seq library from an mRNA binding protein can be
thought of as a sparsely sampled subset of a full mRNA-seq library since
RNABPs by definition bind transcribed RNA. Thus it follows, especially for
RNABPs with defined binding sites, and for which exon exon junctions play a
minor role, that CLIP-seq libraries will be less complex than their parent RNA-seq
libraries, due to the reduced sequence "space" that can be cloned. As a
consequence, one should expect that fold coverages on average will be higher
for CLIP than RNAseq. In practical terms this means that a far greater number of
CLIP experiments can be sequenced per lane than RNAseq experiments. For
instance, in singlet libraries, a Hiseq2000 lane will typically yield approximately
100M reads, for which AGO-CLIP will collapse to around 1-2M reads, a coverage
of 50-100X; the parental RNAseq library would collapse to between 10-30M
reads (3-10x coverage). Ten multiplexed AGO-CLIP libraries in the same
scenario on average will yield around 1M reads per sample (10M total) for a per
sample coverage of 10X, in line with one RNA-seq library.
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Figure 2.8. An analysis pipeline for CLIP data. Key raw and finished files in blue
denoted by format where applicable. Data processing, calculation, and
visualization steps in green boxes.
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Barcoded samples, if any, were split after exact sequence collapse using
the barcode splitter. 5'-degenerate linker sequences were removed for later
estimation of unique binding events, where applicable (Licatalosi et al., 2012).
The 3'-adapter sequence was also removed if present using the clip adapters tool
while for poly-G tailed samples, an "adapter" sequence of GGGGGGG was
clipped from the 3' end. Reads shorter than 18nt were discarded for linker ligated
samples, 15nt for poly-G samples. This final set of groomed reads represented
the input for subsequent alignment.
Alignment of mRNA sample reads to either the human (hg18) or J6/JFH1Clone2 (WT, U3 or m15) genome was carried out using the Bowtie (Langmead et
al., 2009) or Novoalign (Novocraft) mapping programs allowing at most 2
mismatches (or indels) and discarding reads with multiple hits. Alignment of
miRNA samples was performed similarly, but allowing for zero mismatches. After
mapping, we collapsed reads on coordinates such that only those reads with
sufficiently different degenerate linkers were kept; this distinguished unique
binding events (tags) from PCR duplicates (Darnell et al., 2011; Licatalosi et al.,
2012). Coordinates for mature miRNAs were constructed from mirBase (v18) for
annotation and counting of miRNAs based on uncollapsed mapped reads.
Clustering of mRNA reads to genomic loci was carried out as in (Chi et al.,
2009) where we typically specified a minimum biologic complexity (BC) of at least
half of the libraries in the comparison (3 for 6 libraries, 5 for 10, etc). Reads at a
particular cluster from different experiments were normalized to the read-depth of
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their respective libraries for cross comparison. The resulting clusters were
intersected with UCSC genes (a union of RefSeq, Uniprot, and Genbank gene
definitions) to determine the genic identities and positions of AGO binding sites.
Seed searches were carried out within robust AGO clusters (+/- 32nts) for all
miRNA families identified from miRNA-CLIP specifying perfect base pairing for
miRNA seeds to targets following 8mer, 7mer-A1, 7mer-m8, and 6mer(2-7)
pairing rules (Bartel, 2009).
Log2 fold changes comparing conditions were calculated as follows. A
pseudo-count of 1 was added to all summed clusters per condition to allow for
incorporation of conditions with zero clustered reads. After binning by BC, the
sum total number of reads per cluster per condition was normalized to the read
depth

for

that

condition.

Dividing

these

normalized

CLIP

abundance

measurements per condition, we arrived at estimates over mock or controls for
change in CLIP binding due to HCV, LNA and KO conditions.
Significant peaks on HCV RNA were called based on using scan statistics
as described previously (Licatalosi et al., 2012). Gene wise p-values underwent
Bonferroni multiple test correction where the significance cut-off on HCV RNA
was set at 0.001. CIMS analysis on viral RNA was performed as described
previously (Zhang and Darnell, 2011).
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Figure 2.9. An analysis pipeline for RNAseq data. Key raw and finished files in
blue denoted by format where applicable. Data processing, calculation, and
visualization steps in green boxes.

RNA-Seq bioinformatics
Figure 2.9 outlines the pipeline for RNAseq analysis. Analysis of these
data was carried out by first filtering FASTQ reads such that 80% of the read
contained a mean score of 20. Reads were then directly mapped to hg18 using
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Bowtie, allowing up to 2 mismatches and discarding reads with multiple hits.
Mapped read coordinates were then intersected with a meta-transcript file of the
longest isoform of every coding gene in UCSC genes and then counted. The
resulting reads per gene count, for each RNA-Seq replicate then underwent
statistical analysis and quantification using EdgeR (Robinson et al., 2009).
Conservation analysis
Interval coordinates of miRNA seed target sites within CLIP clusters were
intersected with PhyloP scores (Pollard et al., 2010) for available mammalian
nucleotides from the UCSC table browser. The resulting per-nucleotide scores
were averaged across the core 6mer. The same procedure was performed for
miRNA seed target coordinates from TargetScan6.2 (Lewis et al., 2005)
predictions.
Statistical tests
Statistical analysis was carried out in Graphpad Prism or in R. Two-sided
KS-Test were employed for CDFs to test both for goodness of fit and a difference
in means. Mann Whitney U test (non parametric t-tests) were used for datasets
for which no normality assumption could be made, Student's t-test were used
otherwise. Where multiple ad-hoc or post-hoc comparisons were made, care was
taken to account for multiple testing correction using one-way ANOVA and
bonferroni correction.
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Meta-analysis of published array data
Microarray datasets from the chimpanzee miravirsen study (Lanford et al.,
2010) were processed by computing the log2 fold change across each gene for
each paired chimp array (post- versus pre-treatment) and then averaged. Liver
biopsy datasets were obtained from Gene Expression Omnibus (GSE15331,
(Peng et al., 2009); GSE14323, (Mas et al., 2009)) and processed with GEO2R
to remove non-median centered datasets. For GSE15331, a total of 96 HCV
positive datasets representing 24 individuals in technical quadruplicate were
compared to 20 HCV negative datasets representing 5 individuals in technical
quadruplicate. For GSE14323, a total of 19 normal liver datasets were compared
to 41 datasets from HCV infected patients with pre-malignant cirrhosis but no
hepatocellular carcinoma. The above processed datasets from three independent
studies were intersected with all conserved 8mer and 7m8 miR-122 or miR-15
predictions from TargetScan, or with CLIP derived miR-122 targets (7-8mers)
from at least two miR-122 perturbation conditions.
Gene Ontology analysis
Gene ontology analysis was perforemd with unranked lists using the
DAVID suite of bioinformatics tools (Huang et al., 2008) or the GOrilla suite for
GO term enrichment (Eden et al., 2009). Gene list comparisons were carried out
between the list of interest and a background set of AGO bound transcripts.
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Conservation analysis
Interval coordinates of miRNA seed target sites within CLIP clusters were
intersected with PhyloP scores (Pollard et al., 2010) for available mammalian
nucleotides from the UCSC table browser. The resulting per-nucleotide scores
were averaged across the core 6mer. The same procedure was performed for
miRNA seed target coordinates from TargetScan6.2 (Lewis et al., 2005)
predictions.
Statistical tests
Statistical analysis was carried out in Graphpad Prism or in R. Two-sided
KS-Test were employed for CDFs to test both for goodness of fit and a difference
in means. Mann Whitney U test (non parametric t-tests) were used for datasets
for which no normality assumption could be made, Student's t-test were used
otherwise. Where multiple ad-hoc or post-hoc comparisons were made, care was
taken to account for multiple testing correction using one-way ANOVA and
bonferroni correction.
Quantitative modeling of miR-122 sponging by HCV RNA
Our mathematical model expands upon a previously developed model for
miRNA regulation (Mukherji et al., 2011) by adding the behavior of HCV and its
interaction with miR-122. The mathematical model we developed describes the
concentrations of a target mRNA species (r), an HCV mRNA species (h), and
binding of miRNA (m) to form complexes with target or HCV mRNA species,
respectively (r*, h*), see Figure 2.10.
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Figure 2.10. Illustration of model reactions for miR-122 dynamics, including
transcription and translation of a target mRNA, binding to miR-122 and decay of
mRNA species. HCV RNA can replicate, be degraded, or bind miR-122,
functionally sequestering miR-122 and leading to de-repression of mRNA targets.
See text for details.

Production of a target mRNA comes from transcription of a gene at a rate (kr)
with a corresponding degradation rate (γr). We assume the miRNA-mRNA
complex (r*) does not undergo translation and degrades at a rate allowing for
recycling of the miRNA species into the pool. The total amount of miRNA is
assumed to be constant and can bind to either target mRNA (r) or HCV mRNA
(h). HCV RNA also decays at a particular rate (γh). We assumed a model where
HCV RNA is only degraded in its unbound form, consistent with previous data (Li
et al., 2013d; Shimakami et al., 2012).
From the schematic presented in Figure 2.10, from the mass-action
equations for this system, we have the following set of equations:
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where the total pool of miRNA is defined be:

Initially we performed numerical simulations of the full model, however to provide
insight into the sponging effect of HCV we made simplifications to the model for
analysis. Free miRNA (m) can be bound to either target mRNA (r) or HCV mRNA
(h). At equilibrium, the amount of miRNA bound to the two species is proportional
to the relative binding strengths as given by rearranging the equilibrium relations
for these two species. Thus, the proportion of miRNA bound to each target is
given by: r*	
   /	
   h*	
   =	
   Kr	
   /	
   Kh

,

where Kh	
   (k+h/k-‐h) and Kr	
   (k+r/k-‐r) are the

equilibrium constants for the binding-unbinding reactions.
To simplify further, if we assume that the proportion of unbound miRNA is
low in comparison to miRNA bound to HCV or mRNA target, then our
conservation relation becomes mT	
   =	
   r*	
   +	
   h* and we can estimate the amount of
miRNA bound HCV RNA combining the above relations to be:
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Solving for steady states in our full model as in Mukherji et al., the solution for r is
given by the equation below:

where,

With HCV RNA present, the difference in this relation is a reduction in the total
miRNA pool (mT) such that the parameter theta is changed to:

Examining this relation, it is evident that as the binding strength of miR-122 to
HCV RNA gets stronger, the available miR-122 pool is reduced. As the HCV
binding strength approaches zero, then all of the original mT pool is available. We
can also approximate the effect of the number of binding sites and stoichiometry
by assuming that N binding sites produces a similar effect to a single binding site
with N * the binding strength. Simulating and fitting our data to values theta, we
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used this formula to estimate the reduction in the pool of miRNA's caused by
HCV mRNA.
Data fitting was initially performed on the N = 4 construct by
simultaneously fitting the lambda and theta parameters to the steady-state
equation for r	
  =	
  f(r0) above using a least-squares error fitting algorithm. In Figure
4.24C, lambda was scanned and fit to the different experimental N constructs'
curves. In contrast to Mukherji et al., we found there to be inherent basal
expression differences between the variable number of miR-122 sites as
observed in the LNA data curves. We corrected the basal expression differences,
which resulted in the alignment of the data sets at high BFP expression. In Figure
4.24 D-E, fitting was performed while changing only the value of theta
representing a change in the available free miRNA but not in the binding strength
parameter lambda. For N = 4 curves in both cases, we noted experiment-toexperiment variability in theta fits, though the relative changes within each
experiment were consistent. For all fits, the inherent signal bias between RFP
and BFP was corrected by using the difference in a group of approximately 10
data points at the high signal end for each curve, since they are expected to fall
on a line of x=y.
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Chapter 3: Argonaute HiTS-CLIP studies of HCV RNA

This chapter describes the overall scheme of studying HCV interactions
with small RNAs using the AGO-CLIP method, and considers how these
functional genomics techniques were used to address many questions in HCV
RNA virus molecular biology in an unbiased manner. As CLIP permits the
empirical observation of AGO binding sites with minimal technical perturbation,
and is adaptable for in vivo work, we will define the interaction landscape
between AGO and HCV RNA during infection in Huh-7.5 cells. Following this, we
will demonstrate how AGO-CLIP profiles change in response to a variety of
perturbations to include time, perturbing or removing miRNAs, utilizing miRNA
independent viruses, and swapping the miRNA tropism of the virus. The impact
on virus biology will be considered throughout.
The positive interaction of miR-122 with HCV RNA presents a unique
outlier for miRNA function as it contradicts the canonical function of miRNAs as
repressors of gene expression. A major goal of the current work is determining
whether the miR-122 interaction with HCV RNA represents the predominant
small RNA interaction with the viral genome, or is one of many. Moreover, with
the HCV genome harboring multiple and conserved miR-122 sites beyond those
in the 5’UTR, the timing and amount of binding at these and potentially other
sites offers a window on the dynamics of small RNA usage by the viral genome.

107

Experimental setup
The first task for AGO-CLIP in virus infected cells is deciding the number
of cells needed per CLIP sample. The initial AGO-CLIP paper obtained results
from miR-124 transfected HeLa cells in 10cm dishes, which assuming 80%
confluence at the time of harvest would correspond to ~8x10^6 cells per sample
(Chi et al., 2009). A similar cell number was selected for work done in Clone2
HCV infected Huh-7.5 cells, initially starting from electroporation, and later
switching to infection. Importantly, independent electroporations or infections
were performed, both in separate plates, but also on separate days and always
with paired mock treated samples.
The experimental setup, as mentioned in the methods, was to
electroporate HCV RNA or infect with virus approximately 5x10^6 cells per
sample in a 15cm dish, allow for growth for between 48 and 72 hours, when most
cell are infected and proceed with CLIP. Post electroporation, we measured
infection frequency by flow cytometry of NS5A expression or by using the IPSRFP reporter cells (Jones et al., 2010) and observed 80-90% infection frequency
that was stable between 48 and 72 hours (Figure 3.1).

108

Figure 3.1. Infection frequency measurements for Huh-7.5 cells infected with
Clone 2 HCV. (A) FACS analysis of NS5A stained cells at indicated timpanist
post-electroporation, showing >80% infection frequency. (B) IPS-RFP cell
reporter analysis of HCV infection, showing >90% infection frequency. In these
cells an RFP with an NLS sequence is fused to the mitochondrial targeting
domain of IPS1 (aka MAVS). HCV NS3/4A protease expression cleaves IPSRFP, thus relocalizing fluorescence to the nucleus (Jones et al., 2010). In
general, this assay for measuring HCV replication is slightly more sensitive than
NS5A staining, due to the enzymatic nature of NS3/4A. Consequently, slightly
higher infection frequency (or at the very least protein translation) can be
measured with this method compared to NS5A FACS. Overall, both methods
approximately agree.
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Following crosslinking and harvest, cells were processed for CLIP as
described in the methods, using a pan-AGO antibody that recognizes all four
known mammalian AGOs (Nelson et al., 2007). A typical autoradiogram is shown
in Figure 3.2A. Here,

32

P-labelled RNA crosslinked to AGO was run on an 8%

Bis-Tris gel, transferred onto nitrocellulose and exposed for 2 days. An IgG
antibody was used as a non-specific antibody control. Additionally, a no crosslink
control is shown where only a faint band around 105-110kDa is apparent. This
would correspond to tightly associated AGO:miRNA complexes (Lima et al.,
2009). UV crosslinking results in a dramatic increase in signal, where importantly,
130-150kDa "smears" corresponding to AGO:mRNA or AGO:miRNA:mRNA
complexes appear alongside a more apparent 110kDa band. High RNAse
conditions tend to collapse the signal to the model size of the protein plus a
protected RNA fragment, though this is not always the case. In this experiment,
regions from mock or HCV infected lanes were cut corresponding to 110, 130 or
150kDa as a first size selection step for the isolation of AGO bound miRNAs and
mRNAs.
As a measure of IP efficiency, pre- and post-IP lysates were probed via
western blot to monitor the extent of AGO depletion (Figure 3.2B). In both
uninfected and infected cells, approximately 60% of total AGO protein was
depleted in lysates, indicating that the majority of AGO:RNA complexes were
recovered for CLIP.
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Figure 3.2. Autoradiogram of AGO bound RNA and measure of AGO depletion.
(A) Autoradiogram of 32P-labelled RNA bound to AGO after IP using the panAGO 2A8 antibody. AGOs migrate at 97kDa, which shifts by RNA species bound
by approximately 1kDa/3nt, thus AGO bound to ~22nt miRNA should be around
105kDa. IgG used as a non-specific control. Minus crosslink control shows the
stringency of washes in that only a faint Ago:miRNA complex remains. High
RNAse and low RNAse conditions indicated. Regions excised corresponding to
110, 130 or 150kDa are highlighted. (B) Pre and post IP lysates were probed for
Ago, NS5A and Actin. Percent of Ago depletion from mock or HCV infected cells
is indicated and are based on normalizing to actin.

Excised membrane regions underwent proteinase K treatment to liberate
the RNA, which then underwent 5' adapter ligation and RT-PCR for DNA library
generation (see Methods). The "first" PCR provides the next size selection step
after the autorad, and yields a key measure of success or failure for library
cloning (Figure 3.3). Here, the cDNA derived from each membrane fragment
(110,130 or 150kDa) underwent PCR for various cycle numbers. Importantly,
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care was taken to catch the earliest cycle number for which an amplified signal
could be detected on a 6M Urea-PAGE gel, to preserve the maximum library
complexity and minimize the long known non-uniformity of PCR amplification of
cDNA libraries (Patanjali et al., 1991). Adapter flanked miRNAs of ~60nt could be
observed with as few as 20 cycles of PCR. Target mRNAs typically migrated as
"smears" owing to the partial RNAse digest, ran between ~80-180nt, and were
observed in as few as 24 cycles. In general, PCR from the 110kDa membrane
fragments tended to yield miRNA+adapter sized products, though this was not
always the case, as some mRNA smears could be observed. 130-150kDa
regions almost always yielded mRNA "smears."
After isolation of miRNA or mRNA "smears," a second PCR step was
performed to append 4mer indices (one per sample) to enable multiplexing, and
to add Illumina sequences for NGS. This PCR step was typically very short
(between 4-10 cycles). In the end, libraries with miRNA sized fragments were
~150nt; mRNA between ~175-250nt. These libraries were concentration
normalized, pooled such that each index was represented once, and submitted
for high-throughput sequencing.
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Figure 3.3. 1 PCR results from cloning AGO bound RNAs. Each panel depicts
the results for excised membrane fragments (110, 130 or 150 kDa) after PCR
amplification for indicated number of cycles. Minus reverse transcriptase (-RT)
and minus template (-Temp) PCR controls are shown. Bands corresponding to
miRNA + adapters (~60nt) and mRNA targets + adapters" smears" (~80-180nt)
are indicated. Note that while 110kDa bands predominantly yield miRNA sized
products, this is not exclusive. mRNA smears are more common in 130 and
150kDa bands, where miRNAs can also be seen. Regions selected for 2 PCR
multiplexing steps were chosen such that no "bandiness" was evident for mRNA
smears.
st

nd
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Figure 3.4. Multiplex adapter 2 PCR results from cloning AGO bound RNAs.
After amplification with muliplexed primers at indicated cycle number, mRNAs
from 150 and 130kDa regions yielded products between 180 and 200bp as
expected. Cloned miRNAs plus adapters from 100kDa regions yielded a sharp
band at ~150bp. Libraries from Mock or HCV infected libraries were qualitatively
identical at this stage.
nd

An AGO binding map of HCV RNA confirms extensive miR-122 engagement
Three matched experiments were prepared and sequenced in the above
manner, resulting in a total of six libraries. After processing reads for quality and
trimming adapters, reads were mapped on to the input Clone2 HCV RNA
genome, and collapsed on the basis of a degenerate linker sequence introduced
during RNA linker ligation (see Methods). Thus, each resulting unique read
("tag") can be considered an individual AGO binding event. Approximately 1-2%
of input reads mapped to the HCV genome. The resulting AGO binding map is
presented in Figure 3.5, where tags from independent experiments are
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delineated by color and are displayed across a linear representation of the HCV
genome.

Figure 3.5. An Argonaute binding map on HCV RNA. (A) Mock-subtracted
binding map of Ago-CLIP reads across HCV genomic RNA, from three biological
replicates, denoted by read color. Statistically significant peaks above a uniform
background are indicated by asterisks. Bottom CIMS track shows location of all
deletions (gray) and statistically significant CIMS deletions (red). (B) Schematic
of a miR-122 binding model to S1 and S2 highlighting locations of CIMS
deletions. (C) Zoom in view of Ago binding from (A) across the viral IRES into the
coding sequence. IRES domains (II-IV), associated stemloops (a-d) and the
pseudoknot (pk) region are indicated. Upper track displays seeds for the top 50
miRNA seeds from CLIP data, seed types denoted by colors. A proposed noncanonical miR-122 site is highlighted in red (Pang et al., 2012).(D) Zoom in view
of Ago binding from (A) across the NS5B peaks. Known stem loops in the NS5B
coding sequence are indicated.

Not displayed is the negative strand or alignments to mock infected cells, where
in either case a vastly low percentage of reads mapped to HCV (not shown). This
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not only presents a relief in terms of experimental success (no HCV mapping
reads in the mock), but it also gives a sense of the high strand asymmetry
exhibited by AGO binding. After removing reads mapping to the polyU tract
(which is polyA on the negative strand and upon which mapped reads are
indistinguishable from Illumina sequencing artifacts), >98% of reads mapped to
the positive strand, and no peaks for the remaining low number of reads were
observed on the negative strand. This would be consistent with AGO exclusively
binding the positive strand, and playing little role, if any, on anti-sense genomes.
Moreover, it also likely indicates that no RNAi-like response is occurring, given
that this would imply Dicer activity on dsRNA in a manner that would generate
siRISCs that target both strands of HCV.
By far, AGO binding to positive strands at the extreme end of the 5'UTR,
overlapping with S1/S2 miR-122 sites, and is the most frequent binding event on
the HCV genome, accounting for 50% of all HCV mapped tags (Figure 3.5A). The
high sequencing depth achieved at S1/S2 sites enabled nucleotide resolution of
AGO crosslink sites, based on the observation that RT tends to skip crosslinked
amino-acid-RNA adducts and thus results in deletions at the site of crosslinking
(Zhang and Darnell, 2011). The resulting crosslink induced mutation analysis
(CIMS) revealed a statistically significant enrichment of deletions in areas of
close proximity to, but not within, the miR-122 S1 and S2 binding sites (Figure
3.5B). Interestingly, the most significant crosslink site was at the G in position 28
of the HCV genome. A recent report described G28A mutations as natural HCV
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variants resistant to miR-122 antagonism: the G28A mutant was attenuated in
WT cells, but could replicate in cells with reduced miR-122 levels (Israelow et al.,
2014). While the significance of this crosslink site remains to be determined, one
possibility is that AGO binding to HCV RNA is tuned by contacts outside of the
seed regions which structurally remain flexible in the AGO binding pocket in the
absence of base-paring with the miRNA (Schirle et al., 2014). A G28A mutation
might favor tighter miR-122 binding given that the opposed base on miR-122 is a
U. Moreover, its position, between S1 and S2 auxiliary pairing may be relevant
for the simultaneous AGO:miR-122 occupancy, though the precise contribution is
unknown.
Returning to the CLIP map, additional peaks of AGO binding were
observed. To identify which peaks were "significant", we employed scan statistics
to test if a peak was above a hypothetical background where all tags were
uniformly distributed across the HCV genome (Darnell et al., 2011; Licatalosi et
al., 2012). In this manner, the S1/S2 peak was significant as were peaks in the
IRES, E1, E2, NS5A and NS5B regions of the genome.
The second largest peak in the viral IRES specifically overlapped with the
pseudoknot and the coding start site (Figure 3.5C). We noted no canonical 7mer
or 8mer binding site for the top 50 miRNA families expressed in these cells,
opening the possibility that some type of non-canonical or miRNA independent
AGO binding is occurring. Interestingly, a non-canonical miR-122 site in the IRES
was proposed based on SHAPE analysis of the HCV 5'UTR with miR-122 in vitro
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(Pang et al., 2012). Our results with AGO could be consistent with miR-122
engagement. Alternatively, as the 5'UTR is highly structured, the rather broad
IRES peak could be due to crosslinking with AGO:miR-122 bound at S1/S2, but
on the outer surface of the AGO protein. This would imply that the IRES peak is
dependent on AGO binding to S1/S2, which is an idea that we will return to.
Additionally, a role for AGO in regulating IRES translation, however minor, cannot
be ruled out (see below).
Along with S1 and S2 binding, four additional miR-122 sites are known on
the HCV genome, notably in the NS5B coding sequence and in the 3'UTR
(Jopling et al., 2005; Nasheri et al., 2011). Consistent with previous data, no
significant AGO binding was observed on the 8mer miR-122 site in the 3'UTR
(Figure 3.5D). The largest peak outside of the 5'UTR, in NS5B, overlapped with
two miR-122 7mer seeds, one of which has been shown to be very slightly
repressive (Nasheri et al., 2011). While reports have suggested numerous
miRNAs that interact with HCV RNA (reviewed in (Gupta et al., 2014)), among
these we only observed expression of let-7 and miR-196 families in our miRNACLIP data (see next chapter), and no seeds from either of these families were
observed within significant Ago binding peaks. Taken together, these data
suggest that miR-122 constitutes the predominant miRNA interaction with HCV
RNA in these cells, and is largely confined to the 5'UTR.
We can only speculate as to the nature of the low-level amount of AGO
binding across the HCV coding sequence. Given the high abundance of HCV
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RNA in Huh-7.5 cells, it's possible that the low level binding reflects AGO-CLIP
"noise" of rare binding events that are likely to survive filtering because they
uniquely map. Still, it remains possible that some biology is at play. AGO was
initially cloned as eukaryotic initiation factor 2C (EIF2C), which remains the root
game name for AGOs 1-4 (Zou et al., 1998). As the name suggests, the initial
phenotype for AGO suggested a role in translation, specifically in the ternary
complex formation between eIF2, Met-tRNA, and GTP, known to be the first step
in translation initiation (Roy et al., 1988). In this work, AGO (refered to in this
study as Co-eIF-2A) was found to be important for stabilizing ternary complex
formation on an mRNA prior to its transfer to the 40S ribosomal subunit (Roy et
al., 1988). This literature has been largely superseded by emphasis on posttranscriptional gene silencing by AGO, but it raises the possibility that AGO may
be "moonlighting" with a role in HCV translation. The HCV IRES is unique in that
it can bind to the 40S subunit in the absence of any initiation factors; it appears
that only after 40S subunit engagement do eIF3 and the ternary complex bind to
initiate translation (Ji et al., 2004; Pestova et al., 1998). If AGO plays a role in
stabilizing the ternary complex and is already in the neighborhood by binding at
miR-122 sites, then perhaps its primary function extends beyond protecting the
uncapped genome, and is required to get translation initiation going efficiently.
The observed CLIP map on the IRES may be consistent with this.
In a general sense, the overall view of the AGO-CLIP map, with a large
peak at the 5' UTR and AUG start, broad coating along the CDS and basically
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zero signal from the stop codon into the 3'UTR, looks very similar to ribosomal
profiling on a highly expressed gene. A prototypical example is FMRP, an
RNABP known to be associated with translating risbosome such that CLIP with
this protein reveals broad coating of coding exons (Darnell et al., 2011). Could
this be evidence of a role for AGO ahead of the translocating ribosome or in
association with it? Clearly, more work is needed to resolve this.
The above are but a few interpretations drawn from the AGO-CLIP map on
the HCV RNA genome and I hope they raise more questions than answers. It
bears keeping in mind that a map constructed from cells infected for two days,
undoubtedly reflects the AGO binding of a mixture of viral genomes at various
stages of the viral life cycle. Thus we cannot conclude based on this static map
which binding events are linked and therefore dependent on one another. Nor
can we assign a weight to each binding event, assuming that they are
independent: does the 50% engagement at the 5'UTR mean that 50% of viral
RNAs are engaged with miR-122? This is perhaps the wrong question. But we
can begin to address the dynamics of AGO binding on HCV RNA by turning our
attention toward a timecourse.

AGO binding to miR-122 sites on HCV RNA occurs early and is replication
independent
The motivation behind this experiment was to manipulate as little as
possible. Unlike work aimed at overexpressing or knocking down AGO or miR-
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122, we aimed to use CLIP to measure how endogenous AGO:miR-122
complexes would react to a flood of incoming HCV genomes. We tested three
genomes: the WT Clone 2 HCV genome which could launch an infection; a viral
polymerase defective mutant (GNN) in the same background which could be
translated, but could not undergo RNA replication; and a miR-122 null binder with
S1 and S2 sites mutated at position 3 (p3). We reasoned that replication
dependent and independent AGO binding could be distinguished in addition miR122 dependent binding with these mutants. We performed CLIP at 6, 12, 24, and
48 hours post-electroporation in these contexts. We observed comparable AGO
binding at the 5'UTR miR-122 sites of WT and GNN mutants as early as 6 hours
post electroporation and not at all for the p3 mutant (Figure 3.6A-C). AGO
binding to miR-122 sites in particular remained stable throughout the WT
timecourse, but decreased steadily for the GNN mutant. Interestingly, in all three
contexts we observed some AGO association with the IRES, suggesting miR-122
and replication independence. AGO binding to regions outside the 5'UTR
emerged after 24 hours of replication, and were not observed in the GNN or p3
mutants. The overall amount of Ago binding for all three genomes' RNAs
correlated with RNA abundance as measured by qPCR (Figure 3.6D-E),
suggesting replication or abundance dependent Ago targeting of the viral ORF.
This would not be inconsistent with sequencing noise. The persistence of IRES
binding can be interpreted in at least two ways. As previously hypothesized, a
non-canonical miR-122 site may be responsible (Pang et al., 2012).
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Figure 3.6. Ago binding timecourse of WT and replication deficient (GNN) HCV
RNA genomes. (A-C) Cells were electroporated with WT, and replication
defective GNN, or p3 genomes and harvested for CLIP at indicated timepoints.
The p3 mutant contains a C→G mutation at the third position for both S1 and S2
binding sites and is considered a miR-122 null binder. Data are displayed across
the HCV genome as a density plot of raw peak height. The maximum peak height
for S1/S2 binding is indicated if beyond scale. (D) Normalized percentages of
HCV mapping unique reads for WT, GNN and p3 mutants across the timecourse.
(E) qPCR measurements of HCV RNA copies / ng of total RNA across the
timecourse for WT, GNN and p3 electroporations. Dashed line indicates the limit
of detection. All data are mean ± SD.
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Alternatively, AGO may be playing a miRNA-independent role in regulating the
IRES. Future work using replication defective genomes that cannot undergo
translation due to poor eIF2 ternary complex recruitment might help shed light on
this. Overall, these data indicate that while HCV RNA is bound by endogenous
AGO at S1/S2 miR-122 sites early upon infection, additional replication or
abundance dependent Ago binding of the viral ORF can occur at a lower level.

An HCV resistant to miR-122 antagonism engages miR-122
In 2011, Li, Bukh, and colleagues described an interesting HCV that was
resistant to locked nuclei acid (LNA) based miR-122 antagonism (Li et al., 2011).
After passaging HCV genomes lacking stem-loop I (SL1) of the 5'UTR, a
replication competent recombinant virus was isolated where SL1 was replaced
with part of cellular U3 snoRNA (Figure 3.7A). Interestingly, this "U3" virus lost
the S1 miR-122 site but retained the S2 site. Based on U3 virus' ability to
replicate despite miR-122 inhibition, we reasoned that CLIP with the U3 virus
could yield insight on miR-122 independent binding with a replicating virus. We
additionally hypothesized that this virus would generally behave as a miR-122
null binder.
Surprisingly, CLIP revealed extensive AGO binding to the 5'UTR,
specifically overlapping with the S2 miR-122 site (Figure 3.7B). CIMS analysis
corroborated the likely engagement of miR-122 at S2 as significant crosslinking
was observed 1nt upstream of S2 auxiliary pairing, mirroring results with WT
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Figure 3.7. An HCV mutant resistant to miR-122 antagonism engages Ago and
miR-122. (A) Schematic of the U3 virus 5'UTR with proposed S2 miR-122
binding. U3 snoRNA sequence is shown in green, adapted from (Li et al., 2011).
For reference, the WT HCV end with stem loop I is shown. (B) Ago binding map
(top track) and CIMS locations (bottom track) across the U3 virus 5'UTR
corresponding to miR-122 binding at S2. Relevant CIMS deletions sites are
shown in gray (not significant) and red (significant). U3 snoRNA sequence is
shown in green. (C) Ago binding map across the U3 virus genome after treatment
with increasing doses of LNA122. Significant peaks are named by location and
are indicated by asterisks. Bottom CIMS track shows location of all deletions
(gray) and statistically significant CIMS deletions (red) for the untreated dataset.
(D) Ago binding in significant peaks from untreated U3 datasets in (C) shown as
normalized read densities calculated per dataset. **** P<0.0001, * P<0.05, oneway ANOVA with bonferroni correction. Error bars, ± SD. This CLIP experiment
was performed with Troels Scheel.

virus presented earlier. To verify the LNA resistance of this virus, we performed
CLIP in U3 virus infected cells after treatment with 3nM or 30nM LNA-122. Here
we observed a sharp dose dependent decrease in AGO engagement of the
5'UTR, and a less extensive decrease across the genome, consistent with a pro124

viral effect for miR-122 binding to S2 (Figure 3.7C-D). Thus, it appears that miR122 is capable of residually engaging the U3 virus genome by binding S2,
despite its relative miR-122 independence. One possible reason for this might be
that miR-122 makes many more base contacts with the U3 virus, as modeled in
Figure 3.7A, and as a result miR-122 bound to the U3 viral genome may be less
susceptible to LNA based antagonism. Attempts to make S2 p3 mutants of the
U3 virus were all inviable (not shown), which at first glance argues that miR-122
binding to S2 remains required for viability. And yet, it's also possible that the S2
sequence has overlapping functions, such as PCBP2 binding (Masaki et al.,
2015). Thus a bit of caution is warranted. Despite the preponderance of evidence
that the U3 virus still binds miR-122, we cannot firmly conclude that this binding
plays the same critical role that it does with WT virus. Most importantly, the
striking miR-122 independence of this virus points to a potential avenue of
resistance to LNA based therapeutics in the form of recombinant viruses with
similarly large 5'UTR stem-loops.

CRISPR disruption of small RNA biogenesis, part I
The results so far have primarily drawn upon the introduction of RNA
genomes into the cell and rely upon CLIP of endogenous AGO:miRNA to reveal
the binding landscape of miRNAs on the HCV genome. As a followup, we
wondered what would happen upon perturbing the miRNA content of the cell as a
complementary means of exploring miRNA:HCV RNA interactions. The approach
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Figure 3.8. A CRISPR based targeting strategy to delete miR-122 and Drosha
from Huh-7.5 cells. (A) Guide RNAs were designed to delete a 38bp region
encompassing the 5' end of the miR-122 stemloop, including the entire miR-122
seed, and an adjacent DdeI restriction site. DNA cleavage sites indicated with red
triangles. miR-122-5p highlighted in gray. PAM: protospacer adjacent motif. (B)
DNA chromatogram indicating the precise genomic location (red triangle) for nonhomologous end joining following CRISPR cleavage, resulting in miR-122
deletion. (C) Guide RNAs were designed to delete a 166bp region encompassing
exon 9 of the Drosha gene, highlighted in gray. DNA cleavage sites indicated with
red triangles. (D) DNA chromatogram indicating the precise genomic location (red
triangle) for non-homologous end joining following CRISPR cleavage, resulting in
Drosha exon 9 deletion. (E) Western blot analysis of ΔmiR-122 and ΔDrosha
Huh-7.5 cells for Drosha, Dicer, and Actin. (F) Small RNA northern blot analysis
of ΔmiR-122 and ΔDrosha Huh-7.5 cells for miR-122, miR-21, miR-16, and U6
RNA as a control. Mature and pre-miRNA bands are indicated. (G) HCV
susceptibility of ΔmiR-122 and ΔDrosha Huh-7.5 cells supplemented with 3nM
miR-122 mimic, assayed via flow cytometry 72hrs after Clone2-Ypet infection.
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using LNAs, as in the U3 virus experiments, has the main benefit of being
transient and simple to carry out, yet is not without confounding factors. Quite
simply, no one really knows how LNAs inhibit miRNAs, beyond the basic
mechanism of behaving like a very stable and tightly binding nucleic acid analog
that can hybridize to a target sequence. Do LNAs inhibit pri-, pre-, mature, and/or
AGO loaded mature miRNAs? Can we assume that results obtained with LNAs
preclude ANY activity for the miRNA being inhibited? The same concerns
surround the alternative approach of inhibiting small RNA biogenesis by siRNA or
shRNA knockdown of Drosha or Dicer, with the added theoretical wrinkle of
relying on circular logic that is self-limiting. The very enzymes required to
generate silencing RNAs are themselves the targets of silencing.
To avoid these issues, we opted for an approach using CRISPR genome
engineering to delete the miR-122, Drosha, and Dicer genes from Huh-7.5 cells.
The scope of small RNA disruption enabled by these CRISPR mutants ranges
from the minimal to the drastic: from the targeted deletion of one miRNA to the
removal of all miRNAs. Schematized in Figure 3.8A, we targeted the miR-122
locus with transfected Cas9 to delete a 38bp stretch encompassing the miR-122
seed and a DdeI site used for genotyping (see methods). For Drosha deletion,
we targeted exon 9 in a manner that would result in an out-of-frame splice
between exons 8 and 10 resulting in a nonsense mediated decay substrate
(Figure 3.8B). This was the same strategy used to generate the Drosha knockout
mouse (Chong et al., 2008). Single cell dilution and expansion yielded ΔmiR-122
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and ΔDrosha clones harbored the intended deletions (Figure 3.8C-D). We
observed the specific loss of Drosha protein only in ΔDrosha cells via western
blot (Figure 3.8E). Functional characterization of miRNA processing via Northern
blot showed that both pre- and mature miR-122 was specifically lost in ΔmiR-122
cells, but not other abundant miRNAs such as miR-21 or miR-16. In ΔDrosha
cells, all three of these Drosha-dependent miRANs were lost (Figure 3.8F). The
successful creation of both of these cell lines, despite altered miRNAs, suggests
that miR-122 and miRNAs in general are not critically required for cell viability.
However, some differences in proliferation rate were noted: while ΔmiR-122 cells
grew no differently than WT cells, ΔDrosha cells proliferated at half the rate (not
shown). This is consistent with known role for miRNAs in regulating the cell cycle
(Bueno and Malumbres, 2011).
We next tested HCV susceptibility of ΔmiR-122 and ΔDrosha cells. As
expected, HCV could not replicate in either cell line, but importantly, replication
could be rescued with miR-122 mimic transfection (Figure 3.8G). In ΔmiR-122
cells, this rescue was complete at 3nM, and not significantly different from
unedited cells. In contrast, HCV replication could not be fully rescued in ΔDrosha
cells. In this context, ΔDrosha cells lack all miRNAs with the exception of miR122, thus it's possible that either additional miRNAs are directly or indirectly
required for HCV replication, or that global miRNA suppression is toxic to virus
for non-specific and pleiotropic reasons. Nevertheless, the ability to launch HCV
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infection in these cells after miR-122 mimic transfection opens the possibility of
exploring the role of all miR-122 independent binding on the HCV genome.

Probing non miR-122 dependent AGO binding on HCV RNA
With HCV permissive cell lines lacking miR-122 or all canonical mature
miRNAs, we next decided to pursue CLIP in these contexts after HCV infection.
ΔDrosha cells were first transfected with 3nM miR-122 mimic and then infected
with WT HCV for three days before CLIP. Importantly, no HCV replication was
observed in these cells without miR-122 supplementation (Figure 3.8G). We
reasoned that compared to WT cells, CLIP in HCV infected ΔDrosha cells
supplemented with miR-122 would only retain or enhance miR-122 dependent
peaks, and that peaks lost in ΔDrosha might be indicative of other miRNA
binding. We observed that the S1/S2, IRES, E1.2 and NS5B peaks remained
significant in ΔDrosha+miR-122 cells, but the low level background generally
persisted (Figure 3.9A). Ago binding to E1 and E2 peaks was reduced in
ΔDrosha cells, suggesting that a minor proportion Ago binding on HCV RNA is
due to other miRNAs, however no canonical seeds were found for these peaks.
As a means of quantifying the relative amounts of Ago binding across peak
regions between cell types with different infection frequencies, the density of
reads under each peak region was normalized to total read depth and plotted per
dataset.
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Figure 3.9. Argonaute binding maps on HCV RNA in the absence of miRNAs. (A)
Mock-subtracted binding map of Ago-CLIP reads across HCV genomic RNA in
WT or ΔDrosha Huh-7.5 cells. Data were normalized to total cellular and virus
read depth for cross track comparison. Statistically significant peaks per track are
named by location and are indicated by asterisks. Bottom CIMS track shows
location of all deletions (gray) and statistically significant CIMS deletions (red)
from the WT track. (B) Ago binding in significant peaks from WT Huh-7.5 cells in
(A) shown as normalized read densities calculated per dataset. Data were
normalized to background read density of non-peak regions and set to one
(dashed line). Asterisks, ** P<0.01, * P<0.05, Student's t-test. Error bars, ± SD.

We can appreciate the relative amount of AGO binding per peak region and
determine the extent of signal loss or gain upon removal of miRNAs (Figure
3.9B). Clearly, S1/S2 and IRES binding are unaffected, and peaks in NS5B
(mainly 5B.2 and the emergence of 5B.3) were enhanced in ΔDrosha cells, all
suggesting miR-122 dependence. The 5B.3 peak is truly novel, and is perfectly
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conserved among consensus HCV genotypes (Figure 3.10). The proximity of the
remaining peaks to the read density of regions not in peaks (aka, the
background) suggests AGO-CLIP noise as mentioned previously. Based on
these results, we can be more confident that miRNAs other than miR-122 play
little, if any, role in binding HCV RNA, at least in the context of an Huh-7.5 cell.

Figure 3.10. miR-122 binding sites in the NS5B coding sequence and 3'UTR of
HCV RNA. (A) Ago binding map in HCV infected WT cells across the NS5B
coding sequence, from three experiments. (B) Sequence alignments for indicated
major HCV genotypes (1-6) of bound miR-122 sites presented in (A). miR-122
seed highlighted in red. Third codon positions shaded in gray; amino acids are
colored according to physiochemical properties and are presented as the Clone2
sequence with deviations in other genotypes below. Conserved nucleotides are
marked with asterisks.
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The U3 virus replicates in the absence of miR-122 and miRNAs
Given the seeming miR-122 independence of U3 virus replication, we
decided to test U3 replication in ΔmiR-122 and ΔDrosha cells, and if possible,
perform AGO-CLIP to resolve the miRNA dependence of the unique AGO binding
pattern on this viral genome. We hoped to address the paradox observed with
this virus: the U3 virus is resistant to miR-122 antagonism, and yet retains the S2
site that is clearly and specifically bound by AGO.
Starting with ΔmiR-122 cells, we compared WT versus U3 virus infection
in these cells measuring HCV RNA over a timecourse. As expected, WT virus
was completely abolished in ΔmiR-122 cells, but could be rescued with 3nM miR122 supplied in trans (Figure 3.11A). Notably, no difference was observed in U3
virus replication in WT versus ΔmiR-122 cells, and miR-122 supplementation had
a mild enhancing effects for the U3 virus, that was only significant in the last
timepoint (Figure 3.11B). These results strongly suggest that U3 virus replication
is independent of miR-122. This was further corroborated by AGO-CLIP in U3
infected ΔmiR-122 and ΔDrosha cells. U3 virus replication was slower in
ΔDrosha cells compared to ΔmiR-122 cells (Figure 3.11C), however, we
achieved sufficient percentages (>30%) to enable AGO-CLIP. The U3 virus
displayed no notable AGO binding in both ΔmiR-122 and ΔDrosha contexts
(Figure 3.11D). These data alongside our LNA results confirm that the S2 site
engages miR-122, but that this binding is somewhat dispensable. Furthermore,
this suggests that S1 and S2 might have distinct non-overlapping functions. In
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the case of the U3 virus, the S1 site appears to have been replaced with a large
stem loop. The recent observation that the S2 site also binds to PCBP2 and may
compete with miR-122 binding points to a different role beyond RNA stabilization
(Masaki et al., 2015).

Figure 3.11. Timecourse qPCR measurements of WT-Clone2 virus (A) or U3Clone2 virus (B) in WT cells or in ΔmiR-122 cells with or without 3nM miR-122
supplementation. Error bars, ± SD. AGO-CLIP with U3 virus in ΔmiR-122 and
ΔDrosha cells. (C) Percent cells ΔDrosha cells infected with U3 virus over time.
(D) U3 virus AGO-CLIP in WT Huh-7.5 cells (top), ΔmiR-122 (middle), and
ΔDrosha Huh-7.5 cells (bottom). These experiments performed by Troels Scheel.
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Swapping miRNA tropism of HCV: an attempt with miR-21
The results thus far have focused on the WT virus and the U3 virus, which
no longer critically requires miR-122, but can still bind it. To get around the
confounding factors of the U3 virus, such as its large SL1 and its loss of the S1
miR-122 site, we opted to swap the miRNA tropism of WT virus as a means of
minimally creating a miR-122 independent, but not miRNA independent, virus.
This idea was first explored with miR-21 as a miRNA expressed in Huh-7 cell
derivatives, but with a sufficiently altered seed compared to miR-122 (Figure
3.12A-B) (Jopling et al., 2008). The added benefit of starting with miR-21 was
that there was some interesting negative data worth revisiting. In an early report,
the S1 miR-122 site in an HCV replicon system was mutated to a miR-21 site and
found to be inviable in Huh-7 cells (Jopling et al., 2008). Based on this result, it
was argued that the AGO:miR-122 complex might be unique in its engagement
with HCV RNA, and that mutation of S1 may be interfering with an overlapping
function. With the discovery of critical auxiliary pairing at positions 2-3 and 30-31
of the HCV genome with miR-122, the issue was revisited using a chimeric
miRNA that consisted of the miR-21 seed (positions 1-8) and the remainder as
miR-122 (positions 9-22). This miRNA was not capable of rescuing replicons
bearing tandem miR-21 S1 and S2 sites, despite the fact that this chimeric
miRNA should have been able to bind the auxiliary sites (Roberts et al., 2011).
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Figure 3.12. Exchanging miRNA tropism for HCV to use miR-21. (A) WT HCV
RNA in complex with miR-122 based on extensive genetic and SHAPE data
(Jopling et al., 2008; Machlin et al., 2011; Mortimer and Doudna, 2013). (B) A
proposed model for miR-21a engagement with a miR-21 family dependent HCV
("m21"). (C) A proposed model for miR-122 engagement with a S1/S2 miR-21
HCV. Note that G:U wobbles are capable at positions 2 and 6. (D) Full length
mono-cistronic secreted luciferase reporter virus (Jc1 background) timecourse of
various mutants on the way to a miR-21 depdendent virus. WT and GNN mutants
were contained miR-122 S1 and S2. Variations in swapping S1 or S2 seeds, or in
mutating positions 2 or 29 to accomodate miR-21 are noted. Samples were
washed at 24 and 48 hours after supernatant harvest. (E) Luciferase reporter
virus measurements as in (D) with additional mutants. Samples were washed
after all timepoints measured. All samples plotted as means ± SD.

Additionally, an important HCV seemed to be missing: a miR-21
dependent virus that incorporated the appropriate base changes at positions 2
and 30 to enable endogenous miR-21 recognition in a manner analogous to miR135

122 (Figure 3.12B). We set out to make this virus, reasoning that individual S1
and S2 miR-21 swaps would not be viable, and that the full miR-21 swap mutant
with additional C to U mutations at positions 2 and 29 would replicate.
To our surprise, both S1 and S2 seed mutants were individually viable
when swapped for miR-21, each exhibiting one log attenuation compared to WT
genomes (Figure 3.12D). The S1/S2 double mutant was viable though attenuated
by closer to three logs compared to WT (Figure 3.12E). These results with fulllength virus contradict earlier reports and showcase a tolerance for seed
mutations. Interestingly, the full miR-21 binding mutant shown in Figure 3.12B
was not viable (in black, Figure 3.12D-E). Working backwards from this mutant,
we uncovered a high sensitivity for mutations at nucleotide 2 of the HCV genome.
In all cases, mutations to U at this position were either inviable or very highly
attenuated. A complete S2 swap (including a C29U mutation) was as viable as
an S1 swap, however combining these mutations did not result in any viral
replication (in gray, Figure 3.12E). That miR-21 S1/S2 swaps were viable, but
when combined with C2U or C29T mutations had lost this viability, suggested
that miR-21 was not rescuing this virus as thought and that perhaps, miR-122
was still engaging this genome. Following the observation that S1/S2 virus
replication could be boosted with miR-122 mimic (not shown), we settled on a
model whereby this virus represented a maximal deviation from canonical miR122 binding in that many G:C base pairs were replaced by G:U wobbles (Figure
3.12C). Furthermore, the drastic inhibition of the C2U mutation hinted at an
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overlapping function beyond miRNA pairing that was

perturbed upon

mutagenesis.
Swapping miRNA tropism of HCV to use miR-15
Perhaps the biggest lesson of our experience with miR-21 was that the C
at position 2 of the HCV genome likely has an overlapping function beyond
binding a miRNA. A likely candidate for this additional function is a role in RNA
replication. Learning from this, we reasoned that a viable replacement for miR122 would need to maintain a GG at analogous positions to pair at auxiliary sites,
should not allow for G:U wobbles in the seed, and should be expressed at similar
levels to miR-122. Taking this candidate approach over a literature based
approach, we settled on the miR-15 family. In particular, miR-15a/b satisfied the
above criteria, with five non-G:U changes in the seed compared to miR-122,
maintenance of GG at positions 15-16, and present as ~4.8% of miRNAs in the
cell compared to ~8.3% for miR-122 (Figure 3.13).
While miR-16 dependent viruses were inviable (not shown), an
electroporated miR-15a/b dependent HCV luciferase reporter virus (m15) was
viable, and replicated to within one log of the WT virus after 72hrs (Figure 3.14A).
Notably, the miR-15 virus was resistant to increasing concentrations of LNA122
(IC50 > 50nM) but susceptible to LNA15a/b (IC50 = 10nM) (Figure 3.14B). Unlike
WT virus, the m15 virus was also viable in ΔmiR-122 cells (Figure 3.14C).
Taken together, these data strongly support miR-122 independent virus
replication by exchanging miRNA tropism to use miR-15a/b.

137

Figure 3.13. Exchanging miRNA tropism for HCV. (A) WT HCV RNA in complex
with miR-122 based on extensive genetic and SHAPE data (Jopling et al., 2008;
Machlin et al., 2011; Mortimer and Doudna, 2013). (B) A proposed model for
miR-15a engagement with a miR-15 family dependent HCV ("m15"). (D)
Conservation of miR-122 (the sole family member) with the miR-15 family reveals
extensive differences in the seed (6 changes with no possibility for G:U wobble
pairing), maintenance of seed GC content, and importantly, the preservation of
the GG at positions 15-16, critical for the 3' supplementary pairing shown in (C).
Note that GG is not preserved in miR-161. Percent abundances of these miRNAs
on AGO as measured by polyG-CLIP (see next chapter) are indicated.
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Figure 3.14. Functional characterization of a miR-15 dependent HCV. (A)
Luciferase measurements of supernatants from WT and m15 HCV reporter virus
electroporations (± SD). Non-replicating GNN control is shown. Media was
replaced at each time point measured. (B) Dose response of WT and m15
reporter viruses following pre-treatment with LNA inhibitors of miR-122 or miR15a/b at indicated concentrations, measured at 96 hours post-infection (± SD).
(C) Time course post infection of ΔmiR-122 Huh-7.5 cells with indicated viruses
(± SD). These experiments were performed with Katharina Shaw.

We expanded these analyses with the non-reporter viruses in the Clone2
background and measured sensitivities to 50nM LNA122 or LNA15 prior to virus
infection. As expected WT HCV RNA levels were reduced 20-fold with LNA122
treatment but were resistant to LNA15, the converse was true for the m15 virus,
though with less attenuation (Figure 3.15A-B). We noted that the expected
inhibitory LNA treatment for either WT or m15 virus reduced infected cell
frequency (Figure 3.15C-D). Lastly, as expected, WT virus infectivity was
severely reduced in LNA122 treated cells but was unaffected by LNA15 (Figure
3.15E). The infectivity for the m15 virus presented an interesting result in that it
was reduced in the presence of LNA15 as expected, but also in the presence of
LNA122 (Figure 3.15F).
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Figure 3.15. LNA sensitivity assays comparing WT HCV and m15 HCV. (A-B)
qPCR measurements for WT (A) or m15 (B) viruses were performed at indicated
timepoints post infection, after mock treating, or treating with LNA inhibitors to
miR-15a/b (blue) or miR-122 (red) at 50nM, from duplicate experiments. Data
presented as Genome Equivalents (GE) / ng of total cellular RNA (± SD). (C-D)
Percent NS5A positive cells (± SD) in WT (C) and m15 (D) virus infections
following LNA treatment as above, measured by flow cytometry. (E-F) Infectivity
titer measurements of virus released from LNA or mock treated cells as above for
WT (E) and m15 (F) virus infections, as FFU/mL (± SD). These experiments were
performed with Troels Scheel and Eiko Nishiuchi.

At least two possibilities might explain the apparent reduction in m15 virus
titer upon treatment with LNA122. Conceivably, miR-122 may have direct proviral roles on HCV RNA beyond S1/S2 sites, such as the putative IRES binding
site, or sites in NS5B. Alternatively, and not mutually exclusively, the miR-122
regulated transcriptome if globally de-repressed may alter the intracellular
environment such that it is "less pro-viral." I hesitate to use the term "anti-viral" for
LNA122 treatment in this indirect context, since this would imply some level of
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cellular intent. For example, consider a miR-122 target that if de-repressed would
signal the cell to mount an anti-viral response or initiate cell-cycle arrest. Such
scenarios have been recently proposed with limited experimental support (Xiong
et al., 2014; Zhao et al., 2013). Arguably, such a target could constitute a sensor
for miR-122 levels. However, if de-repressing miR-122 targets inhibits m15 virus
due to a passive indirect effect, such as altering the lipid composition or
trafficking, but playing no selected for role in detecting or combatting virus, this
would be evidence of a non-specific "anti-viral" effect. In any case, as the above
two scenarios are simultaneously possible and are completely dependent on the
underlying host transcriptome, we will revisit them in the next chapter. What is
common to both perhaps, is that the virus faces a miR-122 defined ceiling that
limits its replication.
Refocusing on the virus, the ability of the m15 virus to replicate in ΔmiR122 cells offers an alternative means to explore miR-122 dependent binding as
an obverse experiment to that presented in Figure 3.9. Recall how that
experiment was performed with WT virus in ΔDrosha cells supplemented with
miR-122, thus only miR-122 binding was expected to be observed. In the
experiment presented in Figure 3.16, we performed CLIP in m15 virus infected
WT and ΔmiR-122 cells. Here we expect a specific loss of miR-122 dependent
binding where no change should be observed at S1/S2 sites since these depend
on the miR-15 family.
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Figure 3.16. AGO binding maps on m15 HCV reveal extent of miR-122
dependent targeting. (A) Ago binding map of m15 virus infection in WT Huh-7.5
(top panel) or ΔmiR-122 Huh-7.5 cells (bottom panel). Data were normalized to
total cellular read depth for cross track comparison. Statistically significant peaks
per track are named by location and are indicated by asterisks. (B) Ago binding in
significant peaks from (A) shown as normalized read densities calculated per
dataset. Two-sided Student's t-test used. Error bars, ± SD.

The AGO-CLIP pattern on m15 virus was similar to that observed with WT virus,
indicating that the S1/S2 swap can recapitulate the previously observed binding
pattern (Figure 3.16A, top panel). In ΔmiR-122 cells we noted the reductions in
AGO binding in the viral IRES and in the NS5B peaks, strongly supporting miR122 dependent binding at these sites (Figure 3.16A, bottom panel). Quantification
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of read density within peaks revealed statistically significant reductions in putative
miR-122 dependent sites (Figure 3.16B). These data offer confirmation for
endogenous miR-122 dependent binding outside of S1/S2.
The above discussion on the apparent reduction of m15 virus to LNA122
suggests a miR-122 defined ceiling for viral replication. While it remains to be
determined if miR-122 binding on the viral RNA, outisde of S1/S2, plays a direct
role in augmenting HCV RNA levels, the ΔmiR-122 cell context offers a platform
to address the general ceiling question. In this experiment, we re-introduced miR122 at various concentrations into ΔmiR-122 cells, and infected with m15 virus. If
the ceiling hypothesis holds, then we could expect to see a miR-122 dependent
enhancement of m15 virus. Comparing untreated ΔmiR-122 cells or cells treated
with 3nM or 30nM of miR-122, we noted a two-fold enhancement of viral RNA
and infectious titer levels in the presence of miR-122 (Figure 3.17A and C). We
also detected a slight increase in the percentage of infected cells (Figure 3.17B).
These data, combined with the observations of LNA122 inhibition of the m15
virus, lend support for a replication ceiling that is in some measure dictated by
miR-122 levels. Moreover, as we'll see in the next chapter, this ceiling appears
modified by the virus to functionally reduce the miR-122 levels in the cell.
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Figure 3.17. Effect of miR-122 reintroduction to m15 virus infected ΔmiR-122
cells. (A) qPCR measurements for m15 virus RNA in ΔmiR-122 cells
supplemented with miR-122 mimic at indicated concentrations, from
quadruplicate experiments. (B-C) FACS analysis of infection frequency (B) and
infectivity measurements (C) as in (A). Asterisks: ****P<0.0001, ***P<0.001,
**P<0.01, one-way ANOVA with Bonferroni multiple comparison correction.

CRISPR disruption of small RNA biogenesis, part II
In contrast to Drosha, which is required for miRNA biogenesis but plays no
role in RNAi, Dicer represents a critical node for both miRNA and siRNA
biogenesis. Successful deletion of Dicer in Huh-7.5 cells would thus enable an
unbiased exploration of any role for RNAi in HCV infected cells. In combination
with ΔDrosha cells, we also reason that these reagents may also prove useful in
revealing the respective contributions of miRNAs or siRNA in other virus
infections.
More proximally, ΔDicer cells have the potential to resolve seemingly
contradictory data regarding miR-122 usage by HCV RNA. One study found that
Dicer knockdown reduced HCV RNA accumulation and could be rescued by
adding back mature miR-122 duplexes (Zhang et al., 2012). Based on these
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results, the authors concluded that mature miR-122 produced by Dicer activity on
pre-miR-122 was key for maintaining HCV RNA abundance. And yet, mounting
evidence suggests that pre-miR-122 may play an active regulatory role,
especially in liver, where pre-miR-122 oscillates in a circadian manner and
correlates with oscillating miR-122 target repression despite invariant (and high)
levels of mature miR-122 (Gatfield et al., 2009). This work suggests an
interesting hypothesis whereby mature miR-122 levels may not necessarily
explain the full regulatory potential of this miRNA. Conceivably, newly
synthesized miR-122 or the pre-miR-122 intermediate itself, may play a
regulatory role distinct from "old" miR-122 (Gatfield et al., 2009). Starting from
this premise, Cox, Doudna, Sarnow and colleagues tested the abilities of premiR-122 molecules to maintain HCV RNA abundance. By using pre-miR-122
hairpins with DNA bases at known positions of Dicer processing, they were able
to make hairpins refractory to Dicer cleavage in vitro (Cox et al., 2013). These
Dicer resistant hairpin molecules were observed to function in miRNA and siRNA
assays, and in addition appeared to maintain HCV RNA abundance. Further
testing of a bulged pre-miR-122 that exhibited poor Dicer processing and not able
to function in miRNA and siRNA assays was also able to maintain HCV RNA
abundance (Cox et al., 2013). Overall, these results suggest a role for pre-miR122 in binding and stabilizing HCV RNA.
The above two studies present somewhat contradictory findings. The first
essentially argues that mature miR-122 is required for HCV RNA maintenance,
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and thus implies a critical need for Dicer enzymatic activity. The second argues
that pre-miR-122 can function to maintain HCV RNA, and therefore could imply
that Dicer is largely dispensable. So which is it? Note that the results of the first
study do not entirely rule out pre-miR-122 function so much as provide clear
evidence that mature miR-122 functions on HCV RNA.

Figure 3.18. Functional characterization of CRISPR engineered Dicer mutants in
Huh-7.5 cells. (A) Western blot of Dicer in WT, ΔEX1, ΔEX2, ΔEX19 and
ΔEX2.19 cells. Drosha served as a loading control. (B) Small RNA northern
analysis of each of the above Dicer mutants probing for miR-122, miR-15a, miR16 and miR-21. U6 RNA served as a loading control.

To address this unambiguously, we decided to delete Dicer in Huh-7.5
cells and test their susceptibility to HCV. Our initial attempt focused on deleting
the first coding exon, where we reasoned that removing the start codon would
prevent Dicer translation. Exon 1 was successfully deleted, but to our surprise,

146

Dicer protein was made at near WT levels and miRNA processing proceeded
normally (Figure 3.18). In some experiments we also noticed that the loading
control U6 RNA appeared degraded specifically in these cells (not shown). The
nearest in-frame methionine is in exon 4, which would result in a protein missing
149 amino acids from the N-terminus, corresponding to approximately a 17kDa
reduction in size (from ~220kDa to 203kDa). In terms of protein structure, this
would result in a Dicer mutant with a non-functional DEXDc helicase domain.
Such mutants have been extensively characterized in vitro and are known to
exhibit WT reaction velocities for miRNA processing but intriguingly, were found
to be dramatically enhanced in siRNA processing (Ma et al., 2008; 2012). In this
manner, the Dicer helicase domain is thought to be an inhibitor of Dicer siRNA
but not miRNA processing. More recent work has revealed a curious form of
Dicer active in mouse oocytes that essentially lacks the helicase domain (Flemr
et al., 2013). This oocyte specific Dicer, called Dicero, arose from a retrotransposon inserted alternative first exon between exons 6 and 7 of the Dicer
gene. Found only in mice and rats, this Dicer also exhibits enhanced siRNA
biogenesis and is thought to promote endogenous RNAi in the mouse germline
for reasons that are still not yet clear (Flemr et al., 2013). Could our DicerΔEX1
Huh-7.5 cells be used to illustrate an antiviral RNAi response in somatic cells?
Experiments are currently underway to address this.
Taking a cue from ΔDrosha cells, where an exon was deleted to promote
an out-of-frame splice to generate an NMD substrate, we next deleted exon 2 of

147

Dicer, thinking that by preserving translation in exon 1, no truncated Dicer would
be made. DicerΔEX2 cells exhibited a a near complete absence of Dicer protein
levels; however a very faint band could still be detected in long exposures and
resembled DicerΔEX1 in seize (Figure 3.18A). These cells also displayed a
marked increase in pre-miRNAs, suggesting a major defect in Dicer processing.
Unlike pre-miR-15a, pre-miR-16 and pre-miR-21, the precursor for miR-122
yielded additional unprocessed bands (Figure 3.18B). And yet, a small amount of
mature miRNA could clearly still be made from miR-122 and miR-16, likely due to
residual truncated Dicer activity (Figure 3.18A). Total Dicer knockouts these cells
were not.
As a last attempt, I deleted exon 19, which is immediately upstream of the
RNAse III domain coding exons, and whose deletion would induce an out-offrame splice (DicerΔEX19). Protein made any upstream start codon would
encounter a stop before RNAseIII domains and thus would not function, if it
happened to survive NMD. Additionally, any start downstream would make
protein consisting only of the RNAseIII and the dsRNA binding domains, and also
would not function (Ma et al., 2012). Exon 19 was also deleted DicerΔEX2 cells
as an additional redundant strategy (making DicerΔEX2.19 cells). This third
targeting strategy finally worked. Dicer protein levels were completely abolished,
as was pre-miRNA processing in cell lines lacking exon 19 (Figure 3.18).
CRISPR mediated genome engineering is rightfully lauded as a superior
alternative to traditional knockdown and knockout approaches for its ease and
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flexibility. As the above exercise shows, targeting a few regions in the same gene
largely bears this out, with the important caveat that not all knockout engineering
attempts will yield the same results. In this instance, we fortuitously achieved a
few very interesting mutants: a putative "super" Dicer expressing cell, a cell
expressing very little Dicer, and true Dicer knockouts.
Testing HCV dependence on Dicer: a role for pre-miR-122?
Now with a panel of endogenous Dicer mutant Huh-7.5 cells, we next
tested their permissiveness to HCV. If pre-miR-122 can function to stabilize HCV
RNA as posited by (Cox et al., 2013), we would expect to see HCV replication in
DicerΔEX19 and DicerΔEX2.19 cells, were only pre-miR-122 is made. On the
other hand, these cells should be refractory to HCV replication if only mature
miR-122 is required.
We observed no replication in both DicerΔEX19 and DicerΔEX2.19 cells
after infection with Jc1 luciferase reporter virus (Figure 3.19B). Virus replication
could be rescued in these cells by transfecting 30nM miR-122 mimic, largely
bypassing the Dicer requirement. We also tested DicerΔEX1 and DicerΔEX2
cells, and found that virus replication was attenuated by one log in both contexts.
This was notable in light of the fact that DicerΔEX1 cells expressed WT levels of
protein, while DicerΔEX2 cells expressed 95% less Dicer (Figure 3.19A). This
may reflect more promiscuous Dicer activity in ΔEX1 cells, though this has yet to
be fully confirmed. Overall, these data preliminarily suggest that endogenous premiR-122 cannot promote HCV replication. As this conclusion disagrees with
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previous work, there are alternative hypotheses to consider in reconciling these
disparate findings. Conceivably, Dicer may play a role in loading pre-miR-122
molecules apart from its RNAse activity. Restoration of Dicer mutants that cannot
cleave miRNA stem loops will need to be tested to see if HCV replication can be
rescued in this context. Additionally, we've yet to test if transfected pre-miR-122
can rescue HCV replication in DicerΔEX19 and DicerΔEX2.19 cells. This is
important considering that the increase in pre-miR-122 yielded multiple RNA
species, in contrast to miRs -15a, -16, and -21 in which a single pre-miRNA was
unregulated (Figure 3.18B). Taken together, these data bring up many
fascinating questions to explore using genome engineered manipulations of small
RNA activity in the cell.
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Figure 3.19. HCV replication timecourse measurements in various Dicer CRISPR
mutants. Jc1 luciferase reporter virus was used at an MOI of 1 to infect WT Huh7.5 cells, or Huh-7.5 cells harboring genomic deletions of the indicated coding
exons of Dicer. Experiments were performed in the absence or presence (+122)
of 30nM transfected miR-122 mimic. Cells were washed at each timepjoint
measured. Panels A and B present the same WT data for comparison of the
remaining mutants. Dashed line indicates mean signal from mock-infected cells.
Error bars, ± SD.
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Chapter 3 summary and discussion
By applying AGO-CLIP to a virus that appears to require a miRNA for its
replication, we've generated conclusive biochemical evidence of the miR-122
interaction with HCV RNA that overwhelmingly agrees with the genetic evidence.
Additional and likely miRNA dependent AGO binding was also observed and may
reflect additional roles for small RNAs in HCV biology, though by and large, miR122 appears to be the most important for this virus. We've also explored multiple
host and viral contexts for HCV replication. By deleting miR-122, Drosha, or Dicer
genes, we've begun to probe endogenous small RNA function on HCV at the
genomic level. Establishing a miR-122 independent virus (U3) in conjunction with
swapping HCV miRNA tropism to use miR-15, we've also added new viral
contexts to address HCV small RNA use. Driven by CLIP, these results provide
answers to many questions that can now be addressed.
One major question still to be resolved in HCV biology is how positive
strand genomes "decide" between multiple fates: to undergo translation, to
package into virions, serve as templates for negative strand synthesis, or get
degraded. miR-122 has been proposed as a regulator in these processes,
specifically favoring RNA synthesis, by competing at the S2 site with PCBP2
induced RNA circularization, which favors translation (Masaki et al., 2015). Its
aforementioned roles in stabilizing viral RNA and perhaps promoting translation
make it seem as though miR-122 indeed plays multiple parts. Thus, our results
with CLIP likely capture a mixture of RNAs at various stages of the virus lifecycle.
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We can consider future means of leveraging CLIP to address the central issue: at
which stage(s) of the viral lifecyle is miR-122 important?
One way to frame this question is to consider whether S1 and S2 sites
possess

distinct

functions.

Pioneering

work

established

that

miR-122

engagement at both S1 and S2 sites was critically required for HCV replication
(Jopling et al., 2008). CLIP data agrees with this, though both S1 and S2 are too
close to distinguish individual AGO binding events. One way around this would
be to use chimeric viruses, where S1 binds miR-122 and S2 binds miR-15, or
vice versa. Preliminary work with Yingpu Yu and Troels Scheel in the Rice lab
has shown the viability of such swap mutants. Combined with detailed CIMS
analysis and recent AGO-CLIP advances to identify miRNA:target ligation events,
the stage is set to functionally unravel S1 and S2 activities in the future
(Grosswendt et al., 2014; Helwak et al., 2013)(Moore, et al. Submitted). AGO and
miR-122 relocalization to lipid droplets upon HCV infection provides yet another
clue to interpret CLIP maps (Ariumi et al., 2011; Berezhna et al., 2011). It's
conceivable that an AGO-CLIP experiment can be designed to specifically
interrogate AGO association in different subcellular compartments. We can draw
inspiration from the recent development of proximity specific ribosome profiling
on this front (Jan et al., 2014).
Perhaps a more compelling approach with potential inroads to in vivo
interrogation of miR-122 usage by a virus is to consider the recently discovered
hepaciviruses of horses, rats, and mice (Drexler et al., 2013; Firth et al., 2014;
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Kapoor et al., 2013). Non-primate hepacivirus (NPHV), commonly found in horse
sera, contains at least one miR-122 site in its 5'UTR and is thought to be
engaged with AGO (Scheel et al., 2015). Rodent hepacivirus (RHV) has also
been shown to contain a miR-122 site in the 5'UTR (Kapoor et al., 2013). If these
viruses represent hepatotropic ancestors of HCV, they may help explain how
HCV acquired the usage of miR-122 as a key determinant in the virus life-cycle.
Clearly, much work remains to to done in this area.
Of course, given the success of AGO-CLIP in HCV studies, one also gets
the impression that even more compelling applications of these methods lie with
other RNABPs, in other viruses, and certainly other host contexts per the above
discussion. One compelling example are arthropod borne (arbo) viruses that
cycle through insect and mammalian hosts and uniquely face two very different
immune systems. As mentioned in the introduction, RNAi plays a key role in
innate anti-viral defense in insects, while the protein based interferon response
appears to dominate in mammalian hosts. AGO-CLIP is thoroughly poised to give
an unbiased picture of endogenous small RNA function in both contexts, and
may uncover host:viral interactions at the RNA level as targets for therapy.
Arboviruses such as chikungunya virus (CHIKV, of the Togaviridae), yellow fever
and West Nile viruses (YFV and WNV, both of the Flaviviridae) are good starting
candidates, and current work in the Rice lab is aimed at elucidating small
RNaAinteraction maps for these viruses in insect and mammalian hosts. That all
of the above viruses are emerging threats driven by human induced climate
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change lends a sense of urgency to the mission (Fischer et al., 2014; Gould and
Higgs, 2009).
The general application of AGO-CLIP as a screening and discovery tool
warrants some discussion as we consider how viruses may exploit small RNAs to
their benefit, and how to properly interpret CLIP maps. Obviously, viruses
encoding their own miRNAs present an intuitive case for AGO-CLIP whereby
reads perfectly aligning to a 22-23nt stretch are likely to be miRNA genes, as has
been extensively shown for many herpesviruses (Haecker et al., 2012; Riley et
al., 2012a; Skalsky et al., 2012). These primarily constitute evidence of AGO
loading, while AGO association with mRNA, which yields a broader peak, can be
reasonably assumed to be repressive. Clearly HCV requiring miR-122 is an
outlier in this regard, and we propose that the differences in the proportional
amount of AGO binding (its "peakiness") across the viral genome may indicate
whether a small RNA is required by the virus. HCV, where over 50% of all AGO
binding events map to the first 50nt of the viral genome would largely bear this
out. AGO-CLIP work in Pestiviruses by Troels Scheel has identified miRNA
dependence among certain members of this virus family, where again, a single
peak predominates (unpublished observations). In the case of requiring a small
RNA, we would expect the amount of AGO binding to be both peak-like and to
positively correlate with RNA abundance, an observation we were able to confirm
with HCV comparing WT and GNN timecourses (Figure 3.6).
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Repressive events are somewhat harder to interpret on the basis of AGOCLIP results alone. Given that AGO binding typically results in RNA degradation,
CLIP results that "catch" these moments should at steady-state be an
underestimation of the amount of AGO binding at these loci. As a result, AGOCLIP alone is not sufficient to conclude which binding events on viral genomes
are repressive and which may be informatics noise. This is especially true in light
of CLIP results on viruses that do not yield peaks, but instead are broadly
"coated" with AGO binding (not shown). However, by pairing AGO-CLIP with
RNAseq (or for a single virus, qPCR), and then manipulating small RNA levels
with inhibitors or as genomic deletions, one can overcome this limitation and
focus on the change in AGO association in these contexts. This is essentially
what was done with the U3 virus in ΔmiR-122 and ΔDrosha cells. Establishing
what a true AGO-CLIP signature of viral RNA repression can also be done by
miRNA overexpression or by forcing an RNAi response (with siRNA) and
watching how AGO binding changes. These experiments have not yet been
systematically performed and no doubt provide a compelling jumping off point for
future studies.
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Chapter 4: Argonaute HiTS-CLIP studies of HCV infected host cells
In the previous chapter, we focused on the insights from AGO-CLIP on the
HCV genome in a variety of infection contexts. This arguably constitutes the main
goal of AGO-CLIP in HCV infected cells. But part of the utility of CLIP is that it
provides a wealth of data on the host transcriptome in addition to the virus. With
this data, we can begin to piece together the cellular miRNA regulatory response
to a viral infection in an unbiased manner. To do this, we’ll begin by analyzing the
small RNA populations within AGO and how they are similar and different from
total RNA based measurements. We’ll then move on to a novel and globally
observed phenomena of miR-122 sponging by HCV RNA. This sponge effect will
be used to establish the miR-122 regulated target network in Huh-7.5 cells and
will be the subject of rigorous experimental examination and validation. It is
remarkable, but to some degree unsurprising in hindsight, that the critical miR122:HCV interaction could have a specific and de-repressive effect on the host
miR-122 targetome. The results to be presented here simultaneously offer a
global yet transcript specific view of miR-122 sponging by HCV, for which many
possible functions and consequences will be discussed.

AGO-CLIP miRNA abundance measurements - correcting ligation bias
Perhaps the most basic analysis to perform with AGO-CLIP data is the
determination of the AGO associated miRNA profile. This can either be done by
aligning groomed reads to a database of mature miRNA sequences (such as
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miRbase) or by aligning to the genome and counting reads overlapping with
annotated miRNA coordinates. The former approach Is the easiest to carry out
but is constrained by exact sequence; the latter is constrained mainly by mapping
coordinates and has the potential to pick up novel miRNAs.
Applying either approach we noted significant differences between
previous data on miRNA abundance in Huh-7.5 cells and results with AGO-CLIP.
In previous small RNA cloning measurements from the lab, miR-122 was
measured to be the most abundant miRNA in Huh-7.5 cells, at around 20% of
total miRNA (Randall et al., 2007). In contrast, AGO-CLIP miRNA abundance
measurement placed miR-122 as the 65 most abundant miRNA, closer to 0.16%
th

of the total (Figure 4.1A). Combined with miRNAs that displayed enrichment in
AGO-CLIP, very little correlation was observed with previous small RNA cloning
results (Figure 4.1A).
We can extend this analysis further by inferring the miRNA profile based
on mRNA clusters. This was based on the intuitive idea, first brought up by (Chi
et al., 2009), that counting miRNA seeds within mRNA clusters, and weighting by
cluster read density could be used to infer the underlying miRNA profile. In other
words, the AGO abundance on mRNA targets likely reflects which miRNAs are
actually used. The resulting target normalized total frequency showed that miR122 was among the top ten most frequent seeds within mRNA clusters, indicating
its functional abundance on AGO. And yet, CLIP derived miRNA abundance
measurements displayed no correlation with the inferred profile (Figure 4.1B).

158

Figure 4.1. miRNA bias in linker- ligation dependent AGO-CLIP. (A) Scatterplot
comparing published miRNA percent abundance measurements from total RNA
(Randall et al., 2007) to linker ligation CLIP. Squared correlation coefficient of the
linear regression best-fit line is shown. miR-122, miR-15/16 and miR-21 families
are highlighted. (B) Scatterplot comparing linker ligation CLIP miRNA percent
abundance to the normalized abundance of miRNA seeds on mRNA clusters,
from linker ligation CLIP, as in (Chi et al., 2009). Squared correlation coefficient of
the best-fit line is shown.

There are a few possible reasons for this discrepancy, at least one
biological and two technical. As most miRNA measurements are made from
biochemically purified total RNA where levels are assumed to be functional (that
is, AGO associated), one possibility is that the assumption of functionality does
not hold. Conceivably, the miRNA profile from total RNA could be categorically
different from the miRNA profile that is actually AGO associated. Such a bold
biologic hypothesis would challenge most miRNA measurements made form total
RNA as they are devoid of cellular context and RNABP interactions key to their
function. Perhaps AGO-CLIP provides the real answer?
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As attractive as the above hypothesis may be at first, there are two
technical concerns related to cloning bias that warrant attention: the effect of UV
crosslinking and linker ligation. As UV crosslinking is thought to work on the order
of ångstroms, perhaps different miRNAs sit in the AGO binding pocket each in
their own way and as a result are not uniformly cross-linked. Added to this is the
concern that crosslinking, while amenable to stringent purification, may
differentially impact a miRNA's ability to be be reverse transcribed into cDNA due
to the crosslinked amino-acid:RNA adduct that may interfere with RT. We can
use this last point by considering CIMS deletions on miRNAs to see if the pattern
and amount of CIMS deletions varies as a function of miRNA abundance. Shown
in Figure 4.2, we can appreciate the uniqueness of CIMS deletions per miRNA in
line with previous analyses in brain (Zhang and Darnell, 2011). Notably, CIMS to
miRNA seeds is largely absent, which agrees with structural studies of miRNA
occupancy in AGO (Schirle et al., 2014). The most crosslinked nucleotides are
between positions 8-12, in regions not generally observed to base pair with
targets. Additionally, among this representative cohort of miRNA examined, all
four RNA bases are somewhat equally crosslinked (7U, 3G, 6A, 5C). Perhaps the
most striking feature is the percent deletions across miRNAs. The most abundant
miRNA measured by CLIP is miR-21 (19% of total reads), less than 0.5% of
these reads harbored CIMS deletions. In contrast, over 6% of miR-122 reads
(0.16% of total) exhibited CIMS. By and large, it appears as if the most abundant
miRNAs in CLIP are among the least cross-linked. However, whether this is a
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cause or a symptom of the altered miRNA profile on AGO compared to total RNA
is unclear. Cloning miRNAs from non-crosslinked AGO IPs revealed a similar
miRNA profile to CLIP in these cells, with drastically lower depth (not shown).
Taken together, these results imply, but as yet do not confirm, a cross-link bias in
miRNA abundance measurements with AGO-CLIP.

Figure 4.2. CIMS analysis of select miRNAs from AGO-CLIP. The percent of
reads mapping to each respective miRNA with CIMS deletions is plotted by 5' to
3' position. miRNAs are ordered by decreasing CLIP abundance. miRNA
sequences are shown below with significant CIMS nucleotides highlighted in red.

The second technical concern, and one that compounds the potential
cross-link bias raised above, is that of cloning bias. Stemming from sometimes
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conflicting results across labs, over the past decade it has been increasingly
clear that the dual RNA linker ligation steps using T4 RNA ligase to clone small
RNAs can dramatically influence the resulting miRNA profile, and must be taken
into account. The key enzyme involved, RNA ligase 1 (Rnl1) from T4 DNA
bacteriophage, evolved primarily to counter a host-mediated defense mechanism
whereby the anti-codon loop of lysine charged tRNAs is cleaved in phage
infected cells (Amitsur et al., 1987; Silber et al., 1972). By repairing cleaved tRNA
with Rnl1 and T4 poly-nucleotide kinase (T4 PNK), T4 DNA phage is able to
ensure availability of tRNA-Lys (Amitsur et al., 1987). Not surprisingly, more
recent work has found that RNA ligation of adapters to miRNAs using Rnl1
prefers structural features that most closely mimic anti-codon loops, and as a
result introduce cloning bias (Zhuang et al., 2012). Solutions to this problem
range from using RNA ligase mutants with altered ligation efficiencies to
modifying RNA adapters to a random pool (Brown et al., 2013; Hafner et al.,
2012; Zhuang et al., 2012).
As an alternative, we opted to try an RNA ligation independent approach
(Figure 4.3A). Inspired by ribosomal profiling cloning methods (Ingolia et al.,
2009), we pursued an approach where miRNAs are tailed with G nucleotides
(see methods). This tail then serves as a handle for reverse transcription using a
primer containing linker sequences separated with an APE1 ssDNA digestion
site. Following RT, the cDNA is circularized with an ssDNA ligase, and cleaved
with APE1 to generate a cDNA product amenable to PCR. This cloning
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technique, called polyG-CLIP, thus provides an RNA ligation independent means
to quantify miRNAs from crosslinked AGO IPs. Note however, that polyG-CLIP
isn't totally ligation free: an ssDNA ligase, modified from an RNA ligase is used.

Figure 4.3. miRNA bias correction with polyG-CLIP. (A) . A 3' adapter ligation
independent miRNA cloning strategy consists of poly-G tailing small RNA (in
black) followed by reverse transcript (RT) using an anchored oligo (in gray)
containing an APE1 cut site. Resulting cDNA products are circularized and relinearized with APE1 nuclease, prior to PCR. (B) Absolute miRNA quantification
of select miRNAs measured by qPCR, ordered by decreasing abundance. The
table highlights the abundance of these miRNAs via linker ligation or poly-G
CLIP. (C) Scatterplot comparing published miRNA percent abundance
measurements from total RNA (Randall et al., 2007) to polyG CLIP. Squared
correlation coefficient of the linear regression best-fit line is shown. miR-122,
miR-15/16 and miR-21 families are highlighted. (D) Scatterplot comparing polyG
CLIP miRNA percent abundance to the normalized abundance of miRNA seeds
on mRNA clusters, from linker ligation CLIP, as in (Chi et al., 2009). Squared
correlation coefficient of the best-fit line is shown.

163

Applying polyG-CLIP and comparing to qPCR results of select miRNAs,
we noted that polyG-CLIP agreed with qPCR abundance order, unlike standard
ligation based CLIP (Figure 4.3B). Moreover, comparisons to previous miRNA
data yielded a much higher correlation (Figure 4.3C). Poly-CLIP miRNA
measurements were also well correlated to the inferred miRNA profile from
standard ligation based CLIP (Figure 4.3D). Taken together, these results
strongly suggest a miRNA cloning bias as a result RNA ligation that can be
corrected with alternate approaches.
And yet one question lingers regarding the standard RNA ligation
approach: why would bias be observed on the miRNA profile, but not on mRNA
targets? I reason that this is due to the nature of the RNA cloned: unlike an
individual miRNA with a fixed nucleotide sequence (and not thought to be
accessible by RNAse), mRNA targets undergo a partial RNAse digestion such
that a variety of 5' and 3' ends are generated for each target. As a consequence,
the "cloneability" of an mRNA target is likely to be much more uniform than a
miRNA, and thus mRNAs should not exhibit such a drastic bias. This would
explain why the inferred miRNA from mRNA clusters in standard CLIP agrees
with polyG-CLIP miRNA measurements (Figure 4.3D). While polyG-CLIP
appeared to be superior to quantifying miRNAs, the overall read depth for both
miRNAs and mRNAs was lower compared to standard CLIP (not shown). For
miRNAs, few in number, short and relatively abundant, the lower depth did not
present a major hurdle for quantification, as showcased above. The same cannot
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be said for mRNAs, whose much lower read depth in polyG-CLIP (compared to
standard CLIP), limited the utility of this technique for studying mRNA targets.
As a compromise, polyG-CLIP was used to determine the AGO bound
miRNA profile, while the standard RNA ligation based approach was used to
determine mRNA targets. For subsequent analysis on mRNA-CLIP clusters, we
focused on searching the top 50 seed families derived from poly-G CLIP studies,
which constituted over 97% of miRNA identified in Huh-7.5 cells.
As a last point, it should be noted that addressing the above concerns
does not preclude the initial biologic interpretation, that the AGO associated
miRNA profile may be categorically different from the profile measured from total
RNA. Indeed, despite correcting for cloning bias, the correlation between polyGCLIP and either total small RNA cloning or the inferred miRNA profile is not
perfect (Figure 4.3C-D). It remains plausible, perhaps even likely, that miRNA
measurements from total RNA can miss the real picture of AGO:miRNA function
precisely because they fail to capture the functional RNABP complex in action.
Future work based on AGO-CLIP provides a fantastic means to address this
largely overlooked and somewhat mysterious assumption (Chen, 2013).
A tour of AGO binding in Huh-7.5 cells
Before we go into global and somewhat abstract bioinformatic analyses of
AGO-CLIP targeting during HCV infection, it's perhaps useful to get a feel for the
data by simply looking at it in a genome browser. In this manner, we can observe
what AGO binding an mRNA transcript looks like "in the wild" so to speak. This
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provides the most accessible introduction to viewing these data, and it's also
where I began historically, not knowing what else to do with a 2GB sequencing
file. Exploring it with a genome browser seemed as good a place to start as any,
and importantly, was the jumping off point for many hypotheses to be discussed.
But before we launch our guided safari, a few particulars. mRNA CLIP
reads were aligned to the human genome and clustered (defined here as any two
reads overlapping by at least 1nt). As a quick sanity check, we can perceive the
important of biologic replicates by considering where reads annotate from any
one or more independent libraries. The idea here is that the more something is
independently and repeatedly confirmed, the more likely it is to reflect the true
global picture of RNABP activity. Such an analysis was first performed with the
3'UTR binding nElavl protein CLIP in mouse brain, where increasing biologic
complexity increased the 3'UTR signal (Ince-Dunn et al., 2012). These results
showed that repetition can dramatically lower spurious clusters from individual
libraries. Performing a similar analysis on AGO-CLIP data from Huh-7.5 cells, we
observed something very similar (Figure 4.4). Here, clusters in at least one library
are great in number (>250K) but mostly map to introns and deep intergenic
regions, and are thought to represent one-off spurious noise. As we increase the
stringency for clusters, where constituent reads must come from two, three and
so on up to six libraries, we can appreciate how the percentage of clusters
mapping to 3'UTRs and CDS exons, places of well known AGO association,
increases with BC. Note however, that the total number of clusters decreases
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with increased BC stringency. This tradeoff introduces a decision point in defining
a cutoff for what is significant. While the lowest BC contains all true positives by
definition, it is plagued by a high number of false positives. On the other hand,
the highest BC is likely too stringent as it selects for highly abundant (or highly
clonable) mRNAs at the expense of lower abundant, but true, mRNA targets. In
other words, it suffers from a false negative problem. Thus an arbitrary decision
must be made. For the purposes of these studies, we split it down the middle: I
stipulated a minimum BC of the number of libraries divided by two, in the case of
these six libraries (3 Mock, 3 +HCV), we consider clusters composed of reads
from any three libraries at a minimum.

Figure 4.4. Cluster annotation results by increasing biologic complexity. AGOCLIP reads from up to six libraries were clustered with a minimum overlap of 2nt.
Clusters with reads from any one, two, three and so on up to six libraries the
were annotated. The resulting proportions of clusters overlapping known genic
elements is plotted above, alongside the total number of clusters with the
respective biologic complexity (BC).
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Now, to begin our tour of AGO bound mRNAs, we'll start by focusing on
the hepatic nature of Huh-7.5 cells. The parental line for these cells, Huh-7, was
originally isolated in 1982 from a well differentiated hepatocellular carcinoma in a
57-year-old Japanese male (Nakabayashi et al., 1982). As such, numerous
hepatic transcripts are maintained in these cells befitting their liver origin. One
notable transcript 3'UTR bound by AGO is 3-hydroxy-3-methylglutaryl-CoA
reductase (HMGCR) (Figure 4.5A), the rate limiting enzyme for cholesterol
biosynthesis and famously, the main target of cholesterol reducing statin drugs.
Interestingly, miR-122 inhibition in mice and in chimpanzees reduced serum
cholesterol, and in mice, reduced HMGCR expression was observed (Elmén et
al., 2008; Esau et al., 2006; Krützfeldt et al., 2005; Lanford et al., 2010). Given
the importance of miR-122 to HCV replication and to host lipid biosynthesis, later
work explored a possible connection between the two and found essentially that
there was none: miR-122's activity on HCV and on regulating cholesterol
biosynthesis occurred via separate and distinct mechanisms (Norman and
Sarnow, 2010). With no miR-122 sites and so far no confirmed miRNA sites on
HMGCR, the above data point to some role for miR-122 in regulating an inhibitor
to cholesterol biosynthesis upstream of HMGCR (Norman and Sarnow, 2010).
This possibility remains to be fully explored. Data presented in Figure 4.5A open
the possibility of direct miRNA regulation of HMGCR where interestingly, miR-21
was recently shown to regulate HMGCR mRNA in a cellular model nonalcoholic
fatty liver disease (NAFLD) (Sun et al., 2015).
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Figure 4.5. Genome browser examples of AGO-CLIP binding to notable hepatic
transcripts. AGO binding in the presence of WT HCV or uninfected cells in the
upper red and gray tracks respectively, from triplicate experiments. Reads are
plotted as normalized densities to enable cross track comparison. miR-122 family
seeds noted by red boxes, peaks changing between conditions denoted by
asterisks. PhyloP conservation track shown at the bottom. Genes: (A) 3-hydroxy3-methylglutaryl-CoA reductase (HMGCR), (B) apolipoprotein B (APOB) CAA to
UAA editing site indicated, (C) claudin-1 (CLDN1), and the (D) albumin and
alpha-fetoprotein (ALB and AFP) locus.

Consistent with a hepatic origin of Huh-7.5 cells is robust expression (and
surprising AGO targeting) of apolipoprotein B (APOB) (Figure 4.5B). Long known
to be a key player in very low density lipoprotein (VLDL) secretion, APOB is also
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associated with HCV lipoviroparticles (LVPs) (Felmlee et al., 2013). The APOB
transcript features an unusually long coding exon that in the liver results in a
100kDa protein (ApoB100), whereas in the small intestine this exon is edited by
APOBEC1 to produce an in-frame stop codon, resulting in a truncated 48kDa
protein (ApoB48) critical for chylomicron function. The long APOB exon is coated
with AGO binding, much of it downstream of the editing site (Figure 4.5B). Could
this be a surveillance mechanism to ensure that any errantly edited APOB
transcript does not result in production of the 48kDa protein in liver? This
hypothesis remains to be tested.
Claudin-1 (CLDN1) mRNA, encoding a tight junction protein and coreceptor for HCV, is also bound by AGO via putative miR-155 sites (Evans et al.,
2007; Qin et al., 2013) (Figure 4.5C). Interestingly, Claudin-1 is upregulated in
cirrhosis and HCC, suggesting a tumor suppressive role for miR-155 (Holczbauer
et al., 2014). This parallels observations with occludin (OCLN) another HCV entry
factor and tight junction protein, whose transcript contains miR-122 sites (Ploss
et al., 2009; Sendi et al., 2014). Recent work has shown that miR-122 expression
reduces OCLN mRNA in hepatocytes, and in this manner prevents HCV entry
(Sendi et al., 2014). Whether this represents a bonafide super-infection exclusion
mechanism remains to be determined.
As a fulcrum that captures both the hepatocyte and HCC derived nature of
Huh-7.5 cells, it is notable that both albumin (ALB) and alpha-fetoprotein (AFP)
are robustly expressed and bound by AGO (Figure 4.5D). The former protein is
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the quintessential liver product and is the most abundant blood protein in
mammals, where it's required to maintain osmotic pressure of body fluids
(Theodore Peters, 1995). AFP is thought to be the fetal form of serum albumin
and is normally not present in the adult liver, but is a common marker for tumors,
especially HCC (Bialecki and Di Bisceglie, 2005). Whether AGO binding to the
coding exons of these genes plays any role in their regulation is completely
unknown.
Of course, AFP is not the only indicator of the HCC origin of these cells.
Both MYC and MYCN oncogenes are expressed, the latter while particularly
associated with poor progression in neuroblastoma, is highly bound by AGO in
Huh-7.5 cells (Figure 4.6A). The myc family of transcription factors are well
known drivers of HCC and recent work has implicated tumor suppressive
miRNAs (including miR-122) participating in feedback loops to inhibit myc
expression (Han et al., 2013; Wang et al., 2013a). PEG10, also highly bound by
AGO, is a paternally expressed imprinted gene that, like myc, is upregulated in
many HCC cases and uniquely in the regenerating liver (Okabe et al., 2003; Tsou
et al., 2003) (Figure 4.6B). At least two non-coding RNAs involved in cancer are
also bound by AGO, one aptly named highly upregulated in liver cancer (HULC)
(Matouk et al., 2009) (Figure 4.6C-D). The other XIST, the key non-coding
effector of X-inactivation, is not normally expressed in males but is known to be
deregulated human cancers, regardless of gender (Weakley et al., 2011). As the
function of a miRNA is typically cast as a repressor of protein expression, finding
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non-coding RNAs bound by AGO presents a bit of a conundrum. What is AGO
doing? Long noncoding RNA biology is at an interesting frontier in exploring this,
and perhaps other RNABP interactions in various disease states (Shi et al.,
2013).

Figure 4.6. Genome browser examples of AGO-CLIP binding to notable coding
and non-coding transcripts associated with HCC. AGO binding in the presence of
WT HCV or uninfected cells in the upper red and gray tracks respectively, from
triplicate experiments. Reads are plotted as normalized densities to enable cross
track comparison. miR-122 family seeds noted by red boxes, peaks changing
between conditions denoted by asterisks. PhyloP conservation track shown at the
bottom. Genes: (A) v-myc avian myelocytomatosis viral oncogene neuroblastoma
derived homolog (MYCN), (B) paternally expressed 10 (PEG10), (C)
hepatocellular carcinoma up-regulated long non-coding RNA (HULC), and (D) X
inactive specific transcript (non-protein coding).
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As the above examples indicate, far more questions and testable
hypotheses than answers are raised by observing AGO-CLIP data with "boots on
the ground" level views. The descriptive nature of these data imply a role for
miRNAs in regulating a variety of liver and cancer specific pathways, some not
having anything to do with HCV. Indeed, all of the above examples, with the
exception of PEG10, did not show appreciable change upon HCV infection
compared to mock controls. While certainly a rich dataset for understanding liver
or cancer biology, more comprehensive and miRNA focused means of analysis
are clearly needed to make sense of these miRNA:mRNA interaction maps and
their shifting role during HCV infection.
As the molecular link between AGO and HCV RNA, this is where miR-122
becomes important. Consider three known miR-122 targets (Figure 4.7). The
first, initially called cationic amino acid transporter 1 (CAT-1) was historically the
first miR-122 target validated (Chang et al., 2004). This transcript contains three
7mer sites of which AGO binding is detected in two of them and interestingly,
appears reduced upon HCV infection (Figure 4.7A). A similar observation was
made on citrate synthase (CS) and pyruvate kinase muscle isoform 2 (PKM2)
mRNAs, both confirmed miR-122 targets (Jung et al., 2011; Krützfeldt et al.,
2005) (Figure 4.7B-C). Searching within AGO mRNA peaks for miR-122 seeds to
putatively define novel miR-122 targets, we observed a similar pattern. For miR122 seeds in the 3'UTRs of SLC1A5, SFT2D1 and CANX mRNAs, AGO binding
was again reduced upon virus infection (Figure 4.8). Taken together, these

173

observations suggest a link between the HCV dependence on miR-122, and derepression of endogenous miR-122 targets. To fully explore this, we must
consider miR-122 targets as a group and compare how targets of other miRNAs
as a group respond to HCV infection.

Figure 4.7. Genome browser examples of AGO-CLIP binding to previously known
miR-122 targets. AGO binding in the presence of WT HCV or uninfected cells in
the upper red and gray tracks respectively, from triplicate experiments. Reads are
plotted as normalized densities to enable cross track comparison. 7mer miR-122
family seeds noted by red boxes (6mers in gray), peaks changing between
conditions denoted by asterisks. PhyloP conservation track shown at the bottom.
Genes: (A) solute carrier family 7 (cationic amino acid transporter, y+ system),
member 1 (SLC7A1, aka CAT-1), (B) citrate synthase (CS), (C) pyruvate kinase
muscle isoform 2 (PKM2).
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Figure 4.8. Genome browser examples of novel AGO-CLIP identified miR-122
targets. AGO binding in the presence of WT HCV or uninfected cells in the upper
red and gray tracks respectively, from triplicate experiments. Reads are plotted
as normalized densities to enable cross track comparison. miR-122 family seeds
noted by red boxes, peaks changing between conditions denoted by asterisks.
PhyloP conservation track shown at the bottom. Genes: (A) solute carrier family 1
(neutral amino acid transporter), member 5 (SLC1A5), (B) vesicle transport
protein SFT2A (SFT2D1), (C) calnexin (CANX).
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Figure 4.9. An common assay to detect miRNA and HCV RNA levels. (A) Non
poly-adenylate RNAs (such as HCV RNA or miRNAs) are poly-adenylated and
reverse transcribed with a tagged oligo-dT primer capable of recognizing the
junction with non-polyA. The resulting cDNA uses an HCV 3'UTR primer or a
sense miRNA primer and the common tag primer for qPCR. (B) Absolute qPCR
measurements of miR-122 and HCV RNA levels at indicated time points post
electroporation (n=3). Replication-deficient J6/JFH1-GNN and mock controls are
shown. Dashed line indicates lower limit of quantitation. Error bars, ±SD.

HCV infection functionally reduces AGO binding on host miR-122 targets
Given the crucial requirement of miR-122 for HCV replication, and in light
of the result that HCV RNA levels accumulate to within one log of miR-122 levels
(Figure 4.9), we hypothesized that the HCV genome may act as a "sponge" for
cellular miR-122, where viral replication may exert a broadly de-repressive effect
on host miR-122 targets. This would be consistent with CLIP results on miR-122
targets presented thus far. Two key predictions of the data can be made based
on this hypothesis: (1) AGO binding to miR-122 targets as a population should be
reduced upon HCV infection, and consequently, (2) the aggregate expression of
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this population should increase. We can globally explore this bioinformatically by
assigning a miRNA to all CLIP derived mRNA clusters with a miRNA seed,
computing the fold change at a given cluster between HCV and mock infected
cells, and plotting these values as a cumulative distribution. I assigned a miRNA
family to clusters bearing seeds based on polyG-CLIP abundance of the top 50
expressed miRNA families. In cases where a cluster could be bound by more
than one miRNA family due to the presence of multiple seeds, both miRNA
families were assigned to that cluster. The median number of miRNA seeds per
cluster in these data was 1.4, in line with previous estimates (Farh et al., 2005). A
log2 fold-change between HCV or mock infected cells score was calculated per
miRNA-assigned cluster, and the cumulative distribution of these score was
plotted, binned by miRNA family. In these plots, if there was no difference in AGO
binding between HCV and mock infected cells, the score for that cluster was near
0. Changes showing a decrease of AGO binding upon virus infection would be
<0, while increases in AGO binding would be >0 (Figure 4.10A).
Viewing the entirety of the data in this manner and focusing on 7-8mer
seeds, we found that miR-122 3'UTR targets as a population exhibited reduced
AGO binding upon virus infection (Figure 4.10B). This was highly specific to miR122 targets, as the targets of the miR-15 family, or the top ten miRNA families
exclusive of miR-122, exhibited no such change. Significant changes in miR-122
binding were observed for all canonical seed types (as defined in (Bartel, 2009)).
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Figure 4.10. HCV infection de-represses endogenous miR-122 targets. (A) miR122 dependence definition by Ago binding profiles. (B) Cumulative density
function (CDF) of the log2 fold change in CLIP binding between infected and
uninfected cells for all 3'UTR clusters containing indicated 7-8mer seeds by
family, from triplicate experiments. "Top" refers to the top 10 miRNA families,
exclusive of miR-122. "All" refers to the top 50 miRNA families, inclusive of miR122. Two-sided K-S test p-value between miR-122 and all targets shown. (C) The
mean log2 fold change (± ranges) in CLIP binding on miR-122 3'UTR targets
versus all targets during HCV infection broken down by seed type. (D) A CDF plot
during HCV infection as in (B) but measuring target mRNA expression via RNASeq, from duplicate experiments at 72hrs post-infection. Targets with more than
one miRNA binding site were collapsed such that no gene is represented more
than once per category. (E) The mean log2 fold change (± ranges) in mRNA
expression of miR-122 3'UTR targets versus all targets during HCV infection
broken down by seed type.
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However the greatest change was observed with 7-8mers likely reflecting
the higher intrinsic false-positivity associated with 6mers (Figure 4.10C). Through
RNA-seq measurements we observed functional de-repression of CLIP derived
miR-122 3'UTR targets after virus infection such that greater RNA abundance
was evident when compared to all miRNA targets (Figure 4.10D). Likewise,
significant expression changes for all miR-122 target seed types were observed
in the reciprocal direction as CLIP (Figure 4.10E). Taken together, these results
establish a correlative role for HCV replication in functionally reducing miR-122
activity, both at the level of decreased AGO binding and subsequentlyincreased
mRNA levels.
While emphasis of miRNA activity largely centers on 3'UTRs, we can peer
objectively into CLIP data to look for any effects on other genic elements:
5'UTRs, coding exons and introns. If miR-122 inhibition by HCV is truly general,
we would expect to see AGO CLIP changes similar to 3'UTRs on other genic
regions, where these changes should likely not have much of an effect on mRNA
levels. miRNA activity is well known to be weaker if AGO binding occurs on
coding regions, presumably due to competition with ribosomes (Bartel, 2009).
Moreover, there is very little general evidence that miRNA binding to 5'UTRs or
introns influences mRNA levels, however there are exceptions.
Unlike HCV, AGO rarely binds cellular 5'UTR elements, of those that
appear to be bound, there is no miR-122 specific difference in AGO binding due
to HCV infection, nor is there a a significant change in mRNA abundance (Figure
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4.11A). The low number of 5'UTRs bound is likely the reason for this, as the
results are quite noisy. The story is different with miR-122 targeted coding exons,

Figure 4.11. HCV infection effects on non-3'UTR miR-122 targets. CDF plots of
the log2 fold change in CLIP target binding (left) and mRNA expression (right)
between infected and uninfected cells for 5'UTR (A), CDS (B), and intronic (C)
targets containing indicated 7-8mer seeds by family, from three experiments.
"Top" refers to the top 10 miRNA families, exclusive of miR-122. "All" refers to the
top 50 miRNA families, inclusive of miR-122. Two-sided K-S test p-value between
miR-122 and all targets shown. For mRNA-seq, targets with more than one
miRNA binding site were collapsed such that no gene is represented more than
once per category.
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there is a slight reduction of AGO binding on exons upon HCV infection, however
this difference does not result in a significant increase in mRNA (Figure 4.11B).
This is consistent with previous observations on exonic miRNA targeting as
expected.
miR-122 binding to introns presents an interesting observation as there is
a slight decrease in intronic binding upon HCV infection, and also a very slight
increase in mRNA expression (Figure 4.11D). Whether this points to a role in
miRNA regulation of transcript levels by binding exons is highly speculative.
Recall that the population sizes between 3'UTRs, exons, introns and 5'UTRs are
uneven at any biologic complexity (Figure 4.4). Thus any significance
calculations are likely to be spuriously magnified with a high enough sample size
as is very common in genomics and other data science research. This problem,
known as the "p-value problem", makes it very difficult to interpret if the slight
mRNA change due to miR-122 intronic binding is meaningful (Lin et al., 2013).
It's perhaps more intuitive to consider that the effect of mRNA abundance is very
marginal on introns and coding exons (in Figure 4.11, the red curves are only
slightly difference than the black curves), while for 3'UTRs there is a drastic
difference (Figure 4.10). The most conservative interpretation is that AGO
binding changes on miR-122 targets due to HCV can be observed throughout
genic elements targeted by miR-122, but they are functionally most pronounced
on 3'UTRs.
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As, mentioned in chapter 3, numerous miRNAs beyond miR-122 have
been proposed to bind HCV RNA, even in Huh-7 cell derivatives (reviewed in
(Gupta et al., 2014)). Of these miRNA families, only the let-7 and miR-196
families were identified as AGO associated in polyG-CLIP. Conceivably, binding
of these miRNAs to HCV could reduce their functional activity for host targets in a
similar stoichiometric sponge manner as miR-122. We did not observe this Figure
4.12. AGO binding and mRNA expression of let-7 and miR-196 targets was not
altered by HCV infection. This agrees with the CLIP map on HCV, as neither of
these miRNA seeds were observed in AGO peaks on the viral genome. Overall,
this points to miR-122 as being very unique among miRNAs in that its criticality
for HCV replication results in specific and observable changes to host miR-122
targets.

Figure 4.12. HCV infection effects on miRNA targets for miRNAs that putatively
bind HCV RNA. CDF plots of the log2 fold change in CLIP target binding (A) and
mRNA expression (B) between infected and uninfected cells highlighting let-7
and miR-196 family 3'UTR targets. Two-sided K-S test p-value between let-7
(green), miR-196 (purple), or miR-122 (red) and all targets shown.
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As CLIP permits the biochemical identification of miRNA targets, it is
worthwhile to consider how it compares to bioinformatic prediction. Compared to
Targetscan6.2 (TS) (Lewis et al., 2005), we found that CLIP largely
complemented and expanded upon predicted miR-122 targets (Figure 4.13).
3'UTR targets identified via CLIP and predicted by TS exhibited the greatest
change in Ago binding (Figure 4.13A) and mRNA de-repression (Figure 4.13B-C)
compared to expressed targets unique to either search modality. Of the
expressed 731 miR-122 CLIP targets of all seed types identified via CLIP, 48%
and 9% overlapped with non-conserved and conserved TS predictions,
respectively (Figure 4.13D). Focusing on a more stringent set of 7mer and 8mer
seeds for CLIP data yielded even greater overlap, such that only 5% of CLIP
derived targets were not represented in either TS conservation category (Figure
4.13E). These results highlight a broad convergence between CLIP and
bioinformatic prediction to outline a set of miR-122 targets specifically
derepressed upon virus infection. Given the bias of bioinformatic prediction to
favor 3'UTRs and conserved sites, in addition to being unable factor in the
expressed transcriptome, the empirical nature of CLIP methods make it uniquely
poised to given an unbiased account of AGO binding, as the above results
suggest.
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Figure 4.13. CLIP comparison to the miRNA prediction tool Targetscan6.2. (A)
CDF plot of Ago binding comparing 3'UTR miR-122 targets unique to CLIP ("CLIP
Only"), CLIP targets predicted to be conserved ("CLIP, Conserved") and nonconserved ("CLIP, Nonconserved") according to Targetscan (TS) bioinformatic
prediction. (B) CDF plot of RNAseq data comparing TS conserved miR-122
targets confirmed in CLIP data ("CLIP + TS"), expressed miR-122 targets without
CLIP evidence ("TS Only"), or CLIP targets lacking TS prediction ("CLIP only").
Conservation for CLIP only targets was defined by an averaged PhyloP score
across the miR-122 seed greater than 0.5. (C) CDF plot of RNAseq data as in (B)
comparing non-conserved TS targets. Conservation for CLIP only targets was
defined as in (B) (D-E) Proportional Venn diagram showing the overlap of
conserved and non-conserved TS predictions to CLIP derived miR-122 targets of
all seed types (D) or 7mer and 8mer seeds only (E). Asterisks: ****P<0.0001,
***P<0.001, **P<0.01, *P<0.05, two-sided K-S test.

Thus far, our results suggest that HCV functionally reduces miR-122
levels. If so, then CLIP results obtained from artificially inhibiting or deleting miR122 in the absence of virus should be similar. We decided to corroborate our
observations with HCV by performing CLIP after pharmacologic inhibition of miR122 and in ΔmiR-122 Huh-7.5 cells. The reduced Ago binding on miR-122 3'UTR
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targets during HCV infection was similar to 30nM LNA122 or miravirsen
treatment (Figure 4.14A-B) and to ΔmiR-122 cells compared to unedited controls
(Figure 4.14C).

Figure 4.14. MiR-122 target de-repression in LNA, miravirsen and ΔmiR-122
cells. Cumulative density function (CDF) of the log2 fold change in CLIP binding
between treatment over control cells with LNA122 (A) or miravirsen (B) at 30nM
or genetic deletion of miR-122 (ΔmiR-122) (C), for all 3'UTR clusters containing
indicated 7-8mer seeds by family, from triplicate experiments. "Top" refers to the
top 10 miRNA families, exclusive of miR-122. "All" refers to the top 50 miRNA
families, inclusive of miR-122. Two-sided K-S test p-value between miR-122 and
all targets shown. (D) Proportional Venn diagram showing the overlap of miR-122
targets with reduced (<0) CLIP binding across ΔmiR-122, LNA or miravirsen
treatment, and HCV infection conditions. Hypergeometic p-value of overlap
shown. (E) Proportional Venn diagram showing the overlap of miR-122 targets
with greater (>0) CLIP binding across ΔmiR-122, LNA or miravirsen treatment,
and HCV infection conditions. Hypergeometic p-value of overlap shown.
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Interrogating the list of 3'UTR targets exhibiting reduced Ago binding
across these three conditions revealed highly significant overlap (Figure 4.14D)
suggesting that the effect of HCV replication on lowering functional miR-122
levels is as general as antagonizing miR-122. Interestingly, we can also observe
the noise in this system, by looking the overlap of miR-122 targets that exhibited
enhanced AGO binding in the presence of virus, LNA or miR-122 deletion.
Indeed, there is no significant overlap (Figure 4.14E).
Overall, while the above results compellingly suggest that HCV
functionally de-represses miR-122 targets, it is still only correlative. Establishing
a causative role was in truth the main motivation to construct the miR-15
dependent virus: by swapping the miRNA tropism of HCV, we should expect derepression of miR-122 targets to be relieved and redirected to miR-15 targets.
Parsing RNAseq from m15 versus mock infected cells, we indeed observed that
miR-122 targets were no longer de-repressed, and that miR-15 family targets
were (Figure 4.15A). These results highlight the causal nature of an HCV induced
miRNA sponge as both functional and somewhat modular. We note that the m15
virus sponge effect was generally weaker than for the WT virus, likely due to the
lower replication level observed and possibly to binding of the miR-15 family
member, miR-16, which shares the seed site but may not be able to engage the
m15 genome due to lack of auxiliary pairing (see previous chapter). On a
transcript level, we could also observe via CLIP that binding to miR-15 targets
was reduced in m15 virus but not WT virus infected cells; likewise, miR-122
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targets with reduced binding in WT virus infection showed no reduction in m15
infected cells (Figure 4.15B-C). Thus at the level of AGO binding and mRNA
expression, we can observe HCV RNA as a causal miRNA sponge in action.

Figure 4.15. Exchanging HCV miRNA tropism redirects functional miRNA
sequestration. (A) CDF plot of the log2 fold change in mRNA expression between
HCV m15 infected and uninfected cells for all 3'UTR clusters containing indicated
7-8mer seeds by family, from duplicate experiments at 96hrs post infection. "Top"
refers to the top 10 miRNA families, exclusive of miR-122 and miR-15. "All" refers
to the top 50 miRNA families, inclusive of miR-122 and miR-15. Two-sided K-S
test P-value comparing miR-15 (blue) or miR-122 (red) clusters to "All" is shown.
(B) Genome browser tracks of two known miR-15 family targets, CCNE1 and
CDC25A. AGO binding in the presence of WT HCV (3 libraries) or m15 HCV (4
libraries) in the upper red and blue tracks, respectively. Reads are plotted as
normalized densities to enable cross track comparison. miR-15/16 family seeds
noted by gray bar. PhyloP conservation track shown at the bottom. (C) Genome
browser tracks as in (B) of two known miR-122 family targets, ALDOA and
P4HA1. MiR-122 family seeds noted by gray bar.
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Validation of HCV induced miR-122 sequestration in bulk and single cells
Based on the results so far, it's arguable that HCV RNA can be said to
"validate" miR-122 targets, given the effect of WT virus on host transcripts
containing miR-122 seeds. The same can apply to the m15 virus and miR-15
family targets. It bears stressing that all of the above HCV work was done by
observing the effects of virus on the endogenous transcriptome, without
manipulating miRNA levels. Thus, any further attempts to validate the sponge
effect are likely to yield fruit and may provide additional mechanistic insight on
how HCV usage of miR-122 impacts host targets.
As a first attempt, we decided to observe in practical terms, what mRNA
de-repression due to sponging of a miRNA looks like via qPCR to validate
changes observed via RNAseq, and luciferase reporter assays, to measure the
magnitude and seed dependence of HCV induced miR-122 sponging. In general,
qPCR of 3'UTR miR-122 targets were increased between 1.1 and 1.8 fold in the
presence of virus, in line with the median RNA-seq measurement of a 50%
change, and in line with estimates of miRNA function (Mukherji et al., 2011)
(Figure 4.16). As expected, only 3'UTR targets appeared de-repressed (8 of 12)
and not coding exon targets (0 of 3) Figure 4.16. These results provide an
independent validation of CLIP and RNAseq measurements.
Next, we used luciferase reporters of miRNA activity to validate the HCV
miR-122 sponge on individual 3'UTRs. Using miRNA mimics or LNAs as positive
controls for repression and de-repression respectively, we observed that HCV
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infection broadly resembled LNA inhibition with reporters bearing miR-122 seeds,
or with cloned full length miR-122 target 3'UTRs (Figure 4.17). As expected, this
effect was specific to miR-122 containing seeds, as no de-repression by HCV
was observed on a miR-17 reporter.

Figure 4.16. QPCR of AGO-CLIP derived miR-122 targets after HCV infection,
from triplicate experiments. Two previously known miR-122 targets (SLC7A1 and
SCD) served as positive controls. 3'UTR and CDS miR-122 targets tested are
indicated. A miR-33 target (ABCA1) served as a negative control. Error bars,
±SD.
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Figure 4.17. Validation of HCV induced de-repression of miR-122 targets with
luciferase reporters. Luciferase reporter measurements for synthetic miR-122,
miR-17, or cellular 3'UTR target constructs. Data were normalized to "no oligo"
p3,4 mutant conditions. Significance testing was performed relative to
endogenous "no oligo" repression for each tested construct. Asterisks: ***
P<0.001, ** P<0.01, * P<0.05, ANOVA with bonferroni correction.

Perhaps an under appreciated but salient point of the results presented
thus far is that they stem from measurements on populations of cells. As cellular
mRNA and HCV RNA expression levels are known to vary widely between
individual cells (Kandathil et al., 2013; Sheahan et al., 2014), we sought to
achieve a more thorough understanding of the HCV miRNA sponge on host
miRNA targets at a quantitative single-cell level. Previous work by Mukherji, van
Oudenaarden, Sharp, and colleagues demonstrated that miRNAs generate
thresholds of gene expression such that miRNA repression can be highest on low
abundance targets, and can be virtually non-existent on high abundance targets
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(Mukherji et al., 2011). Furthermore, these thresholds can be altered upon
manipulating miRNA levels. Perhaps the most intriguing feature of this work is
that it provides a testable mathematical model of miRNA function across a range
of mRNA expression patterns. How might the HCV:miR-122 sponge work in this
context?
To test this, we adapted the strategy used by Mukherji et al. to construct
two-color tet-inducible fluorescent reporters of miRNA activity amenable to flow
cytometry (Figure 4.18) (Mukherji et al., 2011). In this assay, a bidirectional Tet
promoter drives expression of blue and red fluorescent proteins (TagBFP and
TagRFP). Each fluorescent protein is tagged with a nuclear localization sequence
(NLS) to aid in flow cytometric analysis. The 3'UTR of TagRFP is engineered to
contain N binding sites for miR-122, or full 3'UTRs of selected miR-122 targets,
while TagBFP serves as an expression control. When expressed in Huh-7.5
TetON cells (see methods), a TagRFP with no miR-122 sites will be expressed at
equal per-cell levels as TagBFP. However, upon introducing miR-122 sites to the
3'UTR of TagRFP, its expression will be repressed by endogenous miR-122
(Figure 4.18A). In this manner, manipulation of miRNA levels with mimic, LNA or
virus can be used to determine miRNA activity on TagRFP across a range of
TagBFP expression values.

191

Figure 4.18. A single-cell assay for miRNA activity. (A) Two-color fluorescent
reporter containing a bidirectional Tet promoter that drives expression of blue and
red fluorescent proteins (TagBFP and TagRFP). Each fluorescent protein is
tagged with a nuclear localization sequence (NLS) to aid in flow cytometric
analysis. The 3'UTR of TagRFP is engineered to contain N binding sites for miR122, or full 3'UTRs of miR-122 targets. (B) Sample processing starts by
calculating the mean cellular BFP and RFP auto-fluorescence from untransfected
cells (mean denoted by lines). The auto-fluoresence of each channel plus two
standard deviations is subtracted from every point. The resulting distribution is
binned across the BFP signal, and the RFP mean calculated for each bin and
plotted. In this example, a construct with four miR-122 sites was transfected
alone or in the presence of 30nM miR-122 mimic. Contour lines for each FACS
plot denote 10% increments of the total density.

Testing reporters with N = 1 and 6 miR-122 binding sites in the presence
of miR-122 mimic, we observed dose dependent miR-122 repression that
increased with N, as expected, whereas adding LNA122 decreased repression
(Figure 4.19A-D). HCV infection, using a Ypet expressing clone2 reporter virus,
in both contexts resembled LNA inhibition where de-repression was notably more
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pronounced in cells expressing low amounts of reporter, extending previously
reported miRNA thresholding effects for miR-20 to miR-122 (Mukherji et al.,
2011)(Figure 4.19A and C). Importantly, no such changes were observed for a
reporter with a p3,4 miR-122 seed ("N1m") (Figure 4.19E-F). Additionally, we
tested a reporter with a perfectly complementary miR-122 site, thus making the
miRNA behave as a siRNA. As highlighted in the introduction, this distinction is
useful to separate the modes of action of small RNAs on AGO: miRNAs appear
to work stoichiometrically to suppress gene expression, and a as consequence,
their repressive activity can be diluted out by expressing more target mRNA. This
is why miRNA repression appears to fail at high target expression levels. In
contrast, siRNAs work catalytically as AGO:siRNA complexes can move on to a
new target after mRNA cleavage. By using miR-122 as an siRNA, we expect that
no such "threshold" should be observed as it would for miRNAs. Indeed, miR-122
as siRNA reporter exhibited no thresholding such that mimic repression, or LNA
and HCV de-repression was observed at all expression levels (Figure 4.19G-H).
Taken together, these data suggest that HCV infection modulates functional miR122 levels to relieve endogenous repression on host targets in a stoichiometric
manner, and is governed by target expression level and the number of miRNA
binding sites.

193

Figure 4.19. Single cell fluorescent reporters of miRNA activity measurements
after modulating miR-122 levels. (A) Log-log transfer functions for N=1 miR-122
site in the presence of increasing concentrations of miR-122 mimic or HCV
infection. (B) Transfer functions for N = 1 miR-122 site in the presence of
increasing concentrations of LNA inhibitors to miR-122. (C-H) Transfer functions
as in (A) and (B) for N=6 (C-D), a mutated miR-122 seed ("1m") (E-F), and N = 1
perfectly complementary ("1pf") miR-122 sites (G-H).

We extended this analysis to measure actual cellular miR-122 target
3'UTRs using this system. We observed modest de-repression upon HCV
infection for previously known targets with one miR-122 site, AldoA, PKM2, and
P4HA1, but not for CS 3'UTRs (Figure 4.20A-D). We also tested novel CLIPidentified targets CTDNEP1, SFT2D1, MASP1 and MAL2 and obtained similar
results, with all four tested being reduced upon miR-122 mimic addition and all
except MAL2 de-repressed upon adding virus (Figure 4.20A-D).
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Figure 4.20. Fluorescent reporter measurements for select cellular 3'UTRs. Loglog transfer functions of full-length cellular 3'UTRs in the presence of miR-122
mimic, LNA inhibitor, or HCV infection. The effective number of miR-122 sites (N)
is indicated for each construct. (A-D): previously reported miR-122 targets
confirmed via CLIP. (E-H): Novel CLIP derived miR-122 target 3'UTRs.

In broad terms, HCV infection resembled LNA inhibition of miR-122 for
these reporter measurements. One caveat that must be addressed is the
apparent discrepancy between miR-122 levels in liver versus those in Huh-7.5
cells. As miR-122 levels in Huh7 derived cells are estimated to be 10-fold lower
than primary adult liver tissue (Chang et al., 2004), we next explored the HCV
sponge effect in the presence of excess miR-122. Exogenous miR-122 addition
increased intracellular miR-122 in a dose dependent manner by up to 10-fold in
Huh-7.5 cells, within the range of miR-122 levels measured from patient liver
biopsies (Figure 4.21A-B). As no changes in HCV RNA levels were observed
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upon adding miR-122, the resulting miR-122:HCV ratio went from ~15:1 fold at
the lowest, to over 100:1 with 30nM of miR-122 mimic added (Figure 4.21C).
Testing N = 1 or AldoA 3'UTR reporter constructs in this in vivo-like context, we
observed that HCV infection was able to relieve 30nM of mimic repression to
untreated levels for low but not high abundance targets (Figure 4.22A-B). The
ability for HCV to rescue excess miR-122 repression was not as pronounced for
the N = 6 construct (Figure 4.22C) whereas a reporter containing a perfectly
complementary miR-122 site was particularly sensitive to rescue by HCV
replication (Figure 4.22D). Similar, dose-dependent results were obtained under
0.3 or 3nM mimic treatment for all constructs (Figure 4.23). Taken together, these
results suggest that miR-122 sponging by HCV RNA can exist in more
physiologic miR-122 concentration settings.

196

Figure 4.21. Boosting miR-122 levels in Huh-7.5 cells to mimic human liver. (A)
qPCR measurements of miR-122 and HCV RNA copy numbers per cell in
infected Huh-7.5 cells after addition of increasing amount of miR-122 mimic. miR122 copy number from human liver biopsy specimens is also shown. n.d.: not
done. (B) The relative miR-122 abundance over mock Huh-7.5 cells, from data in
(A). Significance testing was performed via Student's two-tailed t-test. (C) The
miR-122:HCV ratio from data in (A).
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Figure 4.22. Validation of miR-122 sponging by HCV under in-vivo-like levels of
miR-122. Log-log transfer functions for N = 1 (A), ALDOA 3'UTR (B), N = 4 (C) or
one perfectly complementary (D) miR-122 site single cell fluorescent reporter
constructs in the presence or absence of 30nM miRNA mimic and/or HCV
infection.
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Figure 4.23. Validation of miR-122 sponging by HCV in 0.3nM or 3nM of miR122. Log-log transfer functions for N = 1 (A), ALDOA 3'UTR (B), N = 4 (C) or one
perfectly complementary (D) miR-122 site single cell fluorescent reporter
constructs in the presence or absence of 0.3nM or 3nM miRNA mimic and/or
HCV infection.
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A quantitative model of miR-122 sponging by HCV RNA
Based on these dose-dependent mimic and LNA reporter system
measurements, we expanded the miRNA model of gene regulation presented by
Mukherji et al. to incorporate a competing self-replicating viral target (Figure
4.24A). Here, if HCV RNA is present at sufficiently high numbers or has relatively
high binding strengths compared to other miR-122 targets, it acts to reduce the
available miR-122 pool, and de-represses miR-122 targets (r, measured as
TagRFP fluorescence) relative to non-targets (r0, measured as TagBFP
fluorescence) (Figure 4.24B). We developed a quantitative model for HCV
induced reduction of the miR-122 pool in this scenario (see methods). This model
describes the concentrations of a target mRNA species (r), an HCV mRNA
species (h), and binding of miRNA (m) to form complexes with target or HCV
mRNA species, respectively (r*, h*). Production of a target mRNA comes from
transcription of a gene at a rate (kr) with a corresponding degradation rate (γr).
We assume the miRNA-mRNA complex (r*) does not undergo translation and
degrades at a rate allowing for recycling of the miRNA species into the pool. The
total amount of miRNA is assumed to be constant and can bind to either target
mRNA (r) or HCV mRNA (h). HCV RNA also decays at a particular rate (γh). As
previously demonstrated, HCV RNA degradation is slower when bound to miR122 (Li et al., 2013d; Shimakami et al., 2012), and we therefore assumed a
model of HCV degradation primarily from its unbound form. Assuming steady
state levels of HCV RNA at the time of measurements resulted in a decrease of
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the model parameter theta, which governs the amount of free miRNA in the
system. The number of miR-122 sites is estimated by the model parameter
lambda that is related to the total binding strength of miR-122 to a particular site.
By tuning these parameters, we accurately fitted experimental data of
endogenous miR-122 repression of reporters with increasing numbers of miR122 sites (Figure 4.24C).
To explore the effect of HCV on the miR-122 pool, we fitted the model to
experimental data with four miR-122 sites during infection (Figure 4.24D), and
estimated the change to parameter theta to correspond to an approximate 50%
reduction in available miR-122. A similar result was obtained for the N = 4
construct in the presence of HCV and 30nM miR-122 mimic (Figure 4.24E). The
model estimated that the highest theoretical HCV levels reducing the miR-122
pool by 90% could de-repress mRNA targets by up to 4.5-fold for low-expressed
mRNAs (Figure 4.24F). Synthetic reporter and cellular measurements agreed
with model predictions for 50% reductions in miR-122 levels, where derepression was most drastic for low expressed targets harboring multiple miR122 sites or an siRNA-like context (Figure 4.24G-H). Taken as a whole, the
quantitative model outlines several factors controlling HCV induced de-repression
of host mRNA targets given steady-state levels of HCV RNA: the expression
level of the target mRNA, mRNA-miR-122 binding strength, and the number of
sites on the target mRNA.
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Figure 4.24. Quantitative modeling of miR-122 sequestration by HCV. (A)
Illustration of model reactions for miR-122 dynamics, including transcription and
translation of a target mRNA, binding to miR-122 and decay of mRNA species.
HCV RNA can replicate, be degraded, or bind miR-122, functionally sequestering
miR-122 and leading to de-repression of mRNA targets. (B) Increasing amounts
of HCV (or a relative increase in binding strength at miR-122 sites) leads to
changes in single-cell gene expression as compared to unregulated targets, with
stronger effects at the low mRNA expression levels. Parameters used are fitted
from data in (C). Each curve, from top to bottom, represents a reduction in the
miRNA pool by 20%. Inset displays model on a linear scale. (C) Model fitting of
the steady state approximation to experimental data while increasing the number
of binding sites corresponding to changes in total binding strength. (D) Model
fitting for the N = 4 case showing a 50% reduction in the miRNA pool by HCV
modeled by a proportional change in the theta parameter. (E) Model fitting for the
N = 4 construct under 30nM miR-122 mimic addition ± HCV infection. (F)
Increasing HCV:miR-122 binding strength or HCV RNA abundance results in
functional de-repression of miR-122 targets. The curves (top to bottom) represent
10 percentage-points increases in the available miR-122 pool (10% to 100%
availability). (G-H) Experimental HCV induced derepression of synthetic miR-122
binding site constructs (G) or endogenous 3' UTRs with miR-122 binding sites
(H). Modeling done with Tal Danino.
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As the model largely agrees with previous work, applying this framework to other
more robust miRNA sponge systems (viral or otherwise) or testing other HCVs
with different replication capacities than the robust clone 2 virus, will be useful to
refine our understanding of miRNA function in the cell.
Chapter 4 summary and discussion
In this chapter, we've explored the converse side of AGO-CLIP data in
HCV infected cells by focusing on the host. Starting from genome browser
gazing, continuing with sponge hypothesis formation, global validation using
RNAseq, and further characterization in bulk and single cells, our results chiefly
establish that HCV RNA may act as a competitive inhibitor of miR-122 activity.
Natural viral derived miRNA sponges have been described previously (Cazalla et
al., 2010; Lee et al., 2013) though no examples are currently known from RNA
viruses. Whether this systems-level phenomenon occurs with other, more robust
RNA virus infections remains to be explored, and presents a novel frontier worthy
of followup. For HCV biology, our elucidation of a miR-122 sponge raises a
number of questions that revolve around two key issues, namely, whether the
HCV:miR-122 sponge exists in vivo and whether such a miRNA sponge has a
functional or pathogenic role in HCV disease biology.
On the likelihood of an HCV:miR-122 sponge in liver
The idea that HCV RNA may act as a competitive inhibitor of miR-122 is
closely aligned with proposed roles for competing endogenous RNAs (ceRNAs)
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(Salmena et al., 2011). While both HCV RNA and ceRNAs share the theme of
de-repressing a miRNA regulated network by increasing the pool of available
targets through RNA expression, they importantly differ in their mode of
interaction with miRNAs. HCV genomic RNA critically requires miR-122
interaction to stabilize the viral genome and stimulate translation and replication,
while most cellular transcripts are repressed upon encountering a miRNA.
Moreover, unlike cellular mRNA targets, HCV genomic RNA is its own substrate
for replication, and thus constitutes a direct and positive feedback loop to
sequester additional miR-122. These distinguishing features suggest different
parameters for HCV versus cellular ceRNA based sponge effects on a miRNA
target network.
This is particularly relevant in light of recent findings showing that
endogenous miR-122 repression is only relieved when ceRNAs are forcibly
expressed at super-physiological levels in mouse liver (Denzler et al., 2014). In
this work, the authors over-expressed the AldoA 3'UTR to constitute up to 40% of
RNA in the cell; only at these extremes was de-repression of endogenous miR122 targets observed. Notwithstanding the fact that no attempt was made to
confirm that the over-expressed miR-122 target was at all regulated by
endogenous miR-122, the authors generally concluded that ceRNA effects are
unlikely under the normal paradigm whereby an individual ceRNA is induced,
even if highly so. While perhaps over-generalized, this work raises some key

204

issues that are worth exploring as we consider HCV RNA as a functional miR122 inhibitor.
The first key issue relates to cellular infection frequency and per cell HCV
RNA abundance. Unlike the >90% infection frequencies in Huh-7.5 cells, the
percentage of infected hepatocytes in chronically infected patients based on in
situ hybridization of liver biopsy tissue, ranges from as low as 0.07% to as high
as 100%, with medians in the 20-40% range (Liang et al., 2009; Pal et al., 2006).
Combined with HCV genotype, dynamic replication variation within the liver,
circadian miR-122 expression and regulation, and host variability in innate
immune responses (Sheahan et al., 2014), a complex picture of HCV infection
emerges that would largely mask observations of HCV sponge effects in bulk cell
or tissue Ago-CLIP or RNAseq measurements. HCV levels per cell are estimated
to range from 1 to 102 copies per hepatocyte in contrast to Huh-7 derivatives with
in excess of 103 copies per cell (Kandathil et al., 2013) (Figure 4.21A). However,
extrapolating from liver biopsies or back-calculations of the number of cells
required to account for HCV levels in serum are all confounded such that it is
very unclear what the HCV RNA level truly is in a "highly infected" human
hepatocyte. So, on this point, we can only ask a speculative question: assuming
a distribution centered on a few hundred RNA copies per cell, how likely are
these viral RNAs capable of inducing a sponge effect?
This leads to the second main concern: miR-122 abundance. Our bulk cell
measurements estimate ten-fold higher miR-122 levels in primary liver tissue
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versus hepatoma cell line derivatives (105 vs 104 estimate ranges per cell, Figure
4.21A) and are in line with previous estimates (Chang et al., 2004; Denzler et al.,
2014). Taken at face value, this suggests that the HCV:miR-122 sponge might be
a feature of replication unique to Huh-7.5 cells and likely plays little if any role in
the liver, where viral RNAs are drastically outnumbered by miR-122.
However, there are a number of assumptions with this interpretation that
we must consider. Chief among them is the assumption that miR-122 binding to
HCV RNA is functionally and mechanistically the same as binding to a cellular
3'UTR. Considering the basic premise of miRNA function, this is demonstrably
false: while miRNAs function to repress mRNAs, no target transcript "needs" to
encounter miRNA for its function to undergo translation. HCV RNA on the other
hand, critically requires a miRNA for its function to make viral protein (by
stabilizing the viral RNA and/or directly aiding in translation). In the context of
these opposing outcomes of miRNA binding, ceRNAs are argued to behave as
ordinary mRNA targets (Salmena et al., 2011), as they are neither stabilized by
miRNA binding nor is there as direct a mechanism of propagating ceRNA activity
as cytoplasmic viral RNA replication. Our results that HCV can exert sponge
effects in the presence of excess miR-122 would support the view that HCV RNA
as a miRNA sponge does not abide by simple miRNA stoichiometry assumptions
made for ceRNAs or mRNA targets (Figure 4.22).
But why might this be? This idea of "needing" to encounter a miRNA might
imply a more active mechanism of miR-122:HCV RNA binding, that goes beyond
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passive miR-122 abundance. Conceivably, the virus could have evolved a
specific means to recruit miR-122 as an essential host factor to sites of viral
replication or assembly. Indeed, mounting evidence supports such a hypothesis.
HCV replication is known to disperse and prevent formation of processing bodies
(P-bodies), the sites of miRNA silencing (Ariumi et al., 2011; Berezhna et al.,
2011; Pager et al., 2013). Additionally, AGO2, miR-122 and Dicer, but not RISC
components GW182 and DCP2, selectively partition to sites of HCV replication /
assembly at lipid droplets (Ariumi et al., 2011; Berezhna et al., 2011). These cell
biological findings highlight the possibility that HCV RNA coercion of miR-122
might engender a sponge effect, even when miR-122 is highly abundant.
As mentioned in the introduction but refined here in full, the mouse liver
provides additional evidence that total miR-122 levels aren't the whole story.
Despite invariantly high levels of mature miR-122 in the liver, miR-122
transcription is under circadian control and a number of targets oscillate in a
circadian manner corresponding to repression by miR-122 (Gatfield et al., 2009).
This puzzling finding could be explained in at least two ways (Figure 4.25A-B).
MiR-122 could function to amplify target protein oscillation by repressing basal
translation at an expression trough; thus miRNA function cycles between switchlike and neutral modes (recall Figure 1.7B)(Figure 4.25A).
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Figure 4.25. Potential mechanisms of miR-122 activity despite invariant mature
levels. (A) Constant miR-122 (dark gray) may shape circadian rhythm of targets
(light gray) by repressing basal levels of translation. In this case, only targets
represented by the dotted area is available for translation. This context would
impart higher protein amplitudes throughout the circadian cycle. (B) Conceivably,
a newly synthesized or a chemically distinct miR-122 sub-population may exist. If
this circadian expressed population was functionally distinct from bulk miR-122,
target mRNAs could be subject to circadian oscillation (dotted area again depicts
fraction of mRNA available for translation). (C) In one model of how HCV RNA
might depress miR-122 targets, we can consider miR-122 bound to HCV as
effectively reducing the total miR-122 pool, thus enabling more target to be
translated (dotted area). (D) In another model, HCV RNA may hijack the more
"active" newly synthesized or precursor that is perhaps a limiting miR-122
subpopulation, such that mature levels are reduced through this upstream
targeting. Panels A and B modified from (Gatfield et al., 2009).
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Should a sub-population of miR-122 exist that is either chemically altered and/or
newly synthesized, and assuming this sub-population is functionally distinct from
total levels, then it's possible that circadian expression of this sub-population
influences target mRNA translational ability to oscillate (Figure 4.25B). These in
fact are the main mechanisms proposed by Gatfield, et al. and are bolstered by
observations of cytoplasmic modifications to miR-122, particularly adenylation
and uridylation (Burns et al., 2011; Katoh et al., 2009). Relating changing miR122 activity due to HCV RNA can be similarly considered, whereby viral RNA
replication has a direct and negative impact on miR-122 levels available to
repress targets (Figure 4.25C). Along the lines of newly synthesized miR-122,
perhaps HCV actually targets this lower abundance and limiting precursor of
mature miR-122, and in so doing reduces mature miRNA by preventing
biogenesis (Figure 4.25D).
All of the above suggests additional nuanced factors and raises questions
that are largely obscured from bulk miRNA abundance measurements of high
miR-122 levels in liver, and the assumption that all this miRNA is functional. Are
distinct
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complexes
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to

HCV

RNA

in

special

compartments? Are these complexes limiting? Might coercion of newly
synthesized or chemically distinct miR-122 be the mechanism of miRNA
subversion? What happens to miR-122 after it engages the viral genome?
Numerous experimental paths forward spring to mind to explore these
ideas, a few of which are summarized here. The miR-15 dependent virus
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presents an excellent test case to see if miR-15 family members can be
redirected to sites of HCV replication and assembly in place of miR-122. A
detailed analysis of S1 an S2 swap mutants where one site is miR-122 and the
other site miR-15 could be used to test if the 2x stoichiometry of binding sites is
needed to render an effective sponge. Deletion of a cytoplasmic polymerase
GLD2, that is known to stabilize miR-122 could be used to evaluate the possibility
of mature but largely non-functional "old" miR-122 that is distinct from newly
synthesized miR-122 (D'Ambrogio et al., 2012; Katoh et al., 2009). Combined
with the development of cell compartment specific AGO-CLIP, these experiments
may continue to unravel the unique interplay between HCV RNA and miR-122.
On the functional role of the HCV:miR-122 sponge
The establishment of a miR-15 dependent HCV suggests that the miR-122
sponge effect is largely dispensable for the virus in the Huh-7.5 cell context.
From the previous chapter, recall that LNA-122 slightly reduced m15 virus titers
and that restoring miR-122 in ΔmiR-122 cells increased titers, suggesting that the
miR-122 sponge may reflect a trade-off for the large, positive and direct impact of
miR-122 on WT HCV replication. Conceivably, HCV replication may exert enough
pressure on miR-122 levels to de-repress targets such that the cellular
environment is passively altered to negatively impact viral replication. Or more
actively, some targets may act as sensors for low miR-122 levels, and by
extension, the health of the hepatocyte. While future work will be needed to shed
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light on specific players involved in this process, our data suggest that viral
replication faces a ceiling by reducing levels of an otherwise pro-viral miRNA.
Note that throughout this chapter I have avoided discussing specific
targets that are de-repressed upon miR-122 sponging, even those targets
extensively tested in reporter assays. This has been deliberate. Due to the
hepatoma nature of Huh-7.5 cells, extreme caution is needed when attempting to
extrapolate results to liver biology, no matter how compelling. The transcriptomes
between these cell types, not withstanding hepatic examples above, are so
drastically different so as to be nearly incomparable (not shown, but median
correlation was ~0.2-0.5). So we're likely to suffer from both a false-positive and
false negative problem if we start to seriously parse Huh-7.5 cell data without
informed knowledge of actual miRNA targeting in the liver. This will be the stated
goal of the next chapter.
But we can begin consideration of an important question: how might the
HCV miR-122 sponge impact a hepatocyte? Work with miR-122 knockout mice,
which develop progressive liver disease that spontaneously results in HCC,
suggests that miR-122 tumor suppressor activity is essential for long-term liver
homeostasis (Hsu et al., 2012; Tsai et al., 2012). It is tantalizing to speculate that
miR-122 sequestration in a chronic HCV infection may be a molecular link to the
heterogeneous liver dysfunction that characterizes HCV induced disease(s).
Many miR-122 targets found in Huh-7.5 cells would corroborate this with no
shortage of potential mechanisms. For instance, miR-122 targets that we confirm
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or establish via CLIP and reporter measurements, such as P4HA1, PKM2, and
MASP1 are known to be upregulated in fibrosis or HCC (Jung et al., 2011; Li et
al., 2013b; Liu et al., 2014a), with MASP1 notable for being specifically linked
with HCV-associated HCC (Saeed et al., 2013). P4HA1, or prolyl 4-hdroxylase, is
a key enzyme in collagen maturation; miR-122 suppression of this enzyme is
hypothesized as a mechanism to control fibrogenic responses in the liver and the
associated action of hepatic stellate cells (Li et al., 2013b). Pyruvate kinase
muscle isoform 2, a key enzyme in glycolysis, is thought to be a primary driver in
cancer metabolism. That miR-122 targets PKM2 provides an intuitive hypothesis:
loss of miR-122 promotes PKM2 expression, and alters cellular metabolism to
rely on glycolysis instead of oxidative phoshorylation based cellular energetics.
The enzyme, as a miR-122 target specifically, has been linked to poor
progression of HCC and in breast cancer (Fong et al., 2015; Liu et al., 2014a).
Lastly, mannan binding lectin-associated serine protease 1 (MASP1), known to
be unregulated by HCV via unknown mechanisms (Saeed et al., 2013),
according to our data appears to be a miR-122 target. This secreted protease is
thought to promote the proliferation of hepatic stellate cells which in turn adopt a
pro-fibrotic course. In this manner, levels of this protein are thought to be a
specific indicator of HCV induced liver disease, though the putative role of
MASP1 in the virus lifecycle is unknown. The above examples are but the tip of
the iceberg. As we begin to consider miR-122 targets in the liver, the stage is set
for HCV induced sponging to play a role in defining virus specific pathology.
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Overall, as it remains possible that functional effects of such a sponge
may primarily impact highly infected cells, our data highlight the possibility of
searching for transcriptome level changes to the miR-122 target network in
response to HCV infection in individual hepatocytes. The extension of CLIP and
RNA-seq in single-cell and primary contexts provides a compelling platform to
address these and other long-term disease driven changes to a miRNA target
network.
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Chapter 5: AGO-CLIP studies of mouse and human liver
Thus far, we have focused on a so called HCV driven "sponge effect"
whereby viral RNA uses miR-122 to an extent that host miR-122 targets are
deprepressed. What we haven't delved into very much are the identities and
functions of these actual targets and their roles in HCV or liver biology. Due to the
Huh-7.5 context, this has been appropriate, given that we cannot assume a
similar transcriptome in these cells compared to hepatocytes. The work
presented in this chapter aims to overcome this limitation by exploring miR-122
targeting in its native in vivo setting in both mouse and human liver. The
availability of a miR-122 knockout mouse, and its associated cancer related
phenotype, offers an excellent platform to unambiguously map the entire miR122 regulated network in situ and begin to define the molecular consequences of
miR-122 disregulation. Combined with RNAseq, we are further likely able to
distinguish between primary effects due to loss of direct miR-122 binding, and
secondary effects of altered signaling. In addition, AGO-CLIP studies of human
liver add direct and clinically relevant depth to results obtained in mice, by
providing points of comparison across species and across tissue types (liver
versus Huh-7.5 for instance) in the hunt for targets most likely to impact HCV or
liver disease biology.
Throughout, while this work was conducted squarely with HCV in mind, it
must be noted that no virus will be present in the ensuing work. As we'll see,
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miR-122 use by HCV is but one of the many surprises to be gleaned from this
miRNA.
Experimental setup for AGO-CLIP in miR-122 KO mice
This work was initiated jointly with Kalpana Ghoshal at the Ohio State
University. Shortly after publishing the initial description of a miR-122 knockout
mouse in 2012 (discussed below), Kalpana contacted us about performing AGOCLIP in these mice. Sensing an overlap with the HCV story then forming, I was
brought in to lead the effort. Or more accurately, I enthusiastically volunteered to
do AGO-CLIP in this in vivo context.
My enthusiasm was multi-fold. At this stage, I was convinced that the miR122 sponge effect was probably real, but validating targets became an issue in
Huh-7.5 cells given the high false positive (transcripts expressed in Huh-7.5 but
not in liver) and false negative (liver transcripts lost in Huh-7.5 cells) likelihoods of
RNA expression compared to liver. The literature comparing Huh-7.5 and liver
transcriptomes is thin, but analyzing RNAseq data generated by William
Schneider of human fetal liver cultures (HFLCs), a presumed closer substitute for
liver, the transcriptome correlation of these data with Huh-7.5 was ~0.4 (not
shown). This low correlation for ostensibly the same tissue type did not bode well
for direct extrapolation of relevant liver targets in Huh-7.5 cells.
The miR-122 knockout mouse is the ideal context to solve this problem
and possess an unusual phenotype. While miR-122 has been proposed to
influence liver development (Laudadio et al., 2012; Xu et al., 2010), the first main
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surprise of the knockout mouse is that livers develop normally, with no
observable defects in anatomy and physiology (Hsu et al., 2012). A liver
phenotype does emerge at 10 weeks of age when microsteatosis and liver
inflammation begin to occur. Hepatic triglyceride synthesis increases at this
stage, and yet serum cholesterol, LDL and HDL, all decrease. The result is an
accumulation of fat in hepatocytes (steatosis) that progressively gets worse as
the animals age. Combined with an infiltration of IL-6 producing immune cells,
this steatosis progresses to a well defined fibrosis and hepatitis by six months of
age. Between 12-17 months of age, miR-122 knockout mice then spontaneously
develop HCC where interestingly, the penetrance differs by sex: 50% of males
develop HCC whereas only 10% of females are affected (Hsu et al., 2012). This
difference phenocopies the known male skew of HCC in humans el (El-Serag,
2011).
The the slowly unfolding HCC observed by Hsu, Ghoshal and colleagues
in miR-122 knockout mice appears consistent with the human trajectory of
disease as correlating with age, sex and hepatic injury. It also points to a role for
miR-122 as a key factor in maintaining long-term liver homeostasis,as a putative
tumor suppressor. This last point was addressed in the initial report, as miR-122
overexpression was able to rescue liver tumorigenesis in a model driven by
overexpressed c-MYC, drastically reducing tumor burden (Hsu et al., 2012).
Along the lines of the main hypothesis of the HCV sponge, that chronic
repression of miR-122 may influence HCV associated disease progression, the
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miR-122 knockout mouse permits a refinement of this hypothesis by providing
the extreme case. Since long-term deletion of miR-122 results in spontaneous
HCC, perhaps by investigating the miR-122 targets network in these mice, we
might gain insight as to how HCV may do the same in humans. This was the
main motivation to pursue AGO-CLIP in these mice.
The second point of enthusiasm involves using miRNA knockout systems
for AGO-CLIP studies. Historically, miRNA activity in mammalian cells has
typically been characterized by miRNA overexpression and monitoring of a target
reporter, usually in a contrived cell type or in a context where the miRNA is
usually not expressed. This basic idea was extended in the pioneering AGOCLIP study, where miR-124 (a brain specific miRNA) was overexpressed in HeLa
cells to look for novel miR-124 dependent peaks (Chi et al., 2009). While no
doubt a useful proof-of-principle for "validating" a miRNA target with CLIP, this
idea is plagued with problems: from overexpression artifacts that cannot be
confirmed with knockouts (Vidigal and Ventura, 2015), to the aforementioned
context problem where the miRNA encounters targets it usually never observes
in vivo. Performing CLIP in a miRNA knockout context addresses these
limitations succinctly, and as we've seen with ΔmiR-122 Huh-7.5 cells, allows for
the unambiguous determination of miRNA target by looking for the specific loss
of AGO-CLIP peaks. This approach has been validated in vivo with great
accuracy using miR-155 knockout mice, probing effects of this miRNA on
immune cell function (Loeb et al., 2012)
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To begin, we decided that to avoid any confounding events due to
emerging liver pathology at 10 weeks, we would perform AGO-CLIP in miR-122
knockout mouse livers and floxed littermate controls from 6-week old mice,
before pathology emerges. Both control and knockout mice were on the same
feeding schedule, and importantly, livers were flash frozen at the same time of
day (mornings). AGO-CLIP was performed on four knockout livers (1 female, 3
males) and five floxed controls (2 female, 3 male), for a total of nine mice (Figure
5.1). The autorads gave clear 110kDa miRNA bands in addition to mRNA smears
between 130-150kDa. mRNA sized regions were excised and used to make DNA
libraries compatible with NGS and sequenced.
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Figure 5.1. Autoradiogram of AGO bound RNA in miR-122 KO mice and flowed
controls. Autoradiogram of 32P-labelled RNA bound to AGO after IP using the
pan-AGO 2A8 antibody. AGOs migrate at 97kDa, which shifts by RNA species
bound by approximately 1kDa/3nt, thus AGO bound to ~22nt miRNA should be
around 105kDa. IgG used as a non-specific control. Minus crosslink control
shows the stringency of washes in that only a faint Ago:miRNA complex remains.
High RNAse and low RNAse conditions indicated. Regions excised
corresponding to 110, 130 or 150kDa are highlighted. Left panel depicts signal
from four miR-122 knockout animals, where the gender and the amount of liver
tissue used per sample is indicated. The right panel depicts the same but for five
floxed control mice, treated as "WT."

As a confirmation of miR-122 loss, I first analyzed the miRNA profiles
between WT and KO mice. While standard CLIP was performed with its
attendant miRNA cloning bias issues, this analysis focuses only on comparing
the same miRNA across conditions. Thus, assuming the cloning bias for a
particular miRNA is constant between conditions, this issue is circumvented. We
observed that mature miR-122 (-5p) and its passenger strand (-3p) were the
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most significantly reduced miRNAs in knockout livers, as expected (Figure 5.2).
An additional miRNA, miR-31-5p was also reduced, while a number of miRNAs
were upregulated in knockout livers (Figure 5.2). These results suggest additional
roles for miR-122 in affecting the abundance of other miRNAs.

Figure 5.2. Volcano plot showing the log 2 fold change between miR-122
knockout versus wild-type mouse liver tissue of miRNA-CLIP results. Y-axis
denotes FDR, where p = 0.0001 line is indicated. Notable miRNAs are highlighted
by color and/or label.
Next, groomed reads were aligned to the mouse genome (mm9) and
clustered mapped reads that overlapped by 1nt. Clusters were then grouped by
BC and plotted as before to get a sense of the distribution of clusters across
various genomic regions (see Chapter 4). In contrast to data in Huh-7.5 cells,
where up to 50% of clusters mapped to 3'UTRs, most clusters in mice mapped to
coding exons (>50%) with at best 30% in 3'UTRs Figure 5.3. For downstream
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analysis of miRNA seeds, a cutoff of five libraries with a minimum peak height of
10 reads was used. Unlike Huh-7.5 data where only a BC threshold was used,
the much higher depth of AGO-CLIP achieved in mouse liver made peak height
filter appropriate, if only to enable a more "stringent" definition of clusters, though
in truth, just as specified with Huh-7.5 cells, this call was arbitrary.
With these cluster definitions, a more detailed annotation was performed
comparing all WT clusters to KO clusters, including those commonly shared. We
observed that clusters in 3'UTRs were only mildly reduced in KO libraries (21.4%
to 19.3%) (Figure 5.4). Given that a typically miRNA target contains binding sites
for more than one miRNA, this is perhaps somewhat expected. Less expected
was the decrease in coding exon clusters in knockout virus WT livers (40.2% to
31.5%), suggesting that a substantial fraction of unique miR-122 binding occurs
in coding exons. Other genic regions, such as introns, transposable elements
(TEs), 5'UTRs, and intergenic regions, were not appreciably different between
KO and WT livers.
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Figure 5.3. Cluster annotation results by increasing biologic complexity. AGOCLIP reads from up to nine libraries from mouse liver were clustered with a
minimum overlap of 2nt. Clusters with reads from any one, two, three and so on
up to nine libraries the were annotated. The resulting proportions of clusters
overlapping known genic elements is plotted above, alongside the total number of
clusters with the respective biologic complexity (BC).

Figure 5.4. Proportion of clusters after robust clustering of overlapping reads from
miR-122-deficient (KO) or floxed control (WT) libraries mapping to various
regions of the genome. Clusters unique to each case plus those in common are
indicated. TE, transposable elements; Other, includes non-coding RNA, satellite
repeats, low complexity elements, etc.
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miR-122 dependent peaks in mouse liver: some unexpected findings
Having confirmed miR-122 loss in knockout livers with CLIP, and after
specifying BC and size cutoffs for clusters, we next approached defining miR-122
peaks. To do so in a less biased fashion that searching for the canonical miR122 seed, we opted instead to search for instances where a cluster was
specifically lost in KO libraries, extract the underlying sequence for the AGO
footprint (+/- 32nt from the peak position), and search for enriched motifs (Figure
5.5A-B). For putative miR-122 dependent clusters, this analysis revealed
significant enrichment for 8mer, 7merM8, 7merA1 and 6mer miR-122 seeds
(Figure 5.5B). Unexpectedly, it also revealed a non-canonical miR-122 site motif,
characterized by a G-bulge between the 6 and 7 seed positions (Figure 5.5B
th

th

and D). Such "nucleation" bulges were observed previously with miR-124
between positions 5 and 6, and were demonstrated to be functional (Chi et al.,
2012). We confirmed the presence of both canonical and G-bulged (hereafter
also called miR-122-B) seeds by searching for motifs relative to AGO cluster
peak coordinates. As expected we found significant enrichment for canonical
miR-122 seeds within 20 nucleotides of AGO peaks (Figure 5.5C). We observed
a similar enrichment, though fewer target sites, with the bulged motif (Figure
5.5D). Taken together, these results point to an alternative mode of miR-122
target recognition that occurs in vivo.
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Figure 5.5. Identification of a novel G-bulged miR-122 motif. (A) Example of a
miR-122 dependent peak. Robust WT signal is absent in KO libraries. (B) MEME
analysis table of top motifs within clusters displaying miR-122 dependence as in
(A). (C) Canonical miR-122 motif enrichment around Ago peaks. miR-122 KO
dependent peaks (red) were compared to background clusters (gray). Inset
shows miR-122 motif binding profiles. (D) Bulged miR-122 motif enrichment
around Ago peaks. miR-122 KO dependent peaks (pink) were compared to
background clusters (gray). Inset shows bulged miR-122 motifs binding profiles.

After assigning miRNAs (the top 100 expressed) to clusters by seed
presence, we annotated the miR-122 and miR-122-B targetomes in detail (Figure
5.6). About 8% of CLIP clusters contained no discernable canonical miRNA seed,
consistent with previous reports for "orphan" clusters (Chi et al., 2009; 2012).
Roughly 5% of AGO-CLIP clusters contained a miR-122 seed, an additional 1%
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of clusters contained a miR-122-B seed, for a total of ~4500 miR-122 targets
spread across a variety of genomic regions (Figure 5.6A). We noted that 3'UTRs
were targeted in similar proportion between canonical and G-bulged miR-122
sites, however, coding exon targeting predominated for both, and was
considerably expanded for miR-122-B targets (Figure 5.6B). Additionally,
between 20-40% of miR-122 targeting appears to occur in regions beyond
3'UTRs and coding exons. miR-122 dependent AGO targeting of introns,
intergenic regions, 5'UTRs and TEs is totally novel and functionally unexplored,
but clearly expands the AGO:miR-122 bound transcriptome. Combined with a
binding preference for coding exons, and the identification of a G-bulged miR-122
seed, the classic assumption by virtue of bioinformatic target prediction that most
miRNAs regulate a few hundred targets, is perhaps in need of revision.

Figure 5.6. Annotation of miR-122 dependent clusters. (A) Pie chart highlighting
miR-122 or bulged miR-122 targets as a proportion of all miRNA targets in
mouse. Of the ~64,000 miRNA matched clusters roughly 5% are canonical miR122 bound targets, and 1% G-bulged sites. Total number of clusters per category
indicated. (B) Genomic annotation breakdown of canonical or bulged miR-122
sites.
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Global analysis of miR-122 AGO peaks in WT versus miR-122 KO mice
With an expanded set of RNAs containing miR-122 or miR-122-B seeds,
we next sought to quantify the fold change between WT and KO libraries. Similar
to our analysis comparing HCV versus mock infected Huh-7.5 cells, we first
calculated from read depth normalized data the log2 fold-change between WT
and KO samples per miRNA-assigned cluster. The cumulative distribution of
these score was plotted, binned by miRNA family. Again, for these plots, if there
was no difference in AGO binding at a particular cluster between WT and KO
libraries, the score for that cluster was near 0. Changes showing a decrease of
AGO binding upon miR-122 loss would be >0, while increases in AGO binding
would be <0 (Figure 5.7A).
Focusing on 3'UTRs, we observed a highly significant reduction in AGO
binding in miR-122 seed containing clusters in KO libraries. This was true for
both canonical and G-bulged seeds (Figure 5.7B). Other miRNA families, such as
miR-21 and miR-15/16 were not significantly altered in their AGO-CLIP
distributions. Two examples of canonical and G-bulged miR-122 targeting are
shown in Figure 5.7D-E. In both cases, a miR-122 seed can clearly be discerned
as underlying peaks lost in knockout livers.
To corroborate our CLIP results with effects on RNA abundance, we
performed RNAseq in the same livers used for CLIP. Here we expect that loss of
miR-122 should result in a measurable increase of target mRNA levels
presumably for both seed types.
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Figure 5.7. Global AGO binding changes on 3'UTRs affect mRNA abundance
specifically for miR-122 targets. (A) miR-122 dependence definition by Ago
binding profiles. (B) Cumulative distribution fraction (CDF) plot of the log2 fold
change in Ago binding within cluster harboring indicated miRNA seeds. KS Test
p-values indicated for miR-122 distributions vs all targets. (C) CDF plot of the
log2 fold change in RNA expression of transcripts harboring indicated miRNA
seeds, as in (B). Clusters were collapsed by gene so that no gene is represented
twice. KS Test p-values indicated for miR-122 distributions vs all. (D) Canonical
3'UTR binding example of the Agpat1 3'UTR. Inset nucleotide conservation
scores (PhyloP) and multi-alignments. (E) Non-canonical 3'UTR binding example
of the Neo1 3'UTR. Inset nucleotide conservation scores (PhyloP) and multialignments.
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While we observed robust de-repression for canonical targets, we noted that
3'UTR targets with G-bulged seeds were not significantly de-repressed (Figure
5.7C). Thus it seems that while the non-canonical seed is clearly used in the
sense that AGO:miR-122 complex binds, it does not appear to confer any
repression.
There are a few plausible explanations for this. Unlike the results obtained
with miR-124, where G-bulges occur at between positions 5 and 6 of the mRNA
and maintain full Watson-Crick base pairing (Chi et al., 2012), the miR-122 Gbulge occurs between positions 6 and 7 and induces a G:U base pair at position
7. Conceivably, this may confer a difference in the ability for miR-122 to nucleate
on a target where the end result is a less stable seed with a G:U base pair.
Structural evidence is consistent with this hypothesis, where notably base pairing
at positions 6 and 7 requires that the target mRNA displace an alpha-helix that
normally kinks the miRNA at the end of the seed region and permits binding
beyond position 6 (Schirle et al., 2014). A bulge in the corresponding position in
the mRNA target may alter the conformational dynamics of AGO, to say nothing
of

potentially

modulating

repression.

For

now,

the

most

conservative

interpretation for the lack of repression for G-bulged miR-122 targets is to take
them at face value, and posit that G-bulged targets may be competitive inhibitors
of canonical miR-122 activity, may serve as reservoirs for AGO:miR-122
complexes, and/or possess additional functions beyond mediating mRNA
repression.
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The same conclusion appears to hold for miR-122 binding in regions
beyond the 3'UTR. Summarized in Figure 5.8, we noted that for both canonical
and G-bulged miR-122 targets, significant loss of AGO binding was observed in
KO samples in coding exons, introns, transposable elements (LTRs, LINEs and
SINEs), intergenic regions, and 5'UTRs (Figure 5.8A). However, for transcript
regions that can be measured by RNAseq, only canonical miR-122 seed targets
in 3'UTRs and to a lesser extent coding exons were de-repressed as a class in
KO livers (Figure 5.8B). No significant effects in RNA levels were observed for
intronic and 5'UTR targets ((Figure 5.8B). Taken together, these data provide
robust confirmation for functional miR-122 regulation of 3'UTR targets as a
prevailing mechanism for regulating target mRNA levels, while at the same time
showcasing the limits of miRNA targeting function as strictly impacting mRNA
levels. What all the extra AGO:miR-122 binding is functionally doing can only be
guessed at with these data, though on a transcript level some targets are worth
emphasizing.
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Figure 5.8. Widespread canonical and non-canonical miR-122 targeting
throughout the transcriptome. (A) AGO binding profiles for miR-122, bulged miR122, and the top 10 miRNA family targets (exclusive of miR-122), broken down
by annotated region. Gray shading indicate statistical significance (P<10e-10,
KS-test) for each annotated category compared to the same category among the
top 10 miRNA families. (B) RNA expression profiles (as in a) for miR-122, bulged
miR-122, the top 10 miRNA, and all miRNA family targets, by expressed
annotated region. Asterisks indicate statistical significance (P<10e-10 KS-test) for
each annotated category comparison. All other comparisons were not significant.
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A brief survey of miR-122 dependent AGO binding beyond 3'UTRs
In the following sections, I will focus primarily on 3'UTR targets derepressed in miR-122 KO livers as the key players whose disregulation probably
contributes most to the cancer phenotype of these mice. Still, some discussion is
appropriate for non-3'UTR genic targets, especially those for which a
measureable change in mRNA abundance can be assessed from paired RNAseq
data. While repressive 3'UTR targeting may be the most straightforward to
interpret globally across a transcriptome, it is by no means definitive at the
transcript level, as the case of HCV clearly demonstrates. So we must suspend
our general concept of "miRNAs as repressors of mRNA at 3'UTRs" when we
zoom in, and consider alternatives.
For instance, perhaps miR-122 binding stabilizes cellular RNA, as in HCV,
or activates translation, as in AU rich elements in the 3'UTR of TNF mRNA under
stress (Vasudevan et al., 2007). An enhancement of translation has also been
shown for AGO binding the 5'UTR of ribosomal protein transcripts with miR-10a
(Ørom et al., 2008). Intronic targeting has in general been only obliquely
addressed functionally, but given the plurality of evidence of AGO shutting to the
nucleus, where localization is often dictated by miRNA isoforms, roles in
regulating mRNA stability, alternative splicing, mRNA processing, and perhaps
RNA transcription cannot be ruled out (Hwang et al., 2007; Schraivogel and
Meister, 2014). Lastly, recent evidence that non-linear splicing of exons to form
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circular RNAs (circRNAs) may act as miRNA sponges offers yet another
functional mechanism to consider for non-3'UTR binding (Memczak et al., 2013).
In all of the above cases, it is not necessary that mRNA levels be impacted, so
our inability to see a change in RNA abundance does not preclude additional and
as yet unknown functions. Just the same however, it is important to stress that
the null hypothesis, that these non-3'UTR AGO binding events "aren't doing
much" must be taken seriously, particularly when considering the lack of purifying
selection observed for the majority of non-3'UTR sites (discussed in the next
section). Still, some outliers appear very interesting.
Carboxylesterase1 (Ces1) proteins are a class of enzyme that participate
in drug, lipid and xenobiotic metabolism of small molecules. Primarily expressed
in the liver, the Ces1 gene has undergone many duplication events with at least 5
members clustered in a 0.2Mb stretch of chromosome 8 (Holmes et al., 2010).
Interestingly, Ces family members 1d, 1e, and 1f all exhibit miR-122 dependent
binding in coding exons, and all are significantly down-regulated (~2-3 fold) in KO
livers (Figure 5.9A). Notably, Ces1 expression also goes down in mouse livers
with age (Fu et al., 2012). Thus, it's possible that miR-122 may act to stabilize or
stimulate translation of this protein family, and that over time, lower miR-122
results in lower expression of these detoxifying enzymes. Thinking of miR-122
KO livers from an aging perspective might be an interesting new frame for
interrogating the altered liver biology of these mice.
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Figure 5.9. Two examples of miR-122 regulation on cellular coding exons. (A)
Ces1 or (B) Drosha genes are shown below WT and KO CLIP tracks after read
depth normalization. Zoom in view displays nucleotide conservation scores
(PhyloP) and multi species alignments for indicated regions. miR-122 seeds
highlighted in gray. In both cases, transcript levels were significantly altered in
KO livers. See text for details.
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Another example of coding exon targeting is Drosha, a key nuclear RNAse
involved in miRNA biogenesis. The second exon of Drosha has two miR-122
sites in mice, one of which is reasonably well-conserved (Figure 5.9B). As
Drosha expression goes up in KO livers, it's likely that miR-122 is normally
playing a repressive role on Drosha gene expression. This could constitute a
feedback loop to regulate Drosha expression levels as a means of controlling
global miRNA biogenesis. In this manner, the cell might be able to "sense"
altered miR-122 (or other miRNA) abundance and regulate miRNA processing
accordingly. Along these lines, the Dicer 3'UTR possesses a non-canonical miR122 site, found only in mice (not shown), however, little change in RNA levels
was noted.
Additional interesting results can be observed in 5'UTRs that possess
miR-122 sites. One example is CXC chemokine-ligand-1 (Cxcl1). Previously
called Gro-alpha, this inflammatory cytokine is produced by a variety of cells and
binds the Cxcr2 chemokine receptor to promote fibrogenesis and angiogenesis.
Shown in Figure 5.10A, it possesses clear miR-122 binding sites in its 5'UTR. In
KO livers, Cxcl1 expression is significantly increased (~3.2 fold), thus it's likely
that miR-122 normally plays a repressive role in binding the 5'UTR. Cxcl1
expression has been recognized as an inflammatory hallmark in a number of
cancers, including HCC (Bandapalli et al., 2012; Tang et al., 2012). Moreover,
increased Cxcl1 expression has been identified as a predisposition marker for
HCV and alcohol induced cirrhosis, where interestingly a SNP in the Cxcl1 intron
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appears to be involved (Nischalke et al., 2012; 2013). In mice, two miR-122 sites
are present in the 5'UTR, however, and this is a theme which we'll return to,
neither of them are conserved in humans (Figure 5.10A).
Another example of 5'UTR binding is Mavs, a well known anti-viral
signaling molecule and as discussed in the introduction, a target for the HCV
NS3/4A protease to blunt the innate immune response. The Mavs 5'UTR robustly
binds miR-122 and expression is elevated ~2 fold in KO livers, thus pointing to a
normally repressive role for miR-122 binding (Figure 5.10B). It's certainly
tempting to hypothesize that Mavs regulation by miRNA at the 5'UTR may act as
a miR-122 sensor, where in the case of the HCV:miR-122 sponge, an up
regulation of Mavs may help dampen the effects of NS3. But alas, this makes
zero sense considering that the miR-122 site is not conserved in humans (Figure
5.10B).
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Figure 5.10. Two examples of miR-122 regulation on cellular 5'UTRs. (A) Cxcl1
or (B) Mavs genes are shown below WT and KO CLIP tracks after read depth
normalization. Zoom in view displays nucleotide conservation scores (PhyloP)
and multi species alignments for indicated regions. miR-122 seed highlighted in
gray. In both cases, transcript levels were significantly upregulated in KO livers.
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miR-122 3'UTR targets are poorly conserved
Despite clear and robust miR-122 binding along with a correlated change
in expression level, the preceding examples appear in large part to be species
specific, given that the miR-122 seed sites do not appear conserved in
mammalian lineages, especially between mouse and human. We can explore
this in a more general fashion by considering the nucleotide conservation of the
core 6mer of a miRNA binding site, using PhyloP conservation scores across
sequenced mammalian genomes (Pollard et al., 2010). Importantly, PhyloP
scores are calculated per nucleotide and assume a neutral model of evolution.
Positive scores indicate high conservation, while negative scores indicate rapidly
diverging sequences; scores near zero are undergoing neutral drift. By plotting
the mean PhyloP score across a miRNA 6mer, and binning by miRNA and
genomic region, we can discern how well conserved miR-122 target sites are
relative to other highly expressed miRNAs. The expectation, largely afforded by
miRNA target prediction efforts, is that highly conserved miRNAs (such as miR122) usually regulate a conserved set of targets.
The results are shown in Figure 5.11. As expected exonic regions are
more conserved (>0) than intronic regions (~0) which are largely undergoing
neutral drift. For the top ten expressed miRNAs, conservation on 3'UTRs
approaches that of coding exons. 3'UTR targets for miR-122 however, are
significantly less conserved compared to the top 10 or all miRNAs (Figure 5.11A).
Such a pattern is repeated among coding exon miR-122 targets generally, and is
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magnified by focusing on 3 codon positions, which are under less selective
rd

pressure to maintain protein coding sequences at the nucleotide level (Figure
5.11B). Bulged miR-122 sites generally were not statistically different than the top
ten miRNA or all miRNAs. These results are somewhat surprising in that they
imply that most canonical miR-122 targeting in mice is species specific.
Moreover, it also predicts that only a select subset of targets are shared between
mouse and human, and that humans likely have a completely different set of
miR-122

regulated

targets.

The

causes,

consequences,

and

potential

mechanisms for miR-122 species specificity despite the fact that this miRNA is
highly conserved down to fish will be addressed in the discussion. For now, it
suffices to bring this point up as we begin to consider what classes of targets are
derepressed in KO livers.
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Figure 5.11. miR-122 CLIP targets are not well conserved in mouse. (A) Mean
nucleotide conservation scores for mouse miR-122, bulged miR-122, the top 10
miRNAs and all miRNA targets, denoted by genic region. PhyloP scores from
placental mammals were averaged across the core miRNA 6mer and plotted.
Shaded areas indicate statistical significance compared to the top 10 or all
miRNA targets (P<10e-10, KS-test). (B) Per nucleotide PhyloP scores calculated
as in (A) were further subdivided by codon position for coding exons. Shaded
areas indicate statistical significance (P<10e-10, KS-test).
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miR-122 regulates a diverse set of metabolic proteins
Pioneering studies in mice following miR-122 antagonism with anti-sense
oligonucleotides (ASOs) or locked nucleic acids (LNAs) revealed altered lipid
profiles characterized by reduced plasma cholesterol levels, increased hepatic
fatty-acid oxidation, and a decrease in hepatic cholesterol and fatty-acid
synthesis rates (Elmén et al., 2008; Esau et al., 2006; Krützfeldt et al., 2005).
These studies identified a number of direct miR-122 targets using microarrays,
and further defined secondary targets whose expression was altered but did not
contain predicted miR-122 sites. Indeed several genes with crucial to lipid
metabolism but lacking miR-122 sites (Acc1, Acly, Scd1, Srebp2 and Hmgcr)
were down-regulated (Esau et al., 2006; Krützfeldt et al., 2005). Consistent with
these findings, miR-122 antagonism decreased serum cholesterol levels in
chimpanzees (Lanford et al., 2010).
As the miR-122 KO mouse provides a more detailed identification of all
miR-122 regulated genes (via RNAseq) and enables subsetting of direct targets
(via AGO-CLIP), we revisited proposed groupings of miR-122 targets using gene
ontology (GO) analysis. We first focused on all de-repressed mRNAs in miR-122
livers using all expressed genes as the background control. We found that
transcripts encoding small molecule and lipid metabolism were highly enriched
biologic processes (Figure 5.12A). Significant enrichment for proteins in
membrane bound organelles and secreted vesicles was also observed (Figure
5.12B). Focusing on direct miR-122 targets (CDS and 3'UTR), we observed a
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similar enrichment for biologic process and cellular component (Figure 5.12C-D).
No qualitative difference was observed between GO results of miR-122 versus
bulged miR-122 targets. Taken together, these data largely confirm and expand
upon previous studies with the identification of a non-canonical miR-122 binding
site as contributing to the overall theme of miR-122 as a key regulator of liver
metabolism. And yet, as we consider the apparent species specificity of a
substantial fraction of miR-122 regulation, we must ask: does the same hold for
humans?
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Figure 5.12. Gene ontology (GO) analysis of de-repressed miR-122 targets in
mice. (A) GO term enrichment and FDR significance of the top GO Process terms
for all miR-122 targets de-repressed in miR-122 KO mice. (B) As in (A), but for
the top GO Component terms. (C) GO term enrichment and FDR significance of
the top GO Process terms for all 3'UTR and CDS miR-122 targets de-repressed
in miR-122 KO mice. (D) As in (C), but for the top GO Component terms.
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Establishing a miR-122 target network in human liver
The results presented thus far with miR-122 knockout mice livers have
been illuminating to define the complex web of targets directly and indirectly
regulated by miR-122. Given the high conservation and expression of miR-122 in
mammalian livers, it has so far been reasonable to assume that miR-122 likely
plays similar roles in these varied organisms. Surprisingly, the high frequency of
mouse specific miR-122 targeting suggests otherwise.
To address this and to enable a direct comparison between human and
mouse, we decided to perform AGO-CLIP in human liver samples procured by
Kalpana Ghoshal at OSU. Specifically, we chose liver resections from HCC
patients

to

compare

tumor

to

histologically

"normal"

adjacent

tissue.

Pathologically, these samples exhibited moderate to poorly differentiated HCC
with adjacent fibrosis and cirrhosis (Table 5.1). Importantly, we used lower miR122 expression in HCC tumors compared to adjacent tissue as an additional
selection criteria (Figure 5.13).
We reasoned that the matched nature of these samples (tumor versus
normal from the same patient) combined with differences in measured miR-122
abundance would increase our chances in identifying not just static miR-122
targets (i.e. transcripts with seeds) but also to observe AGO-CLIP binding
changes analogous to the miR-122 KO mouse. AGO-CLIP was performed on five
human HCC samples and five matched controls for a total of ten libraries.
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Table 5.1 HCC subject characteristics

Table 5.1 and Figure 5.13. HCC subject characteristics and concurrent miR-122
qPCR in human liver samples. (Left) Subject characterstics table for five HCC
patients. (Right) miR-122 qPCR in arbitrary expression values for paired tumor
versus normal adjacent tissue for five HCC patient liver samples. Paired t-test pvalue between normal versus tumor samples shown.

Figure 5.14. Autoradiogram of AGO bound RNA in human HCC tumors or
matched normal adjacent tissue. Autoradiogram of 32P-labelled RNA bound to
AGO after IP using the pan-AGO 2A8 antibody. AGOs migrate at 97kDa, which
shifts by RNA species bound by approximately 1kDa/3nt, thus AGO bound to
~22nt miRNA should be around 105kDa. IgG used as a non-specific control.
Minus crosslink control shows the stringency of washes in that only a faint
Ago:miRNA complex remains. High RNAse and low RNAse conditions indicated.
Region excised corresponding to 110-150kDa complexes is highlighted. Left
panel depicts signal from five patient samples of normal adjacent tissue, where
the amount of liver tissue used per sample is indicated. The right panel depicts
five liver tumors matched by number to normal adjacent tissue.
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The autorads gave clear 110kDa miRNA bands in normal tissue, however
some differences in signal intensity were apparent in matched tumor samples
(Figure 5.14). One general reason for this may be the lower tissue volume used
compared to mouse liver. Nevertheless, library construction after excising mRNA
sized regions was successful (not shown) and so we moved forward with
sequencing.
As before, the first analysis we performed was on the miRNA profiles
between tumor and normal samples. We confirmed our qPCR results and
observed that miR-122 was indeed reduced on AGO in tumor samples, in
addition to other miRNAs, notably miR-194 and miR-144 Figure 5.15. Loss of
miR-194 and miR-144 in hepatocytes have been previously implicated in HCC
progression and liver inflammation (Krützfeldt et al., 2012; Li et al., 2015). A
number of miRNAs, such as miR-21 and miR-221/222 exhibited increased AGO
association in tumors, and largely confirms previous and recent observations
(Dong et al., 2015; Karakatsanis et al., 2013; Ogawa et al., 2012; Sun et al.,
2015). Taken together, these largely congruous results set the stage for exploring
miRNA target regulation where clearly miR-122 is one of many miRNAs involved
in cancer progression.
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Figure 5.15. Volcano plot showing the log 2 fold change between tumor versus
normal human liver tissue of miRNA-CLIP results. Y-axis denotes FDR, where p
= 0.01 and 0.05 lines are indicated. Notable miRNAs are highlighted by color
and/or label.

Next, groomed reads were aligned to the human genome (hg18) and
clustered such that mapped reads that overlapped by 1nt. Clusters were then
grouped by BC and plotted as before to get a sense of the distribution of clusters
across various genomic regions (see Chapter 4). A greater proportion of coding
exon targeting was evident across all libraries and this frequency did not appear
to vary much with increasing BC (Figure 5.16). For downstream analysis of
miRNA seeds, a cutoff of five libraries was used.
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Figure 5.16. Cluster annotation results by increasing biologic complexity. AGOCLIP reads from up to 10 libraries from human liver were clustered with a
minimum overlap of 2nt. Clusters with reads from any one, two, three and so on
up to ten libraries the were annotated. The resulting proportions of clusters
overlapping known genic elements is plotted above, alongside the total number of
clusters with the respective biologic complexity (BC).

With these cluster definitions, a more detailed annotation was performed
comparing all normal tissue versus tumor clusters, including those commonly
shared (Figure 5.17). Of the ~19000 clusters at this stringency, close to 20%
were in 3'UTRs and an even greater proportion (~70%) mapped to coding
regions than in mice. Other genic regions, such as introns, transposable
elements (TEs), 5'UTRs, and intergenic regions, were not appreciably different
between made up the remaining 10%. Comparing the same annotation in mouse
livers (Figure 5.4), 3'UTR binding was consistent at 20% of all clusters. The
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marked increase in coding exon binding between human and mouse (or
conversely, the decrease in intronic and TE binding) is a bit puzzling and
probably reflects distinct transcriptome differences between human and mouse
liver. Some amount of bioinformatic noise can also not be ruled out.

Figure 5.17. Cluster annotation of normal adjacent liver tissue (Normal) or
matched tumor (Tumor) CLIP libraries from human liver mapping to various
regions of the genome. Clusters unique to each case plus those in common are
indicated. A BC filter of 5 of 10 libraries was specified. TE, transposable
elements; Other, includes non-coding RNA, satellite repeats, low complexity
elements, etc.

Just the same, we went forward with the same analysis performed in
mouse liver, where clusters were grouped by the presence of miRNA seed and
genomic region, and the log2 fold change between normal and tumor plotted as a
CDF. In this plot, as in the mouse, positive values indicate greater AGO binding
in the normal tissue, while negative values indicate greater binding in tumors
(Figure 5.18A). For miR-122 3'UTR targets, we observed significant reductions in
AGO binding in tumor tissue for both canonical and G-bulged targets, consistent
with miR-122 loss in this context (Figure 5.18B).
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Figure 5.18. Global reduction of AGO binding miR-122 targets observed in liver
tumors. (A) miR-122 dependence definition by Ago binding profiles. (B) umulative
distribution fraction (CDF) plot of the log2 fold change in Ago binding within
cluster harboring indicated miRNA seeds. KS Test p-values indicated for miR-122
distributions vs all targets. (C) AGO binding profiles for miR-122, bulged miR-122,
and all miRNA targets (exclusive of miR-122), broken down by annotated region.
Gray shading indicate statistical significance (P<10e-5, KS-test) for each
annotated category compared to the same category among all miRNA targets.
(D) Pie chart highlighting miR-122 or bulged miR-122 targets as a proportion of
all miRNA targets in mouse. Total number of clusters per category indicated. (E)
Genomic annotation breakdown of canonical or bulged miR-122 sites.
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Intriguingly, we also observed the opposite for some miRNAs, most
notably miR-21, whose increased expression in tumors also results in increased
AGO binding of miR-21 targets.
Focusing on miR-122 binding, we observed as in mice, that reduced AGO
binding was not specific to 3'UTRs and was observed for both canonical and Gbulged sites significantly in genic regions (Figure 5.18C). The miR-122 targetome
in human liver constituted around 9% of all AGO clusters, slightly higher than the
~6% in mice (Figure 5.18D). The miR-122 target network also skewed heavily to
coding exons (>60%) and was generally similar to the global annotation of
miRNA targeting in liver.
In the last analysis similar to that performed in mice, we investigated the
conservation of miR-122 seeds using PhyloP scores and again observed that
3'UTR and to a lesser extent coding exon canonical miR-122 targets were
generally less conserved that the top 10 or all expressed miRNA (Figire 5.19).
Taken together, these results extend conclusions obtained in miR-122 KO
mice with the human observation of a G-bulged miR-122 seed, extensive non-3UTR AGO binding, and importantly, poor conservation of miR-122 seeds that
may point to high species specificity of miR-122 target regulation.
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Figure 5.19. miR-122 CLIP targets are not well conserved in human. (A) Mean
nucleotide conservation scores for human miR-122, bulged miR-122, the top 10
miRNAs and all miRNA targets, denoted by genic region. PhyloP scores from
placental mammals were averaged across the core miRNA 6mer and plotted.
Shaded areas indicate statistical significance (P<10e-10, KS-test). (B) Per
nucleotide PhyloP scores calculated as in (A) were further subdivided by codon
position for coding exons. Shaded areas indicate statistical significance (P<10e10, KS-test).
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Intersecting miR-122 target networks between mouse and human
Considering how well the miR-122 KO mouse appears to phenocopy the
slow and chronic progression to HCC in humans, its reasonable to propose that
miR-122 targets shared between mouse and human might be key drivers of the
HCC phenotype. In this context, the high species specificity exhibited by miR-122
target regulation between mouse and human can be seen as more of a feature
than a bug: by intersecting these disparate datasets and focusing on common
targets, we can filter out species specific noise to settle on a core set of
conserved factors that presumably play the biggest roles in HCC. Of course, the
alternative hypothesis, that much of the species specificity itself may drive
pathogenesis is not without weight. This is especially true given the HCC cancer
phenotype which strikes mice well past the age of sexual maturity, thus
envisioning how natural selection acts to maintain miR-122 targets in this
scenario is highly problematic, absent additional factors that affect individual
fitness. This point will be addressed further in the discussion. For our purposes,
we should simply consider the species specificity of miR-122 targets in the
broader context of the multi-factorial nature of HCC. Or to use an analogy, let's
say there are 1000 ways to get liver cancer. Far from miR-122 deregulation
making that total 1001, the species specificity might make it more like 2001.
As of the writing of this chapter (mid-March 2015), RNAseq in matched
normal and tumor samples has not yet been performed. So for the ensuing
analysis, miR-122 target CLIP comparisons have been made with all transcripts
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de-repressed in miR-122 KO livers. Irrespective of genic region, of the ~3900
genomic loci harboring canonical and G-bulged miR-122 sites in mice roughly
~15% (613) possessed any overlap with human targets in liver (Figure 5.20A).
The human targetome, smaller than the mouse due to lower sequencing depth,
overlapped considerably with all mouse targets. Focusing on the set of targets
de-repressed in mice, only 76 targets (2% of mouse and 7% of human) were
common among these datasets.
This theme is repeated when we zoom in on 3'UTR targets. Of the ~1200
miR-122 3'UTR targets in mice, only 29 (or ~2%) were both de-repressed in
mouse livers and found in human (Figure 5.20B). Focusing on miR-122 targets
identified as HCV de-repressed in Huh-7.5 cells further reduces the overlap to 14
targets with an additional 18 in common with de-repressed mouse targets (likely
what remains to be found if human livers were sequenced deeper) (Figure
5.20C).
It must be noted that even of the 29 targets in common in Figure 5.20B,
nearly half can be considered co-incidental: miR-122 sites are not conserved
between human and mouse paralogs. Thus in these targets, miR-122 regulation
appears to have evolved independently. Such an example is shown in Figure
5.21. This transcript encodes an alkaline phosphatase of unknown function that
is expressed in liver, bone and kidney. In both mouse and human it clearly
possesses AGO bound miR-122 sites, however the primary sequence and
precise location relative to the stop codon are not conserved.
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Figure 5.20. miR-122 target overlaps between human and mouse. (A)
Proportional Venn diagram showing overlap of all CLIP identified canonical and
bulged miR-122 targets in mouse or human liver, compared to all de-repressed
miR-122 targets measured by RNAseq. (B) Diagram as in (A) focusing only on
3'UTR targets. Genes found in all three categories are listed at right, in bold are
any targets with an previous confirmatory data, in red are targets validated using
either luciferase or single cell reporters from this thesis. (C) Diagram as in (B)
displaying overlap with all CLIP derived miR-122 targets from Huh-7.5 cells.
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Figure 5.21. miR-122 targeting ALPL 3'UTR is conserved while the binding site is
not. AGO-CLIP data in mouse miR-122 or WT mouse liver (A) or human normal
and tumor tissue (B). Zoom in view displays nucleotide conservation scores
(PhyloP) and multi species alignments for indicated regions. miR-122 seed
highlighted in gray.
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Of the number of genes that are conserved between human and mouse
and that are derepressed in mouse KO livers, one novel miR-122 target stands
out. Interleukin-1 receptor antagonist protein (IL1RN) is a well studied and potent
negative regulator of IL-1B, a key pro-inflammatory signaling molecule (Gabay et
al., 2010). Deficiency in IL1RN results excessive IL-1B signaling to produce acute
and chronic inflammation in a variety of animal models and human disease
contexts (Aksentijevich et al., 2009; Hirsch et al., 1996; Nicklin et al., 2000;
Reddy et al., 2009). IL-1B has also been implicated as an important mediator in
liver pathology, where increased IL-1B activity has been observed from patients
with chronic liver diseases to fulminant hepatic failure (Sekiyama et al., 1994; Tilg
et al., 1992).
IL1RN is a clear miR-122 target in both mouse and humans, with
additionally conserved supplementary pairing (Figure 5.22). This identification of
IL1RN as a miR-122 target in vivo raises numerous hypotheses. Conceivably,
miR-122 could normally play a role in permitting IL-1B signaling by regulating
IL1RN. Should an IL-1B driven inflammatory response overshoot, and reduce
miR-122 levels as is typically seen in many liver diseases (see Introduction), derepressed IL1RN may work to dampen the IL-1B cascade. This feedback loop
would make sense in the context of an acute HCV infection as a key axis to
silence by potentially sequestering miR-122. As HCV replicates and induces an
inflammatory response, reducing miR-122 would derepress IL1RN to suppress
this exact immune response.
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Figure 5.22. Conserved miR-122 targeting of the IL1RN 3'UTR in murine and
human liver. AGO-CLIP data in mouse miR-122 or WT mouse liver (A) or human
normal and tumor tissue (B). Zoom in view displays nucleotide conservation
scores (PhyloP) and multi species alignments for indicated regions. miR-122 is
highlighted in red, extensively conserved seed waiting highlighted in gray.

In accordance with this, increased IL1RN (and IL-1B) expression has been
observed in patients with acute and chronic active HCV infections (Gramantieri et
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al., 1999; Libra et al., 2006). As an added wrinkle, IL1RN has also been identified
as interferon induced in the context of HCV therapy (Cotler et al., 2002). And so
we conclude with the following testable scenario, should HCV prevent the
activation of an endogenous IFN response via NS3/4A inactivation of RIG-I
signaling, derepression of a negative regulator of inflammation (IL1RN) by
miRNA sequestration might be means to bypass IFN induction as suppress an
inflammatory response.
The above hypothesis is one of many that can be made for the common
targets shared between humans and mice as we begin to consider additional
roles for miR-122 as a positive regulator for HCV proliferation in vivo. Clearly,
much work remains to be done on this front.
Chapter 5 summary and discussion
In this chapter, we've explored efforts to elucidate the miR-122 targetome
in vivo using a miR-122 knockout mouse model and human liver tissue. We've
uncovered both non-canonical G-bulged miR-122 sites and revealed widespread
miR-122 dependent loci, well beyond the normal 3'UTR sites of miRNA function.
Furthermore, we've revealed surprisingly low conservation of targets for such a
highly conserved miRNA. In this section, we'll discuss how this might have come
to be, and what we might expect from the miR-122 targetome if its deregulation
contributes to a similar liver pathology in mice and humans despite regulating
different target sets.
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Redefining miRNA function: the Seitz hypothesis and target conservation
In 2009, Hervé Seitz pointed out that miRNAs present at least three
apparent observational paradoxes (Seitz, 2009). The first paradox is how exactly
a miRNA can have hundreds of targets, and yet many in vivo phenotypes of
specific miRNA loss can be rescued by repressing a few, and often only single
targets. Indeed, the developmental phenotypes for the pioneering miRNAs in C.
elegans, lin-4 and let-7, can each be rescued by introducing complementary seed
mutations in their respective targets lin-14 and lin-41 (Ambros, 1989; Slack et al.,
2000). One well-regarded explanation for this discrepancy is that many in vivo
experiments tend to overlook, or not follow up, on subtle phenotypic changes
associated with other targets. This dove-tails with another view that many miRNA
loss-of-function phenotypes are context specific, and may not exist basally but
require something to induce them. Indeed, a current evaluation of in vivo miRNA
knockout studies agrees with these views, particularly in light of the fact that
many miRNA knockouts possess no obvious phenotypes, often despite ample
overexpression data (Vidigal and Ventura, 2015). On its face, this should strike
fear in the heart of any miRNA researcher who relies on overexpressed miRNAs
to repress luciferase reporters as a surrogate for miRNA target validation. But
this is perhaps a separate discussion.
Compounding the miRNA:target discrepancy is the surprisingly modest
repression exerted by miRNAs. This is the second major paradox. From a
virologist's perspective, miRNA repression of target protein expression by less
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than 2-fold is a pittance compared to the orders of magnitude of RNA replication
and transcriptional regulation observed in viral infections and their counteracting
innate immune responses. Seitz draws a more reasonable parallel by considering
that 2-fold effects are well within intraindividual variations in gene expression and
transcriptional noise (Seitz, 2009). Moreover, that only a fraction of human genes
display haplo-insufficient phenotypes would only further support this argument
(Huang et al., 2010). Fitting weakly repressive miRNAs within a complex and
robust transcriptional control system that is largely buffered from fluctuations in
gene expression is thus at odds with the clear importance of miRNA function.
To resolve these contradictions, Seitz proposed a redefinition of terms.
Instead of positing that the primary function of miRNA is to repress mRNA by
binding to seed sites, we should consider the obverse, that the function of mRNA
seed targeting is to regulate miRNA activity. In other words, most mRNAs
primarily function as miRNA sponges where the 2-fold repression is
inconsequential for most targets except for the select few that are contextually
very sensitive to gene dosage. This explanation provides a framework to resolve
the both of the above paradoxes by predicting that most miRNA targets aren't
functional in the sense that their repression has downstream consequences.
Rather, they function more to set and continuously alter the effective miRNA
concentration where, and this is the key, each targeted transcript responds
uniquely but not independently of other targets. This interpretation is remarkably
consistent at all scales of miRNA function: from thresholding effects on individual
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transcripts thoroughly described and tested earlier (Mukherji et al., 2011), to in
vivo phenotypes that appear only in specific contexts, such as genetic or
environmental stress (Vidigal and Ventura, 2015).
For Seitz, the miRNA sponge or "pseudotarget hypothesis" also solves a
third paradox: while many miRNA targets are conserved among closely related
species, they differ considerably between distant species, even for highly
conserved miRNAs (Chen and Rajewsky, 2006). This is essentially what we've
confirmed for miR-122 targets between humans and mice, in that such targets
are poorly conserved across these species, but often are retained in close
neighbors such as macaques and rats, respectively. The pseudotarget
hypothesis predicts such poor conservation among distantly related organisms
precisely because repression is irrelevant for most targets. During evolution, the
precise targetomes of a miRNA are free to diverge so long as pseudotargets are
replaced with mRNAs with similar expression patterns (Seitz, 2009), or
alternatively, by evolving exquisite control of miRNA transcription and
degradation. As a consequence, this hypothesis strongly argues that target site
conservation is a key feature of "real" targets.
Our results with miR-122 in liver would agree with this view, given that the
vast majority of targets, while AGO associated, do not result in substantive
repression. Still, it's possible that for many putative pseudotargets the right
context for a visible phenotype remains elusive, but conceptually exists. Note
also that the above discussion primarily revolves around conserved targeting in
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3'UTRs. Our CLIP data alongside other work would contest this narrow
framework, given that AGO binding occurs well beyond 3'UTRs, can be
conserved in these regions, and does not often behave according to strict seed
pairing rules (Helwak et al., 2013; Loeb et al., 2012). Moreover, the
demonstration of many species specific miRNA phenotypes in a variety of
systems suggests that the pseudotarget hypothesis can be a source of neofunctionalization for miRNA binding (Vidigal and Ventura, 2015).
The broadened framework originally proposed by Seitz has in large part
underwritten the competing endogenous RNA (ceRNA) hypothesis as its more
formalized and highly debated extension (Denzler et al., 2014; Ebert and Sharp,
2010; 2012; Figliuzzi et al., 2013; Jens and Rajewsky, 2014; Salmena et al.,
2011). Critics rightfully point out that relatively minor fluctuations of individual
target transcripts are unlikely to perturb global miRNA function, assuming that
miRNA levels are in vast excess to the overall target abundance (Jens and
Rajewsky, 2014). For highly abundant miRNAs such as miR-122, only when
target abundance approaches or exceeds the miRNA expression level are
ceRNA effects observed (Denzler et al., 2014). Nevertheless, as researchers are
only beginning to appreciate the extent of AGO targeting outside of 3'UTRs and
the prevalence of non-canonical binding, the general assumption that miRNA
levels are in vast excess to target abundance will require revisiting.
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The miR-122 knockout molecular phenotype and HCV: a proposed evolutionary
connection
So where does the above discussion leave our results with miR-122 and
HCV? I propose that the expansion of miR-122 bound loci defined by AGO-CLIP,
combined with the relatively poor conservation observed for miR-122 target seed
sites (as pseudo targets) may bear directly on two primary and unique features of
this miRNA: its high abundance and its coercion by HCV.
At the outset, miR-122 is both an outlier for being highly liver specific and
also the most abundant miRNA in any tissue measured, especially in humans
(Ladewig et al., 2012; Lagos-Quintana et al., 2002). A sufficient explanaiton for
these observations has yet to emerge. As mentioned earlier, the miR-122 cancer
phenotype occurs after sexual maturity and KO mice display no apparent
problems in breeding (K. Ghoshal, personal communication), unlike other
miRNAs with critical roles in development or cellular differentiaion (de Pontual et
al., 2011; Rodriguez et al., 2007; Vidigal and Ventura, 2015). Assuming that the
the reproductive fitness of miR-122 KO mice is only mildly affected by miR-122
loss, it is difficult to fathom how a miR-122 target network could not undergo
genetic drift (Lynch and Hagner, 2015). Consider a small core set of targets that
are sensitive to ~2-fold repression, among a pool of psuedo-targets which are
insensitive. Absent strongly deleterious acquisition of miR-122 binding which is
cleared though selective avoidance (Bartel and Chen, 2004), most pseudotargets and even non-targets are free to acquire miR-122 sites with no
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deleterious effects. This would explain the the divergence of miR-122 targetomes
between humans and mice and their relative evolutionary proximity to closely
related species. Furthermore, this could also serve as the engine for neofunctionalization which would be expected from such "evolutionary meandering"
of intermolecular interactions (Lynch and Hagner, 2015). Even among highly
conserved miRNAs, such a mechanism could also account for the emergence of
species specific acquisition of sites that may then undergo positive selection as
part of the neofunctionalization process, as has been observed in humans (Li et
al., 2012; Saunders et al., 2007).
Now, one could imagine a scenario where at some point the expanded
miR-122 targetome could negatively impact those core set of targets that must be
repressed, due to the overall target abundance becoming inhibitory to repression.
As a result, the hepatocyte may evolve a means to increase miR-122 abundance,
and the cycle repeats. Notably, absolute miR-122 abundance per cell is well
known in mouse (~66,000 copies / cell) and human, which contains nearly twice
the amount of miR-122 (~135,000 copies per cell) (Chang et al., 2004; Denzler et
al., 2014).
Overall, this hypothesis makes at least four testable predictions: that miR122 level should scale with its absolute target abundance across various
organisms (measured by CLIP and not by informatic prediction), that targetomes
should diverge between distant organisms (as is predicted in vertebrates (Xu et
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al., 2013)), and that miR-122 promoter complexity as well as levels per
hepatocyte should scale with organismal complexity.
If we consider HCV infection in this context, one reasonable argument for
its acquisition of miR-122 dependence as a protective shield is due to the simple
fact that miR-122 is both highly abundant in liver, but mostly irrelevant for most
targets. In other words, HCV has evolved to use miR-122 precisely because it
provides an unexploited niche relative to other miRNAs. At first glance, this
appears to resemble a null hypothesis for any pro-viral role for the miR-122.
However this need not be the case, especially if the substantial and species
specific targeting in humans represents the right mix of targets that would make
sense to de-repress. For conserved targets such as IL1RN (Figure 5.22), and
non-conserved targets such as Drosha (Figure 5.9B), it is straightfoward to
envision pro-viral paths for the HCV sponge in humans.
All of this is to say that many surprises are likely to continue to be in store
for the myriad of roles that miR-122 plays in the livers of vertebrates. Expanding
upon our results to test specific predictions in other organisms and model
systems, using novel HCV variants (such as the U3 and miR-15 depdendent
viruses), putative murine and equine cousins to HCV, and empowered by
unbiased genomic methods such as CLIP, we are poised to unravel the complex
host-viral interaction of information that is centered upon one 22 nucleotide
snippet of RNA, life's indispensable molecule.
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Chapter 6: Concluding remarks
In this very short chapter, I aim less to provide a comprehensive model of
the work presented in this thesis than to highlight the unanswered questions this
work raises and point out viable paths forward.
In succint terms, the following model is proposed that links HCV replication
in the infected hepatocyte to outward manifestations of HCV induced disease.
Mechanistically, miR-122 is positied as a central molecular player in this process.
In normal hepatocytes, miR-122 target repression is required to maintain longterm liver homeostasis. Upon HCV infection, viral RNA coercion of miR-122
results in de-repression of host miR-122 targets (Figure 6.1). Due to this miRNA
sponging by HCV RNA, liver homeostasis is perturbed and can result in a
constellation of liver complications to include HCC. Indirect pro- or anti-viral
benefits from the miR-122 sponge are possible, but currently unknown.
At the outset, the miR-122:HCV sponge relies on a two part assumption:
constant miR-122 levels and sufficiently high enough viral replication to impact
the effective miR-122 concentration in the cell. As shown in this thesis and
addressed in previous chapter discussions, mature miR-122 levels appear
relatively constant in vitro and in vivo. Capturing the dynamic nature of
cytoplasmic HCV replication that underlies long-term chonicity in the liver is the
next major challenge. While the sponge effect decribed in this work can be
thoroughly tested in cell culture systems, its ultimate validation in vivo will require
appropriate model systems and technologies aimed at interrogating single cells.
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Figure 6.1. A concise model for HCV:miR-122 sponge induced liver disese. In
normal hepatocytes, miR-122 target repression is required to maintain long-term
liver homeostasis. Upon HCV infection, viral RNA coercion of miR-122 results in
de-repression of host miR-122 targets, which in turn de-stabilizes liver
homeostasis. Indirect benefits (or road-blocks) to the virus as a result of miR-122
target de-repression are possible but currently unknown. This figure adapted from
(Luna et al., 2015).

To this end, recently decribed hepaciviruses of rodents, as close
homologs to HCV, might offer long sought after disease-causing surrogates for
HCV infection. That these viruses have miR-122 sites in their 5'UTRs is highly
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suggestive of their need for this miRNA and may point to potential sponge
effects.
But given that our data also pinpoint high species specificity to miR-122
targeting between mice and humans, its possible that distinct human specific
miR-122 targets, when de-repressed, might be key drivers for human disease. To
this end, the application of single cell transcriptomic analysis to HCV infected
human liver cells represents an alternative path forward, should murine
hepaciviruses fail to phenocopy human disease. Additionally, the in vitro Huh-7.5
cell context, where the sponge effect was discovered, can continue to play a role
by exploring the stoichiometic requirements for a viral RNA to sponge miRNA.
Testing other HCV genotypes with different replicative potentials, testing
heterzygous miR-122 knockout mutant cells, and probing the sponge effect
induced by the m15 virus offer proximal means to cement our observations while
providing a roadmap for invesitgations of other RNA viruses.
In sum, the genomic portrait I've outlined for HCV and miR-122 in this
thesis is exactly that: a single perspective on the multifaceted relationship
between host and virus. As biology matures in the post-genomic era, and static
reductionist pictures yield to data-driven dynamism, the stage is set for further
systems level views of viruses. Today as ever, Pasteur’s words remain as
relevant as they did in the 19th century: "Messieurs, c'est les microbes qui auront
le dernier mot." (Gentlemen, it is the microbes who will have the last word).
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APPENDIX of OLIGOS
Oligo name

Sequence (5' to 3')
miR-15 dependent HCV construct cloning
Pos43_F
CCTGTGAGGAACTACTGTCTTC
Pos12343_F
CGGCCAGTGAATTCTAATACGACTCA
Pos1293_R
CGGTGTCCAGTGATGGTACCAG
Pos1358_R
GCATCGCGTACGCCAAGATC
CAGTGAATTCTAATACGACTCACTATAGACCTGCCC
m122to15_F
CTAATAGGGGCGTGCTGCTGCCATGAATGCTGCTCC
TGTGAGGAACTACTGTC
CAGTGAATTCTAATACGACTCACTATAGACCTATACT
TTCAGGGATCATTTCTATAGTGTGTTACTAGAGAAGT
m122toU3_F
TTCTCTGAACGTGTAGAGCACCGATTGAATCACTCC
CCTGTGAGGAACTACTGTCTTC
F S2p34
GATTGAATCACAGCCCTGTGAG
R S2p34
CTCACAGGGCTGTGATTCAATC
F S2p3
GATTGAATCACTGCCCTGTGAG
R S2p3
CTCACAGGGCAGTGATTCAATC
Luciferase reporter vector cloning
ATATCTCGAGTCTAGCCACATGACACTCCATATGCG
miR-122_seed_F
GCCGCATTA
miRTAATGCGGCCGCATATGGAGTGTCATGTGGCTAGAC
122_seed_R
TCGAGATAT
miRTCGAGTCTAGCCACATGACACAGCATATGC
122_seedmut_F
miRGGCCGCATATGCTGTGTCATGTGGCTAGAC
122_seedmut_R
/5Phos/TCGAGTCAAGGTCAGCTGCACTTTAGTACAG
miRTCTGTCATGCACTTTATAACGGCCCCGCTTGCACTT
17_4xseed_F
TACAATCAGCAACCTTGCACTTTATATGC
/5Phos/GGCCGCATATAAAGTGCAAGGTTGCTGATTG
miRTAAAGTGCAAGCGGGGCCGTTATAAAGTGCATGACA
17_4xseed_R
GACTGTACTAAAGTGCAGCTGACCTTGAC
miR/5Phos/TCGAGTCAAGGTCAGCTGCACaaTAGTACAG
17_4xseed_seed TCTGTCATGCACaaTATAACGGCCCCGCTTGCACaaT
mut_F
ACAATCAGCAACCTTGCACaaTATATGC
miR/5Phos/GGCCGCATATATTGTGCAAGGTTGCTGATTG
17_4xseed_seed TATTGTGCAAGCGGGGCCGTTATATTGTGCATGACA
mut_R
GACTGTACTATTGTGCAGCTGACCTTGAC
PKM2_3UTR_F1
ATATCTCGAGTGGACCCCAGAGCCCCTCC
881
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PKM2_3UTR_R2
TAATGCGGCCGCGGTGCTTCAGCTGTTGTTTATTG
501
PKM2_seedmut_
GCAGCAAACACAGCACCCTCCACC
F
PKM2_seedmut_
GGTGGAGGGTGCTGTGTTTGCTGC
R
CTDNEP1_3UT
ATATCTCGAGCAGCTGCTCCCCCTCCACCTG
R_F1183
CTDNEP1_3UT
TAATGCGGCCGCTGACTTGGCTTCTCTTTGAGC
R_R1528
CTDNEP1_seed
CGTGTTCACACAGCATGGAAACC
mut_F
CTDNEP1_seed
GGTTTCCATGCTGTGTGAACACG
mut_R
SFT2D1_3UTR_
ATATCTCGAGAAATCAGAAACTTGTGGAAAAGAG
F511
SFT2D1_3UTR_
TAATGCGGCCGCTTTAAAGTTACAAGCATTTAATGG
R699
SFT2D1_seedm
CCATAAAACACAGCAGGAACAAC
ut_F
SFT2D1_seedm
GTTGTTCCTGCTGTGTTTTATGG
ut_R
pTre3G fluorescent reporter vector cloning
EcoRICGGAATTCACCATGGGCCCTAAAAAGAAGCGTAAAG
nlsTagBFP_F
TCATGAGCGAGCTGATTAAGGAGA
NdeIGGAATTCCATATGTTATCCGGAATTAAGCTTGTGCC
nlsTagBFP_R
C
ATGGGCCCTAAAAAGAAGCGTAAAGTCATGGTGTCT
nlsTagRFP_F
AAGGGCGAAGAGC
pT3G-MCS2GGGGCCCAGATCTCCGCGGGGATCCACCATGGGCC
BamHI-nls_F
CTAAAAAGAAGCGTAAAGTC
CTGATTATGATCCTCTGGAGATATCCGGCTCCAGTC
RFP-ClaI-N=1mTTGTATCCTGTTTCCGGCATCGATTTATCCGGAATTA
EcoRV-pT3G_R
AGTTTGTGCCCC
CTGATTATGATCCTCTGGAGATATCCGGCTGGAGTG
RFP-ClaI-N=1TTGTATGGTGTTTCCGGCATCGATTTATCCGGAATTA
EcoRV-pT3G _R
AGTTTGTGCCCC
CTGATTATGATCCTCTGGAGATATCCGGCTGGAGTG
RFP-ClaI-N=1pfTGACAATGGTGTTTCCGGCATCGATTTATCCGGAAT
EcoRV-pT3G _R
TAAGTTTGTGCCCC
RFP-end_R
TTATCCGGAATTAAGTTTGTGCCCC
RFP-ClaI-N=4GGGGCACAAACTTAATTCCGGATAAATCGATCGGCA
EcoRV-pT3G
AACACCATACAACACTCCACTAGAAACACCATAAAA
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RFP-ClaI-N=6EcoRV-pT3G

pT3G-CS3UTR_F
CS-3UTRBamHI-pT3G_R
pT3G-MASP13UTR_F
MASP-3UTRBamHI-pT3G_R
pT3G-MAL23UTR_F
MAL2-3UTRBamHI-pT3G_R
pT3G-SFT2D13UTR_F
SFT2D1-3UTRBamHI-pT3G_R
pT3G-PKM23UTR_F
PKM2-3UTRBamHI-pT3G_R
pT3GCTDNEP13UTR_F
CTDNEP13UTR-BamHIpT3G_R
pT3G-P4HA13UTR_F
P4HA1-3UTRBamHI-pT3G_R
pT3G-AldoA3UTR_F
AldoA-3UTRBamHI-pT3G_R

CACTCCAGATCAAACACCATACAACACTCCAGCATA
AACACCATAAAACACTCCACGGCGATATCTCCAGAG
GATCATAATCAG
GGGGCACAAACTTAATTCCGGATAAATCGATCGGCA
AACACCATACAACACTCCACTAGAAACACCATAAAA
CACTCCAGATCAAACACCATACAACACTCCAGCATA
AACACCATAAAACACTCCAGTGCAAACACCATACAA
CACTCCACGAAAAACACCATAAAACACTCCACGGCG
ATATCTCCAGAGGATCATAATCAG
GGGGCACAAACTTAATTCCGGATAAAACTGGAGACT
GGGTGAAAGTG
CTGATTATGATCCTCTGGAGATATCGGCTCAAGCAT
TGTTAATAAAAACATT
GGGGCACAAACTTAATTCCGGATAAGCTGACTTACT
TCCTCGGGGC
CTGATTATGATCCTCTGGAGATATCTTGGTTATCCAC
GAGGGTTTATTTCCAC
GGGGCACAAACTTAATTCCGGATAACACTCCTTAGA
AACTGGCAG
CTGATTATGATCCTCTGGAGATATCATTATCAAATGA
ATACTTTATTAGAGACA
GGGGCACAAACTTAATTCCGGATAAAAATCAGAAAC
TTGTGGAAAAGAGC
CTGATTATGATCCTCTGGAGATATCTTTAAAGTTACA
AGCATTTAATGGTTTAATC
GGGGCACAAACTTAATTCCGGATAATGGACCCCAGA
GCCCCTCC
CTGATTATGATCCTCTGGAGATATCGGTGCTTCAGC
TGTTGTTTATTGAC
GGGGCACAAACTTAATTCCGGATAACAGCTGCTCCC
CCTCCACC
CTGATTATGATCCTCTGGAGATATCTGACTTGGCTTC
TCTTTGAGCCTC
GGGGCACAAACTTAATTCCGGATAACAAACAGGCTT
CCCTTTTTCTCCT
CTGATTATGATCCTCTGGAGATATCTTAAAAAAGATT
TAAGATCATAAATAGGTCATTG
GGGGCACAAACTTAATTCCGGATAAGCGGAGGTGTT
CCCAGGCTGC
CTGATTATGATCCTCTGGAGATATCGCCGACTCCCC
CTTAAATAGCTGTTTA
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CRISPR mutant cloning and sequencing
122.sgRNA1a
CACCGAGAGCTGTGGAGTGTGACAA
122.sgRNA1b
AAACTTGTCACACTCCACAGCTCTC
122.sgRNA2a
CACCGAGGAAACTCTGTAGCCACGA
122.sgRNA2b
AAACTCGTGGCTACAGAGTTTCCTC
122Genomic_F
GTTGCAAACAGAGTTCCTGTCC
122Genomic_R
GAGAGGCAGGGTTCAGCTAACC
Drosha.sgRNA1a CACCGGAACTCTCTAACAGGGGTT
Drosha.sgRNA1b AAACAACCCCTGTTAGAGAGTTCC
Drosha.sgRNA2a CACCGAGGGCATAAAAACACGCACC
Drosha.sgRNA2b AAACGGTGCGTGTTTTTATGCCCT
DroshaGenomic_
TCATGCCTATAATCCCAGCACTTTAGG
F
DroshaGenomic_
CAGTTTCAATACTAGGCAACATGTATCTTCTGAG
R
Dicer.sgRNAEX1.
CACCGAACCCTGCATGATTGTGTAA
1a
Dicer.sgRNAEX1.
AAACTTACACAATCATGCAGGGTTC
1b
Dicer.sgRNAEX1.
CACCGTTATACGCCAAGAAAATATC
2a
Dicer.sgRNAEX1.
AAACGATATTTTCTTGGCGTATAAC
2b
DicerEX1_Genom
CACTGGGTAAGGTACAGAATGCTTGAC
icF
DicerEX1_Genom
TTAATCAGAAGTGGGAGGCCTGAAAG
icR
Dicer.sgRNAEX2.
CACCGCGTATAAAGACGTAGACTGT
1a
Dicer.sgRNAEX2.
AAACACAGTCTACGTCTTTATACGC
1b
Dicer.sgRNAEX2.
CACCGTATTTTATCAAGTTGTGCA
2a
Dicer.sgRNAEX2.
AAACTGCACAACTTGATAAAATAC
2b
DicerEX2_Genom
CATTTCAACACGTATTTACACAATACAGCTG
icF
DicerEX2_Genom
CAGAAGCAGAACATTTAAGAGAAACAGC
icR
Dicer.sgRNAEX1
CACCGAACCAGTATCTTCAAGTAA
9.1a
Dicer.sgRNAEX1
AAACTTACTTGAAGATACTGGTTC
9.1b
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Dicer.sgRNAEX1
9.2a
Dicer.sgRNAEX1
9.2b
DicerEX19_Geno
micF
DicerEX19_Geno
micR
pX330 and pX458
insert sequencing
primer
miR-122-5p_AS
miR-21-5p_AS
miR-16-5p_AS
U6_snRNA_AS

ND7CIndexGCAT
ND7CIndexGTCA
ND7CIndexACTG
ND7CIndexAGCT
DSFP5a
DSFP3a
SSP2
Anchor_MiSeq_
CTAG_DP5_1
Anchor_MiSeq_
GATC_DP5_2
Anchor_MiSeq_
CGTA_DP5_3

CACCGTTCTTTCTGGCTGACTGCAC
AAACGTGCAGTCAGCCAGAAAGAAC
GAGAGTTTTGTTTTTATACTTGGCCCATT
AGACTGAAAATGCTGATGCAGTAAC
ACTATCATATGCTTACCGTAAC
Small RNA northern probes
AAACACCATTGTCACACTCCA
TCAACATCAGTCTGATAAGCTA
CGCCAATATTTACGTGCTGCTA
GAATTTGCGTGTCATCCTTGCGCAGGGGCCATGCTA
A
Poly-G CLIP
/5phos/GNNNNNNNNTATGCGATCGTCGGACTGTAGA
ACTCT/idSp/CAAGCAGAAGACGGCATACGACCCCCC
CDN
/5phos/GNNNNNNNNTTGACGATCGTCGGACTGTAGA
ACTCT/idSp/CAAGCAGAAGACGGCATACGACCCCCC
CDN
/5phos/GNNNNNNNNTCAGTGATCGTCGGACTGTAGA
ACTCT/idSp/CAAGCAGAAGACGGCATACGACCCCCC
CDN
/5phos/GNNNNNNNNTAGCTGATCGTCGGACTGTAGA
ACTCT/idSp/CAAGCAGAAGACGGCATACGACCCCCC
CDN
AATGATACGGCGACCACCGACAGGTTCAGAGTTCTA
CAGTCCGACG
CAAGCAGAAGACGGCATA
GACAGGTTCAGAGTTCTACAGTCCGACGATC
Multiplexed "Super-CLIP" primers
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTCTAGAGGGAGGAC
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTGATCAGGGAGGAC
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
CTACACGACGCTCTTCCGATCTCGTAAGGGAGGAC
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GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTGCATAGGGAGGAC
GCAT_DP5_4
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTGTGCAGGGAGGAC
GTGC_DP5_5
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTACCGAGGGAGGAC
ACCG_DP5_6
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTCATGAGGGAGGAC
CATG_DP5_7
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_T
CTACACGACGCTCTTCCGATCTTGCAAGGGAGGAC
GCA_DP5_8
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_T
CTACACGACGCTCTTCCGATCTTCACAGGGAGGAC
CAC_DP5_9
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTAGTGAGGGAGGAC
AGTG_DP5_10
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_T
CTACACGACGCTCTTCCGATCTTACGAGGGAGGAC
ACG_DP5_11
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTATGCAGGGAGGAC
ATGC_DP5_12
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTCCGAAGGGAGGAC
CCGA_DP5_13
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTCTCCAGGGAGGAC
CTCC_DP5_14
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTGGCTAGGGAGGAC
GGCT_DP5_15
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTGAGGAGGGAGGAC
GAGG_DP5_16
GATGCGG
AATGATACGGCGACCACCGAGATCTACACTCTTTCC
Anchor_MiSeq_
CTACACGACGCTCTTCCGATCTAACCAGGGAGGAC
AACC_DP5_17
GATGCGG
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MSFP3

CAAGCAGAAGACGGCATACGAGATCCGCTGGAAGT
GACTGACAC
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